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Abstract
Metabolic syndrome (MetS), the development of which is associated with high-caloric Western
diet intake, represents a risk factor for mild cognitive impairment (MCI) and Alzheimer’s disease
(AD) and appears to contribute to AD progression when MetS and AD are comorbid. The
interaction between AD and MetS might be through white matter inflammation, since white matter
abnormalities and inflammation are important early events in the etiopathogenesis of both diseases.
In these investigations, the effect of a high-caloric diet (HCD), to induce metabolic disturbances,
on white matter neuroinflammation and cognitive function was investigated in a transgenic (TG)
rat model of prodromal AD and MCI (APP21 TG). Rats maintained on the HCD developed
obesity, dyslipidemia, hyperinsulinemia and glucose intolerance, but not hypertension. HCDdriven metabolic perturbations significantly exacerbated white matter microglia, but not astrocyte,
activation in the TG rats. There were significant deficits in spatial reference memory in the
comorbid TG HCD group compared to wildtype control rats. There were no changes in
hippocampal neuronal or synaptic density in the comorbid group. In addition, single-regimen
chronic prophylactic treatment with a novel brain-targeted NSAID prodrug Ketoprofen-lysine was
not able to decrease the activation of white matter microglia and alleviate cognitive deficits in the
comorbid model. In fact, the prodrug treatment alone was associated with two deaths and
widespread neuroinflammation and neurodegeneration in a subset of rats further associated with a
spatial working memory decline and cognitive inflexibility. Finally, white matter microglia
activation was positively associated with visceral fat deposition and with transgene presence.
Dyslipidemia was related to the greater white matter inflammation in the entire rat sample,
however, showed an unexpected inverse association in the comorbid model. Thus, the APP21 TG
rat combined with the HCD represents a good model for future studies on prodromal AD pathology
and MetS. It can be used to study related cognitive dysfunction including effects of various
comorbidities on the disease presentation, as well as provide a platform for testing treatment
strategies and biomarker identification. The results support an important role of white matter
inflammation in the interaction between prodromal AD and MetS and as a contributor to cognitive
impairment.
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Summary for Lay Audience
Alzheimer's disease (AD) is a highly prevalent and incurable brain disease in the elderly resulting
in difficulty in thinking and communicating as well as memory loss. Metabolic syndrome (MetS),
is another common disease in the elderly, largely due to the consumption of a hypercaloric Western
diet high in fat and sugar. MetS represents a modifiable risk factor for AD. It can coexist with and
likely interacts with AD, contributing to cognitive impairment. Investigating the pathological links
between AD, especially at the very early stage, and MetS will advance our understanding of early
disease processes, highlight therapeutic targets for early intervention and prevention, and identify
markers of prodromal AD to aid early diagnosis and timely treatment. White matter abnormalities
in brain are associated with cognitive dysfunction and inflammation and are important features of
the initial stage of AD and MetS. Inflammation occurring in the white matter could be the basis of
the interaction between AD and MetS. The studies in this thesis examined the contribution of a
high-caloric (HCD)-induced MetS to the early AD pathology and changes in cognitive function
using a novel genetically engineered rat carrying a human protein implicated in human AD. The
combined model of AD predisposition and MetS demonstrated greater white matter inflammation
which was caused by microglia (resident brain immune cells) and resulted in memory impairment.
A novel brain-targeted chronic prophylactic anti-inflammatory treatment was not able to disrupt
the detrimental interaction of early AD and MetS on white matter inflammation and to preserve
cognitive function. However, serious neurological side effects were observed in several rats on the
treatment. Accumulation of fat around the internal organs and blood lipid abnormalities were
identified as potential biomarkers of increased white matter inflammation. However, abnormal
blood lipids were associated with lower white matter inflammation in the combination of the early
AD and MetS in the rats. In conclusion, the findings support the suggestion that white matter
inflammation is a link between early AD and MetS. This rat model, closely mimicking human
pathological conditions, represents a good platform for future studies on the complex relationships
between AD and comorbidities, therapeutic approaches and biomarkers.
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Chapter 1: Introduction
This chapter introduces the main concepts and current views on Alzheimer’s disease (AD) and
metabolic syndrome (MetS) with a focus on white matter pathology and neuroinflammation in the
pathogenesis of both diseases. AD and MetS often co-exist in elderly individuals and likely interact
contributing to the decline in cognitive status. Investigating the underlying basis of this interaction,
particularly at an early stage, and its effect on the cognitive function will advance our
understanding of AD pathology and highlight potential therapeutic targets and strategies for the
prevention of AD.
This section first addresses the general issues of ageing, mild cognitive impairment (MCI),
dementia and metabolic vascular disorders. This section then provides a detailed description of
many aspects of AD. Thirdly, there is an examination of clinical and pathological aspects of MetS.
Finally, the interaction of AD and MetS is discussed.

1.1 The Problem of Ageing
Aging is a natural and integral part of a human life. Every organ system of a human body undergoes
changes as we age and the brain is no exception. The aging brain changes in morphology,
physiology and function. This may lead to a minor but noticeable general reduction of cognitive
abilities, particularly information processing speed, attention and memory, which together
constitute a so-called normal cognitive aging. Physiological changes in the aging brain including
vascular and metabolic alterations, as well as imbalance in oxidant-antioxidant systems and
dysfunction of the immune system make the brain highly vulnerable and sensitive to disease and
injury. As a result of the overlay of multiple chronic or acute disorders, there may be an
acceleration in impairment of cognitive function leading to a substantial decrease in quality of life
and even loss of independence.
The aging world population has become a major concern. It is estimated that by 2050, 21.1 per
cent of the world’s population will be 60 years or older and the number of older persons from this
age group will increase to more than 2 billion1. Normal healthy aging is not the only course and
1

the number of chronic pathologies is growing and greatly affecting the quality of life of older
people. Two of these chronic disorders that interfere with cognition and furthermore with a daily
living are MCI and dementia. Another group of chronic diseases associated with a high mortality
rate is a group of vascular disorders and related metabolic conditions.

1.1.1 Mild Cognitive Impairment
MCI or mild neurocognitive disorder (as per Diagnostic and Statistical Manual of mental disorders,
fifth edition (DSM-5) classification)2, represents a “transitional” or intermediate state between
normal cognition and dementia 3. MCI may improve or remain stable for many years4. MCI is
defined as a condition of a more severe decline in cognitive domains, usually memory (amnestic
MCI) or generally across multiple domains, than that expected at a given age. Nevertheless,
individuals experiencing a negative change from their usual cognitive level, remain functional and
independent in the daily life tasks with a minimal aid from others.

1.1.2 Dementia
Dementia, or major neurocognitive disorder as per DSM-5 classification2, is a syndrome of severe
deterioration in an individual’s mental status which includes a substantial decline in memory,
attention, executive function (such as planning, organizing, problem solving and multi-tasking),
inappropriate social behavior and severely compromised everyday functioning. The symptoms
presented by an individual may also include language and mood disturbances, more commonly
depression, apathy and anxiety.
Dementia remains one of the biggest global public health challenges. The approximate number of
individuals living with this diagnosis worldwide today is estimated at 47 million and is set to grow
almost twofold in the next decade 5. In Canada, the numbers are expected to be nearly 1 million
people in the next decade according to Alzheimer Society of Canada 2018 facts.
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There are multiple diseases that are manifested as dementia syndrome, but the most commonly
diagnosed form is dementia due to AD which accounts for 60-70% of all cases. The second most
common cause of dementia is vascular dementia.

1.1.3 Metabolic Vascular Disorders
Metabolic vascular disorders represent a group of diseases featuring dysfunction of metabolism
and pathological alterations to the vascular system, representing risk factors for cardio-, cerebroand peripheral vascular diseases6,7. This group includes such major conditions as type 2 diabetes
mellitus (T2DM) and its precursors, obesity and MetS. MetS is a cluster of several conditions
including overweight status, defined by a body mass index (BMI) >25 kg/m2, and obesity (BMI
≥30 kg/m2), hyper- and dyslipidemia, glucose metabolism perturbations, insulin resistance, and
hypertension.
The incidence of these chronic pathological conditions has markedly increased over the past few
decades in the adult population and the prevalence has reached epidemic status particularly from
a global ageing perspective8–12. This growth appears to be primarily associated with unhealthy
lifestyle choices, such as chronic consumption of Western diets high in fat, sugar and salt and low
physical activity13–18. The estimated prevalence of obesity is currently 650 million people
worldwide19. People diagnosed with diabetes, 90% of whom have T2DM, account for 425 million
worldwide20,21.
The global prevalence of MetS, which is difficult to measure, was estimated to be at about one
quarter of the world population, roughly over a billion people8. In Canada, roughly 6 million people
were reported to be obese between 2001-201222. Canada-wide statistics indicated that in 20162017, 64% of adults older than 18 years were overweight and obese23. Obesity accounted for 27%
of this statistic which is approximately 8 million people indicating a progressive increase over the
past 5 years24. Canadian statistics in 2017 on diabetes indicated that more than 2 million people
were diagnosed with diabetes and about 22% of population aged 12-79 had symptoms of MetS 25–
27

. The seriousness of the situation behind these numbers is that these diseases not only represent
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a public health issue and increased incidence of vascular morbidities, but also impose a great risk
for dementia, including AD later in life13,14,17,28–38.

1.2 Alzheimer’s Disease
Alzheimer's disease (AD) is a neurodegenerative disease that leads to severe mental health decline
and incapability to function independently in everyday life. There are two known forms of this
disease. The first and most common form (about 95% AD cases) is sporadic form of the disease
that in most cases presents as senile or late-onset AD (LOAD) in late 60-80s years of life with
occasional early onset AD (EOAD) cases39. The second is a familial form (FAD) with an
autosomal dominant inheritance of genetic mutations that typically has an early-onset, before 65
years, although some later in life onset cases are described40. The progressive, irreversible and
incurable character of this disease, regardless of the form, is a major societal concern given the
high prevalence of this type of age-related dementing disorder in the population. Despite the
extensive research conducted in the AD field, our comprehension of the causal events and
pathological presentation, especially in the very early stages of the disease, is still incomplete and
is an impediment to the development of therapeutic advancements. The search for biomarkers of
the disease to aid in early capture has been developing intensively, and yet a timely and accurate
diagnosis of AD that is essential for early intervention and better prognosis remains a great
challenge.

1.2.1 Diagnosis of Alzheimer’s Disease
Accurate life-time clinical diagnostics of AD is very challenging, even with the existence of
detailed criteria available to healthcare providers and clinical researchers. The diagnosis is mainly
based on the patient’s complaints and their close relatives’ observations of gradually developing
progressive cognitive decline from a previous cognitive level; as well as the patients’ performance
on general cognitive and more sophisticated neuropsychological testing. Patient anamnesis and the
family history provide additional information related to genetic, medical and life-style risk factors
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which can further aid in diagnosis. Laboratory and instrumental diagnostics, including structural
and functional magnetic resonance imaging (MRI), computer tomography and positron emission
tomography (PET) is becoming more critical for early and differential diagnosis. However the
methods are unstandardized and not widely available and therefore are not recommended for
clinical use41. Nevertheless, neuroimaging has become a very useful tool in clinical and pre-clinical
research that has significantly advanced our understanding of pathological processes, particularly
associated with the early stages of AD and MCI.
The core criteria outlined in the DSM-5, and recommended by the National Institute on Aging
(NIA) and Alzheimer’s Association (AA) workgroups, allow for the identification of probable and
possible AD2,42. To qualify for the most typical amnestic type of probable AD, the patient must
present with a decline in memory, and with at minimum, an impairment in one other cognitive
domain. Alternatively, in non-amnestic case at least two cognitive domains from language,
visuospatial and executive functioning should be impaired. The diagnosis of probable AD also
requires no evidence of concomitant substantial cerebrovascular disease, major psychiatric
disorder, or other neurological or systemic conditions that could explain the cognitive
symptomatology. Evidence of autosomal dominant FAD increases the certainty of the probable
AD case. If probable AD is not confirmed, possible AD should be diagnosed. The antemortem
diagnosis is mainly verified during autopsy by the presence of amyloid plaques, neurofibrillary
tangles (NFT) and cortical atrophy in the brain tissue.

1.2.2 Clinical Presentation of Alzheimer’s Disease
Cognitive presentation of AD varies, and it is recognized that variable cognitive domains may be
affected. The two disease forms, sporadic and familial, are largely similar in clinical and
pathological representation, though they have some differences in symptomatology and
progression with a more rapid deterioration in the early-onset form.
Episodic memory impairment is considered the primary and early feature of the disease43. It is
characterized by difficulties in recollection of recent events and recent personal past experiences
embedded in a spatiotemporal context as well as difficulty with learning and encoding new
5

information43–45. Semantic or context-free memory undergoes decline during AD. In fact, semantic
or context-free memory has been proposed to be affected at prodromal stages of the disease
possibly preceding changes in episodic memory46. This hypothesis is confirmed by pathological
findings of an early NFT accumulation in the entorhinal cortex, a region primarily associated with
semantic memory, as well as in the perirhinal cortex. This pathology can precede changes in the
hippocampus, a key structure for context-rich spatial and episodic memory47. Entorhinal cortical
atrophy is suggested to be a better predictor for the conversion from MCI to AD48. However, these
two memory systems are in fact very closely interrelated and therefore it might be difficult to
distinguish which one is solely or early impaired when interpreting the common cognitive
tests46,49,50.
In addition to declarative memory deficits, executive dysfunction is a recognized variant of AD
manifestation and often occurs in a combination with a decline in other domains. Moreover, some
clinical studies suggest it develops early in the course of the disease at a prodromal or mild AD
stage51–57. Individuals with AD show impairment on various executive function processes
including working memory, response inhibition, selective attention and resistance to distraction,
problem solving, set shifting and cognitive flexibility52,55,57.
As the disease progresses, impairments may spread to non-cognitive functions including
visuoconstructional and perceptual abilities, social function and personality changes such as
increased irritability, aggression, combativeness, and inappropriate behavior. Psychiatric
symptoms such as depression and apathy may appear very early and accompany any stage of the
disease58. Very late in the disease sleep disorders, appetite loss, motor and gait disturbances, and
deterioration of vital functions may be evident58.
The early onset familial form of the disease has heterogenic clinical features with certain symptoms
more attributed to the specific genetic profile. As in the sporadic variant, it also presents with
episodic memory, context-free recognition, verbal memory impairment and executive
dysfunctions59,60. Various non-cognitive symptoms are characteristic of the FAD and occur more
frequently than in sporadic AD 60. These can include behavioral, psychiatric, motor dysfunctions
(e.g. extrapyramidal signs, myoclonus, spastic paraparesis), seizures, cerebral haemorrhage.
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1.2.3 Mild Cognitive Impairment Preceding Alzheimer’s Disease
AD is a progressive disease and clinical symptoms develop over many years, even decades. The
early phase of the disease when the symptoms start to appear and are yet not severe enough to
qualify for AD diagnosis is defined as MCI61. Most commonly this phase is characterized by a
mild memory impairment. An additional simultaneous decline very often occurs in overall
executive functioning and in executive function individual components62. Typically decline is
evident in working memory, response inhibition, divided attention and manipulation, task
switching, cognitive flexibility and problem solving62–66. Individuals with MCI, particularly with
decline in multiple cognitive domains, are at a high risk of progression towards dementia including
AD. Executive dysfunction is among the strongest predictors of the progressive decline64,67,68.
There are different patterns and rates of decline in various cognitive domains, which some
gradually deteriorate (e.g. immediate recall, inhibition) while others show a rapid decline just prior
to AD diagnosis after a relatively long stable phase (e.g. delayed recall, episodic, spatial and
working memory)69. From a clinical and therapeutic prospective, the MCI stage preceding AD
appears to be the critical phase for early recognition, intervention and potential delay of the disease
progression. However, negative results of clinical trials with potential treatment agents that were
initiated at the MCI stage, point to the fact that even at this mild stage the pathological processes
in the brain might already be too advanced and largely irreversible. This clinical failure is the
impetus for research on the identification the earliest prodromal phases from both a pathological
and possibly clinical prospective. This prodromal phase of the disease is asymptomatic and is
characterized by developing pathological changes in the brain that can be detected using laboratory
diagnostic measures in blood and cerebral spinal fluid (CSF) and neuroimaging. The NIA and AA
group has developed recommendations for defining the earliest pre-clinical stage of AD that
currently have only research application70.

1.2.4 Risk factors of Alzheimer’s Disease
The biggest risk factors for AD are age and genotype, conditions that cannot be changed. Some
risk factors (i.e. lifestyle) can be controlled and modulated in order to reduce the chance of
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developing metabolic dysfunction and consequently decrease the risk for MCI, AD or progression
of cognitive decline58,71.
One of the most critical factors for developing the most common form of AD, sporadic LOAD, is
age72,73. With increased age our brain homeostatic systems become less functional and many
defense mechanisms weaken, thus creating a favorable environment for development of pathology
in response to a triggering event or injury.
AD has a strong genetic predisposition74–77. Early-onset FAD has been causatively linked to
mutations in three genes encoding amyloid precursor protein (APP) and presenilin proteins
(PSEN1,2), that are directly involved in the amyloid pathway central to AD development60. PSEN1
mutations account for the majority of AD cases60,78. The contribution of genetics to LOAD is also
substantial and heritability accounts for 60-80% of cases79. Sporadic and familial LOAD forms
and sporadic non-familial EOAD have shown a very similar profile to FAD 40,80–84. Known genetic
mutations in APP and PSEN have been found in approximately 2% of sporadic LOAD cases,
although they are unlikely to have a major role in LOAD predisposition81,85.
The only major gene underlying susceptibility to both LOAD types is the APOEε4 gene, which
encodes Apoliporotein E (APOE). APOEε4 is present in more than half of AD cases79,86–91.
Homozygous carriers for this allele have a 10 fold increase in the risk of AD and have an earlier
onset of the disease79,87,88,92. Genome-wide studies have identified rare and more common
mutations in more than 30 genome loci associated with LOAD75,76,80,81,93–96. Most of the genes
found encode proteins involved in cholesterol metabolism, the immune system, endocytosis and
amyloid beta metabolism. However, these genes explain only a small part of LOAD genetic profile
and impose a much smaller effect than that of APOEε4 81,97.
There also appears to be a combinatorial effect of mutations on the risk, age of onset and course
of LOAD, such as was seen in the presence of both APOEε4 and PSEN1 mutations84,98. Thus,
genetics is considered to be an important risk factor for senile AD, however, no causative
mutations have been identified. This suggests there are other conditions such as lifestyle, medical
conditions and environmental factors that impact the onset of the disease. The role of these other
factors is confirmed by a study on twins in which not every individual developed the disease
despite having the exact same genome 77.
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Unhealthy lifestyle choices including cigarette smoking, alcoholism, lack of physical activity and
dietary preferences, that are also linked to the development of vascular and metabolic disorders,
represent a group of modifiable risk factors for AD99–104. Dietary choices are associated with both
high and low risk of AD. Epidemiological and experimental studies indicate that a Western diet,
characterized by high content of saturated fat, simple carbohydrates and salt, has been linked to
cognitive impairment and increased risk of AD

16,18,105–109

. On the contrary, adherence to the

Mediterranean diet, which includes abundance of fruits, vegetables and whole grains, showed an
association with reduced risk for dementia110,111. It has been demonstrated that not only
macronutrient composition of the diet (i.e. fat, protein and carbohydrate) is important, but also a
content of micronutrients. Several vitamin deficiencies including vitamins D, B12, B6 and E have
been linked to AD increased risk101,112–115. The amount of the calories is as important as the nutrient
source. High caloric intake exceeding energy expenditure is associated with MCI and AD15,116–118.
Animal studies have demonstrated that caloric restriction and low percentage of carbohydrates and
fat in foods play a role in a reduced risk for AD119,120.
Many medical conditions, developed throughout the lifespan and particularly during middle age,
represent

risk

factors

hyperhomocysteinemia,

for

AD36.

These

atherosclerosis,

conditions

cardiovascular

include
and

hypercholesterolemia,

cerebrovascular

diseases,

inflammatory diseases such as arthritis, T2DM and MetS that can result in hypertension, obesity
and insulin resistance

33,121–137

. Most of these disorders are tightly linked to lifestyle choices

including dietary preferences, are chronic conditions, and progress with aging. In addition, they
often co-exist with MCI or dementia. Psychological stress, depression, infection and head injury
can also have a significant contribution to the risk for AD36,138,139.
Greater brain or cognitive reserve (largely formed by level of education), complexity of the
working environment, socioeconomic status, social interaction, and involvement in leisure
activities which may be related to higher mental stimulation have been positively related to a
reduced risk for AD risk and may delay cognitive deterioration140–142.
None of these risk factors alone have been proven to be necessary or sufficient for AD
development. However, the more factors that accumulate can have a cumulative effect and increase
the chances of manifestation of the disease pathology143.

9

1.2.5 Neuropathology of Alzheimer’s Disease
1.2.5.1 Current Mechanistic Hypotheses
Various pathological mechanisms are implicated in the etiopathogenesis of AD. The accumulation
of amyloid plaques and formation of NFT are considered to be the hallmarks of AD74,144,145. Other
processes associated with the development of AD include glial activation, excessive
neuroinflammation and oxidative stress, synaptic loss, neuronal degeneration and disruption to the
white matter, as well as vascular and metabolic abnormalities, such as brain insulin resistance and
abnormal glucose metabolism 144,146.
Amyloid hypothesis
Amyloid plaque accumulation in the brain tissue is a core feature of AD. The main component of
these plaques is amyloid-β peptide (Aβ) produced through an altered enzymatic cleavage from
(APP), endogenously expressed throughout the brain, formed by β- and γ-secretases144,147,148.
Amyloid peptide exists in multiple molecular forms starting with soluble monomers Aβ40 and
Aβ42 which self-aggregate into oligomers, then into fibrils which form diffuse and later insoluble
extracellular plaques. While Aβ42 composes the core of the senile cortical plaque, a more abundant
Aβ40 species has a high affinity to the wall of cortical microvasculature and is associated with a
cerebral amyloid angiopathy (CAA)149,150. Oligomeric forms are considered to be the most
neurotoxic and are associated with synaptic dysfunction and loss151–154. Increased production of
Aβ and its decreased clearance from the brain are both considered to be implicated in the disease
pathogenesis74. Support for the amyloid hypothesis as the core origin of AD comes from the
causative role of genetic mutations of APP and amyloidogenic pathway enzymes genes PSEN1,2
in FAD60,78. However, a major limitation of this theory arises with evidence from studies of human
brain showing a lack of correlation between amyloid plaque burden and presence or severity of
dementia symptoms155–157.
Tau hypothesis
NFTs in pyramidal neurons constitute a second proteinopathy occurring in AD144,147. Their
formation is a result of an aggregation of dysfunctional insoluble hyperphosphorylated tau protein,
which normally exists in unphosphorylated form and promotes microtubule stabilization and aids
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axonal vesicle transport. Unlike amyloid plaque burden, tau pathology in the neocortex is highly
correlated with cognitive performance158. Nonetheless, amyloid and tau pathologies interact with
each other, both are integral to AD pathology and both exist in the complex pathological network
interconnected with other processes such as synaptic dysfunction, inflammation, oxidative stress.
Synaptic dysfunction
Synaptic dysfunction is another AD pathology and is related to the disruption of communication
between neurons and has been proposed as an explanation of the early signs of mental
deterioration144. Synaptic loss, particularly in the hippocampus, a structure relevant to learning and
memory, and in the neocortex occurs in MCI and AD and correlates with cognitive
dysfunction159,160.
Cholinergic hypothesis
The brain cholinergic system and its main neurotransmitter acetylcholine (ACh) plays a crucial
role in learning and memory in a complex manner161. ACh promotes neuronal plasticity,
neuroprotection and neurogenesis mainly via nicotinic ACh receptors. It modulates neurotrophin
expression (e.g. brain derived neurotrophic factor (BDNF), nerve and fibroblast growth factors),
interacts with glia cells, including blocking excessive inflammation derived from microglia proinflammatory cytokine production, a pathology that can be detrimental to memory processing161.
A substantial reduction in brain ACh levels through changes in the activity of the main ACh
enzymes (i.e. choline acetyltransferase, acetylcholinesterase), axonal pathology of cholinergic
neurons occurring in the early stages and the loss of these cells in the later stages are evident in
AD162–164. Loss of cholinergic synapses contributes to the dysfunction in the cholinergic system.
The cholinergic hypothesis of AD has led to the development of therapies for AD and are currently
the only drug group approved for symptomatic treatment of the disease165.
Mitochondrial dysfunction and oxidative stress hypothesis
Oxidative stress is a pathological condition in which there is an elevation of toxic free radicals
such as reactive oxygen (ROS) and nitrogen (NOS) species naturally produced by cells. These free
radicals bind to DNA, RNA, protein and lipid molecules leading to cell damage. Mitochondria is
a primary site of oxygen free radical production. Studies investigating the oxidant system in AD
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patients’ brain tissue samples have concluded that mitochondrial damage and oxidative stress are
common and early events in AD, occurring before the hallmark proteinopathies of AD are
established and then gradually decreasing with the disease advancement166. The changes include
mitochondrial DNA alterations, mutations in an oxidative environment, proteasome dysfunction
and low cytochromeoxidase activity144,145,167. Thus, these changes have been proposed to drive
amyloid accumulation and promote tau pathologies. In turn, these misfolded proteins further feed
the oxidative process by inhibiting mitochondrial functioning directly and activating glia cells
which contribute to the free radical pool and drive related inflammatory processes168.
Metabolic dysregulation
Insulin and insulin growth factor 1 resistance, impaired downstream insulin signaling and altered
cerebral glucose metabolism have been consistently reported in AD and accompany NFT
formation, Aβ accumulation, inflammation and oxidative stress 169–177. Evidence has been provided
that brain insulin, locally produced or from peripheral organs, has several effects on the brain
including, positive effects on amyloid metabolism (degradation via insulin degrading enzyme
action); apoptosis (via NFκB pathway) and memory and learning due to changes in various
underlying mechanisms (synaptic plasticity, long-term potentiation and depression, glucose
metabolism, downstream insulin signaling etc.)37,38,178. Studies on cognitive decline associated
with AD and T2DM, with either pathology alone or in a comorbid situation, have shown improved
cognitive performance by memory facilitation with treatment with insulin delivered to the central
nervous system (CNS)179.
Cholesterol and lipid metabolism are also thought to be implicated in AD pathophysiology
primarily via involvement with amyloid metabolism. However, the relationship of lipid
metabolism with AD are complicated and largely debatable180–184. There is an inconsistency in
reports whether hypercholesterolemia and lipid dyshomeostasis in AD are a risk factor for AD184.
The cholesterol hypothesis of the disease has been questioned due to the fact that peripheral
cholesterol does not cross the blood-brain barrier (BBB). Thus, the cholesterol changes outside of
the brain are unlikely to directly contribute to brain homeostatic changes. Furthermore, changes in
fluid cholesterol concentration of AD patients were reported to be low, high or the same as in nondiseased controls185.
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Animal research, using models of high-fat/high-cholesterol diet-induced peripheral metabolic
disorders that develop dyslipidemia and are associated with impairments to cognition, have been
supportive of a role for cholesterol in AD pathogenesis. This could happen via various mechanisms
such as altered brain lipid and cholesterol profiles, increased accumulation of amyloid and
phosphorylated tau proteins, oxidative stress, inflammation, and disruption to the BBB and
microvasculature186–193. The support for a role of cholesterol in AD also comes from the strong
genetic link of APOEe4 allele and high risk of AD development91. APOE encoded by this gene is
an important regulator of lipoprotein metabolism and cholesterol transport. APOE is also related
to the insulin pathway, is involved in Aβ metabolism, including clearance of soluble Aβ and the
Aβ aggregation, and is associated with inflammation and neuroplasticity93,194.
Considerable attention has been granted to the oxysterols as the pathogenic component of AD195.
Oxysterols are products of cholesterol oxygenation, mainly by ROS, which are generated within
the brain and in the periphery and are able to cross BBB180,196,197. They show involvement in the
modulation of cholesterol metabolism, neuroinflammation, apoptosis and Aβ accumulation198.
High blood and CSF oxysterol levels, particularly 24(S)-hydroxycholesterol (24S-OHC) which is
excreted by the brain, have been reported in AD patients and are linked to amyloid cascade and
neuronal stress198–201. Metabolic conditions such as obesity are also associated with the increase in
oxysterols and 27-OHC in particular is viewed as a candidate modulator entering the brain and
interfering with cerebral homeostasis202–204. In the highly interactive pathological environment in
AD, inflammation greatly affects oxysterol levels and these substances in turn effect glial
activation197,203.
Neuroinflammation
Neuroinflammation is one of the earliest and most critical events occurring in the brain in response
to insult and plays an important and likely a key role in the pathogenesis of AD205–208. Microglia
are the key cellular component of the inflammatory processes occurring in the brain and are the
first cells to become activated and proliferate in response to disturbances in cerebral
homeostasis209. Astrocytes play a major role in maintaining brain health and get readily involved
in inflammatory reactions210. A more detailed look at the role of neuroinflammation in AD is
contained in a separate sub-chapter.
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Neurovascular hypothesis
The sophisticated organization of the brain vascular system allows it to maintain its unique strictly
regulated microenvironment. The larger caliber vessels can autoregulate cerebral blood flow via
dilation-constriction mechanisms keeping the brain independent from systemic changes in the
blood pressure. Capillaries are a part of the functional unit of the system called the neurovascular
unit (NVU). NVU consists of anatomically and functionally closely linked endothelial, smooth
muscle cells, pericytes, neurons, interneurons, astrocytes, microglia, and an extracellular
compartment211. Capillary endothelial cells, pericytes and astrocyte end feet contacting endothelial
basal lamina comprise the crucial NVU subunit forming the BBB and is sealed by intercellular
tight junctions212. Each of these components crucially contributes to the proper functioning of the
unit. The NVU serves as a regulator of blood supply with respect to the brain energy needs, a
process called neurovascular coupling213.
The BBB physically separates the CNS microenvironment from the peripheral circulation and
regulates microvascular permeability for selective flux of substances to protect the brain from
peripheral toxins and metabolites. Abluminal and soluble forms of low-density lipoprotein
receptor–related proteins (LRP1) in conjunction with APOE regulate the efflux of brain Aβ42 and
Aβ40 to the systemic circulation. Receptors for advanced glycation end products (RAGE),
normally expressed in low amounts, mediate the influx of molecules from the peripheral blood,
including Aβ. Glucose transporters such as GLUT1 primarily maintain the necessary high glucose
concentrations, but also contribute to the BBB integrity and maintenance of cerebral blood flow214.
AD is associated with both structural and functional alterations of the cerebrovasculature215–222.
Microvascular abnormalities include decreased density, increased tortuosity, deposition of
circulating lipids, and collagen, fibrinogen, amyloid and leukocyte adhesion to the vascular wall
causing damage to the NVU such as endothelial inflammation and pericyte degeneration 217,223–230.
These changes are accompanied by increased vascular reactivity and neurovascular uncoupling,
vasoconstriction, hypoperfusion and ischemia creating a toxic oxidative, pro-inflammatory
environment which further propagates BBB leakage149,220,225,231–234. There is evidence of the loss
of LRP1 and GLUT1 receptors with a parallel upregulation of RAGE235,236. APOEe4 genotype,
associated with the high risk of AD, has been linked to the BBB breakdown194,237,238. Blood-
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derived proteins such as fibrinogen, immunoglobulin IgG and circulating Aβ enter the brain easier
when the BBB is compromised221,233,239–242. Alternatively, clearance of cerebral Aβ is impaired
which leads to its accumulation and amplification of the NVU damage, glia activation and
inflammation, and ultimately axonal and neuronal damage221,228,240,243–249.
The neurovascular hypothesis of AD provides an explanation for the sequential pathology seen in
the disease starting with a diminished Aβ clearance and age-related alterations to the
cerebrovascular system that could initiate neurovascular uncoupling, microvascular inflammation
and degeneration, hypoperfusion and hypoxia. These changes which affect BBB integrity,
compromise the brain biochemical microenvironment leading to synaptic and neuronal damage
and loss216.
The proposed two-hit concept of pathology development in AD implies that there is initial damage
to the neurovascular system, such as by cerebrovascular insults, cardiovascular diseases and other
risk conditions as well as age-related alterations, that leads to damage to the BBB and
microvasculature. The impaired BBB and microvasculature subsequently induce oligemia or blood
supply reduction, hypoxia and create a toxic environment. These vascular changes initiate early
neuronal dysfunction and also promote Aβ deposition via reduced vascular clearance from the
CNS and increased generation of Aβ that in turn exacerbates vascular and neuronal damage215.
While it is still debatable whether cerebrovascular abnormalities are a cause or a consequence of
AD, it is very likely that in fact it is both and NVU dysfunction is a significant contributor from
the very initial to the end stage of the disease250.
White matter changes
AD is a disease impacting both the gray and white matter of the brain251. While changes to the
gray matter in the pathogenesis of AD are well known and continued to be heavily investigated,
the neuropathology of white matter abnormalities still remains not fully understood. White matter
pathology is mainly attributed to cerebral small vessel degeneration and BBB deregulation with a
contribution from inflammatory events, leading to loss of myelin and axonal fibers252–254. White
matter changes in AD are described in a separate sub-chapter.
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1.2.5.2 Neuroinflammation and Role of Glia Cells in Alzheimer’s Disease
Neuroinflammation is a complex process thought to be implicated in the early stages of AD
development largely contributing to its progression205,207,208,255–260. Moreover, it interacts with all
other mechanistic processes in AD pathogenesis and is a component linking these multiple
pathological events. Patients with AD exhibit upregulation of genes associated with inflammation
regulation (e.g. triggering receptor expressed on myeloid cells 2 (TREM2) mutations, cluster of
differentiation (CD) 33, tumor necrosis factor alpha (TNF-α), nuclear factor kappa-light-chainenhancer of activated B cells (NF-κB), cyclooxygenases (COX) 1 and 2) and elevation of
circulating and brain tissue cytokines, particularly TNF-α and interleukin IL-6, acute phase
proteins, chemokines, complement and glial activation80,206–208,255,258,260–264. Epidemiological
studies show a decreased risk of AD associated with the long-term use of non-steroidal antiinflammatory drugs (NSAIDs) which further supports the inflammatory hypothesis of AD and
suggests inflammation is a critical therapeutic target265,266.
Brain inflammation is largely mediated by the resident innate immune cells,

microglia,

perivascular macrophages and immunocompetent astrocytes260. Microglia cells conduct a constant
surveillance of the brain environment and are readily activated when an aberrant process or
pathogen is detected. In the AD context, the main triggers of microglia are aberrantly processed
amyloid protein (e.g. Aβ monomers, oligomers, fibrils), injured neurons including those impacted
by Aβ and p-tau, damaged vasculature and BBB breakdown146,257,267. These triggers activate cells
directly or through receptor binding such as RAGE, scavenger receptors, and toll-like receptors
(TLRs) or through cluster of differentiation. These triggers lead to microglia phenotype changes
promoting phagocytosis of apoptotic neurons, dystrophic neurite and clearance of Aβ
accumulates205,268,269.
Activated microglia further communicate with astrocytes and perivascular macrophages which
help in Aβ plaque degradation via cytokines (e.g. TNF -α, IL-6, IL-1β, IL-12, IL-23), chemokines,
caspases, and production and release of ROS/NOS207. It has been proposed that glia cell numbers
do not increase during AD but only undergo phenotypic change without marked proliferation270.
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Microglia appear to be activated even at the preclinical stage, when subjective cognitive decline is
reported, although cognitive tests show no impairment. This activation gradually increases with
the progression from MCI to eventually AD271.
Astrocytes show a delayed involvement, becoming reactive at the MCI stage271,272. Astrocyte
activation and generation of the reactive phenotype, characterized by upregulation of glial
fibrillary acidic protein (GFAP), RAGE and epidermal growth factor receptor (EGFR) are
associated with Aβ plaques in AD273,274. Reactive astrocytes aid in Aβ clearance and likely help in
restriction of the focal damage though without a glial scar formation275,276. They also interact with
microglia cells and are able to modulate their activity and help down-regulate inflammatory
reaction via release of anti-inflammatory factors277–279. However, the main functions of astrocytes
are metabolic support for neurons, their survival and outgrowth, synaptogenesis, myelination and
BBB maintenance. During chronic inflammation, associated with triggering events, these primary
functions of astrocytes are likely compromised which contributes to the propagation of the
pathology280,281. Furthermore, under pathological conditions reactive astrocytes upregulate the NFkB pathway, overexpressing IL-1β, IL-6, mediator S100β, release pro-inflammatory cytokines and
chemokines, which further activate microglial cells and propagate tissue damage including plaque
formation277.
The relationship between neuroinflammation and AD appears to be very complicated and not
simply either beneficial or detrimental205,208,256,260. While inflammation is a natural response to an
injury directed toward resolving the pathological event, persistent inflammation - chronic cell
overactivation by the trigger and unsuppressed pro-inflammatory cytokine release – can lead to
failure of protective mechanisms, disease development and propagation. Thus, in pre-clinical
studies microglial overactivation has been shown to result in decreased phagocytotic efficiency,
leading to a reduced degradation of amyloid aggregates, while pro-inflammatory cytokine
production was unaffected269,282–284. However, even when microglia are overactivated, amyloid
peptide toxicity, especially of oligomers, acts on glial cells to induce dystrophic state in microglia
and loss of proper function146,285.
The relationship in LOAD is further complicated by the effects of ageing on the immune system.
The term inflammaging describes the age-related chronic low grade pro-inflammatory
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environment in the brain which is associated with increased inflammasome generation and
secretion of IL-1β and IL-18 and may contribute to age-related cognitive decline286,287.
Immunosenescence is viewed as a part of normal aging that presents as changes to cell
morphology, physiology and function, and in a balance between inflammatory initiation-resolution
mechanisms that might lead to cell priming and increased susceptibility to injury288–290.
Microglia senescence is characterized by morphological changes, decreased mobility, loss of
homogenous tissue distribution, altered protein expression (e.g. increased major histocompatibility
class (MHCII) and reduced TREM2), increased oxidative stress and mitochondrial dysfunction291.
These changes result in less effective monitoring, defective phagocytosis and impaired
communication with neurons leading to diminished response to injury, while at the same time
maintaining pro-inflammatory cytokine production and release292. Diminished amyloid peptide
clearance from the brain that occurs with age further triggers activated microglia initiating a
pathological inflammatory response286,293. Experimental data indicates that senescent cell
dysfunction is related to AD pathogenesis. The results show dystrophic microglial cells surround
neurons with NFT pathology, suggesting this association precedes tau pathology and likely
neurodegeneration in AD294,295.
An adaptive immune system is also involved in AD and it may be recruited when resident
microglia cells are not able to manage the pathological process. Circulating monocytes, attracted
by microglia, can infiltrate the brain and participate in Aβ clearance267,296–299. Furthermore, the
perivascular space contains macrophages that act as antigen-presenting cells (APC) and are
regularly renewed by infiltrating monocyte differentiation300.
To support the immune system, pericytes are capable of transformation into microglia and acquire
their function301. T- lymphocytes migration into the brain has also been suggested to be involved
in the AD process296. Microglia in AD show upregulation of genes involved in APC-T-cell
interaction and express MHCII, encoded by the human leukocyte antigens (HLA) genes which
can modify the susceptibility to LOAD268,302. MHCII expression is linked to antigen-presentation
function and could potentially attract T-cells initiating their migration to microglia locations303,304.
Amyloid peptides and cellular debris are potential antigens presented to T-cells which show
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increased reactivity to Aβ305. CD8+ T-cells are thought to be involved in apoptosis, while CD4+
T-helpers can modulate microglial responses.

1.2.5.3 White Matter Changes in Alzheimer’s Disease
There is more white matter than gray matter in the brain and it consists of myelinated and
unmyelinated axons, glia (including microglia, astrocytes, oligodendrocytes) and blood vessels.
The white matter plays an important role in brain connectivity and cognitive function306. Similar
to the gray matter, it undergoes atrophy and structural changes with ageing and is not spared by
neurodegenerative disorders, including AD251,306–311. Eventually, white matter damage results in
the loss of connectivity between gray matter regions and contributes to cognitive decline. These
changes can be seen on T2 - MRI scans as hyperintensities (WMH) known as leukoaraiosis.
Diffuse tensor imaging (DTI-MRI) allows an estimate of white matter spatial area and integrity.
DTI-MRI can detect changes that appear normal in MRI and in histopathological
examination252,312,313. WMH increase with aging, are often present in MCI and AD and have been
shown to highly correlate with cognitive decline108,313–320. Animal models of AD have supported
the clinical findings of white matter alterations in this disease321–324. These white matter
abnormalities have been viewed as an early pre-clinical stage and a core pathological event in AD,
particularly in early-onset FAD, and precede classical gray matter proteinopathies and symptom
onset251,308,310,316,325–327.
WMH, or leukoraiosis, are thought to have a vascular origin, caused by hypoperfusion, and
represent small vessel cerebrovascular disease which is commonly observed in AD and suggests
an overlap between vascular disease and AD251,328–331. WMH are also co-localized with amyloid
pathology in AD brains and are more severe when CAA or microbleeds are present332. This
relationship with CAA and amyloid also emphasizes the involvement of vascular system in the
pathogenesis of AD. These findings suggest the possibility that vascular abnormalities drive AD
development and/or interact in an additive or synergistic way with the classical pathology as
opposed to be independently co-existent250,332–334.
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The prefrontal, temporal and parietal lobes show the highest vulnerability to classic AD pathology
and neurodegeneration. Myelination of axons from these regions continues into mid-life306,335.
These areas, the last areas to myelinate, are associated with encoding and retrieval of new
memories, short-term memory formation and executive functions. These cortical areas are the first
to deteriorate with normal aging and most impacted by preclinical and early AD and can explain
the clinical profile observed in early AD54,65,306,336,337. Cortical regions that are myelinated early in
life (primary motor, sensory cortex) appear to be more resistant to degeneration and are affected
only in the late stages of AD. These observations fall under the neuropathological retrogenesis
concept which implies that aging degenerative changes begin in the last developed structures.
Atrophy of the corpus callosum is evident in MCI and mild AD, begins in the later myelinating
anterior subregions and propagates to posterior subregions which receive axons directly from
temporo-parietal lobe regions primarily affected in the later stage of overt protein pathology in
AD338,339.
White matter degeneration and associated volume loss occurs in a spatial pattern that is depending
on the AD variant and correlates with symptomatology340,341. White matter damage and atrophy in
rare disease variants was observed in the lateral temporal and parietal regions, including cingulum,
posterior corpus callosum, fornix and occipital region of the brain. LOAD was associated with a
less intensive regional involvement. However, there was damage and atrophy in frontal and
parietal regions and the medial temporal region342. Even when the conventional MRI scans
appeared normal, the white matter of AD patients showed abnormalities with DTI in limbic
pathways, cortico-cortical association tracts, interhemispheric tracts, and corticospinal tracts,
which correlated with regional gray matter atrophy337,343,344. This association between gray and
white matter is not evident in MCI patients312,337,343,344. This data suggests that in early stages of
the disease, white matter damage is unlikely to be caused by anterograde Wallerian degeneration
related to neuronal damage. The white matter degeneration originates from local events directly
damaging myelin and axons, that leads to retrograde neuronal degeneration321. Thus,
neurodegeneration in the later stages of AD could be associated with progression in white matter
damage.
The underlying pathology of WMH and abnormal white matter seen with DTI may include
demyelination and axonopathy, which can be accompanied by gliosis and glial dysfunction,
20

pathology which is also observed in animal models of AD251–254,306,311,312,314,321,327,345–354. Animal
studies suggest that demyelination itself does not lead to axonal degeneration when normal glial
function is maintained. However, these demyelinated and unmyelinated axons could be exposed
to and damaged by various pathological stimuli present in AD355. Vascular events including
hypoperfusion and ischemia associated with BBB leakage, microvascular pathology, aberrant
neuroinflammation and oxidative stress, can all contribute significantly to axonal and myelin
damage252–254,311,330,344,346,351,356–360.
These pathological conditions can act on vulnerable oligodendrocytes and precursor cells and
promote pericyte degeneration and loss that propagates white matter damage251,306,315,347,351,361–363.
Local accumulation of Aβ40 and Aβ42 amyloid in white matter, due to increased production and/or
impaired clearance of amyloid, can also damage glia cells and axons, aggravating axonal transport
and demyelination, and promote vascular and BBB damage, including pericyte degeneration and
loss, and glial overactivation251,321,351,360,364. Diminished axonal APP transport, vascular clearance
of APP and damage to myelin can in turn contribute to amyloid accumulation

351,353,360,365

. This

pathological cascade appears to be self-propagating due to a high level of interaction and influence
between these events. The interaction contributes to the difficulty in identifying a causative event
in the white matter disease and AD etiology as a whole.

1.2.6 Biomarkers of Alzheimer’s Disease
The use of biomarkers can increase the specificity and accuracy of the clinical diagnosis of
probable and possible AD by addition of pathophysiological evidence to the observed
symptomatology42,61,366–368. There are multiple biomarkers which have long been proposed and are
currently used, mainly in clinical research. However, this area is continuing to be actively explored
and various new markers have been identified41,369,370. The principle idea of a biomarker is to
demonstrate an in-vivo pathology that can be observed at various stages of the disease including
the prodromal asymptomatic phase. This would allow the biomarker to be used for diagnosis and
likelihood of disease progression. The primary markers for AD are based on the key pathologies:
amyloid

deposition,

NFT,

oxidative

stress,

neuroinflammation,

neurodegeneration,

hypometabolism, BBB integrity, perfusion status, brain atrophy and WMH. These biomarkers are
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grouped into factors in blood and CSF, and neuroimaging markers371–373. Genetic screening for
causative mutations associated with FAD and APOEε4 also complement diagnosis371.
Evidence of cerebral amyloid deposition can be obtained from plasma or serum and CSF. These
fluid measures can include Aβ1-42, Aβ1-40 and fibrinogen γ-chain levels371. Low levels of fluid
Aβ are suggestive of increased brain amyloid accumulation. The presence of fibrillar amyloid
plaque and amyloid angiopathy can also be detected using PET with the 11C-Pittsburg component
B tracer (Pi-B). Elevated concentration of total (t-tau) and phosphorylated tau (p-tau) protein
measured in blood or CSF are also associated with the ongoing neurodegenerative process. It is
recommended to use amyloid and tau markers in combination to increase level of information and
accuracy366. Thus, a combination of these proteins in a CSF Aβ1-42/t-tau ratio showed a high
specificity and sensitivity as a marker371. Amyloid PET scans have shown to be good at predicting
progression to AD from MCI and are used in parallel with or to back up fluid amyloid level
markers.
Inflammation and oxidative stress are two critical processes that are present from the very initial
prodromal stages of AD, preceding protein pathologies and are promising therapeutic targets.
These events can be detected using both fluid analysis and PET imaging technology. The PET
imaging utilizes radiological tracers for the detection of specific proteins largely expressed by
activated cells374. These biomarkers can be a key to treatment management and disease assessment.
PET imaging of both microglia and astrocytes, uses tracers for a highly specific microglia 18 kDa
translocator protein (TSPO) and less specific astrocytic monoamine oxidase B inhibitor (MAOB)375. Increased concentration of cytokines in blood and CSF, including c-reactive protein (CRP),
IL-6, TNF-α, or microglia associated proteins (e.g. TREM2 receptor) have also been shown to
reflect neuroinflammatory status372. Specific markers of brain oxidative stress, including lipid
peroxidation products (oxysterols), can be detected in blood or urine with chromatography or mass
spectrometry376.
Clinically, biomarkers that can be detected in blood receive a great deal of attention since they are
easily obtainable using minimally invasive and potentially more widely affordable methods. A
recent study examined plasma metabolites to identify novel diagnostic markers and reported a
group of 24 metabolites associated with preclinical LOAD373. Neurofilament light chain is another
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promising marker of disease progression. It is specifically associated with degeneration of
myelinated axons and can be measured in plasma or serum as well as in CSF372,377,378. Elevated
levels and increased rates of change of neurofilament light chain in prodromal FAD were shown
to be predictive of a faster symptomatic onset and highly correlated with cortical thinning 377. AD
patients also have significantly elevated levels compared to MCI and healthy individuals
suggesting there is a correlation with cognitive deficits378. Another group of blood-derived
biomarkers are autoantibodies against various neuronal proteins involved in inflammation,
vascular and metabolic alterations that can be observed at various pathological stages of the
disease369.
BBB integrity is compromised in early stages of AD and is independent of changes in amyloid or
tau pathology. Permeability of BBB can be assessed with dynamic MRI with contrast agent and
CSF-serum albumin ratio250. Microvascular damage, particularly in the hippocampal region is
related to early AD and is detected in the CSF using a capillary pericyte loss marker that is a
soluble platelet-derived growth factor receptor-β. Cerebral hypoperfusion is associated with the
pathology of AD can be detected using single-photon emission computed tomography (SPECT)
imaging. Another marker of late stage neurodegeneration is hypometabolism in temporoparietal
regions and is associated with synaptic dysfunction that is detectable on PET images with a
fluorodeoxyglucose ligand (18FDG). However, these markers are evidence of the ongoing
advanced stage and lack specificity.
MRI provides information on structural changes of the brain. Atrophy of the hippocampal
formation and medial temporal and parietal lobes seen on MRI scans is a proven marker of
progression to AD dementia. However, this atrophy is usually suggestive of a more advanced stage
of the disease marked by neurodegeneration379. MRI fluid attenuated inversion recovery (FLAIR)
and T2-sequencing are able to detect WMH that are commonly present in AD and MCI and have
been shown to highly correlate with cognitive decline108,316,318,380. Of great interest is the clinical
finding that WMH, leukoaraiosis volume, specifically in the parietal and occipital lobe, tend to be
present a couple of decades before symptoms of cognitive deterioration start to appear308,310,316 and
suggest they are promising biomarkers of early disease stages for MCI and subsequent conversion
to AD.
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Although, often seen in AD, WMH are not specific to AD pathology. Thus, the exploration of
WMH as a biomarker should be extended beyond the absence and presence, and look deeper at
the underlying WMH pathology specifically associated with AD. The neuropathology of white
matter abnormalities still remains not fully understood and is mainly attributed to cerebral small
vessel degeneration, inflammatory events, as well as loss of myelin and axonal fibers252–254,311.
Inflammation, as an early process in AD pathogenesis, might be also developing in the white
matter. Markers specific to white matter inflammation including imaging and fluid-derived
approaches should be studied. A high level of peripheral inflammatory cytokine IL-8 in the serum
was shown to be related to WMH in AD and this further suggests an inflammatory basis of
leukaraiosis381.
A high priority is the detection of MCI in the elderly population and in particular those individuals
likely to convert to dementia. The best predictors of conversion from MCI to AD are hippocampal
volume and levels of p-tau in the CSF. In addition, these measures in combination with CSF Aβ142 or blood phospholipids levels provide the highest predictive power61,371,382–385. Progression of
an increase rate in WMH volume is a predictor of both conversion from a healthy brain to MCI
and from MCI to dementia due to AD of either a vascular or mixed pathology386,387.
Some of the biomarkers discussed above can show relatively high specificity and accuracy,
although they also have certain limitations. None of them are widely accessible or have been
clinically validated, standardized or approved. They are generally recommended for use only for
research purposes41,42,61,367. Most of the diagnostic biomarkers reflect an advanced pathology and
likely have limited relevance to potential disease treatment. Most of prognostic biomarkers are
usually predictive of a conversion in cases that are already symptomatic. Comorbid conditions
including chronic metabolic and vascular diseases, age, gender and belonging to a specific ethnic
group may modulate the relationship of the markers to AD or MCI pathologies or change the
specificity and sensitivity of some biomarkers, suggesting that extensive investigations in this area
are required.
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1.2.7 Treatment Strategies for Alzheimer’s Disease
Currently there is no available treatment to stop AD progression and cure the disease. However,
there are few approved treatment agents available for symptomatic relief43,58,165,388. One of the
drugs approved for use in mild to moderate AD cases belong to the group of reversible
acetylcholinesterase inhibitors including donepezil, rivastigmine, and galantamine389–391. The
mechanism of action of these drugs is a prolongation of neurotransmitter ACh lifetime and its
action at synapses, facilitating cholinergic transmission392. With the progression of pathological
processes into more advanced stages of neurodegeneration and loss of neuronal synapses, these
drugs lose their ability to improve cognitive deficits.
Another agent proven beneficial in patients with mild to moderate disease stages is cerebrolysin,
an agent that mimics properties of neurotrophic factors393. Memantine, a glutaminergic N-methylD-aspartate (NMDA) receptor antagonist, is an approved pharmacological agent for moderate to
severe AD dementia394. Beneficial effects on cognition are thought to be related to its ability to
reduce excessive stimulation of cortical and hippocampal neurons by glutamate via calcium cell
entry reduction and diminish cell apoptosis and also increase long-term synaptic potentiation
associated with memory formation. While the drugs described above show some benefit in overt
AD, few or none were found to be of use in MCI395. The final class of drugs that is prescribed are
antidepressants used to alleviate psychiatric and behavioral symptoms of AD patients, including
depression, anxiety and agitation. However, their use provides very modest beneficial effect and
is associated with increased cerebrovascular complications and mortality, therefore their inclusion
in clinical practice should be done with great caution165.
With the increased evidence for the association between AD and metabolic disorder, including
T2DM and MetS, drugs used in the treatment plan of these disorders is receiving greater attention.
The peroxisome proliferator activated receptor γ (PPARγ) agonists pioglitazone and rosiglitazone,
which are conventional T2DM drugs, did not demonstrate any benefit over placebo in randomized
clinical trials (RCT) when used in mild to moderate AD396,397. A pilot study on insulin sensitizing
via intranasal insulin administration have shown beneficial effects in early AD398. RCT on the
potential for nasal insulin therapy has recently ended in 2018 and results are pending. Statins or 3hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (e.g. pravastatin,
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simvastatin, atorvastatin) demonstrated no positive effects in preventing cognitive deterioration in
the elderly399,400. Nilvadipine, a calcium channel blocker, is widely used for the management of
hypertension, showed promising results preclinically, however, there was no benefit in patients
with mild-to-moderate AD401.
Currently, experimental pathology-modulating treatments are being increasingly developed388,402.
The main preclinical and clinical research directions are chosen based on the key AD pathologies
– amyloid and tau pathology, inflammation and oxidative stress403.
Inhibition of β- (BACE) or γ-secretase and promotion of α-secretase activity are the key ways to
reduce Aβ production and accumulation404. Treatment agents with such mechanism of action have
failed to show beneficial effects in clinical trials, although clinical trials on several new agents
inhibiting BACE activity are ongoing403,405. Vaccination with Aβ42 or passive immunization with
antibodies against Aβ as well as intravenous gamma globulin which can promote clearance of
amyloid from the brain, have also been studied. Although, this approach led to cognitive
improvement in early trials, it did not stop further decline and, moreover, was associated with
serious adverse effects406–408. However, immunization against amyloid is being further
investigated and a few antibodies, including crenezumab, gantenerumab, and aducanumab, are
currently in phase II-III clinical trials involving early and mild AD stages403.
Another way to interfere with the amyloid aggregation pathway is based on soluble Aβ42 binding
reducing oligomerization and subsequent deposition. A small glycosaminoglycan-like molecule,
Tramiprosate, with this mechanism of action failed to show clinical efficacy in a phase III clinical
trial, although it unexpectedly showed benefits in APOE4 carriers409–411.
Modulation of tau proteinopathy can be achieved by tau phosphorylation inhibitors, prevention of
aggregation, microtubule stabilization or active immunization403. The tau aggregation inhibitor,
TRx0237, is currently in a phase III clinical trial in mild AD patients. Other trials completed with
this agent produced negative results or indicated a high rate of side effects incompatible with a
clinical use of these drugs403. Tau immunization is also currently under clinical testing.
Another pathway of intervention is enhancement of the brain serotonergic system, which is
disturbed in the AD and greatly contributes to behavioral and also cognitive symptoms of the
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disease, using 5-HT6 serotonin receptor antagonists (e.g. intepirdine) which is currently being
clinically tested for mild-to-moderate AD treatment412–414.
The strategies to reduce oxidative stress associated with AD pathology throughout the entire course
of the disease and particularly at the early prodromal stages, can include the use of the natural or
human-made antioxidants and modulation of oxidative-inflammatory pathways. Antioxidants
comprise a large group of natural or synthesized substances able to reduce cell damage by free
radicals due to oxidative stress415. Vegetables and fruits are enriched with these substances and
when included in the diet are thought to be beneficial for mental health. Epidemiological studies
suggested a positive effect of such diets with natural substances or supplements with antioxidant
properties. These studies examined the impact of antioxidants on cognitive function and lowering
the risk for dementia. The preclinical research demonstrated the capability of antioxidants to
reduce cellular pathology and improve cognitive outcome, however, clinical research indicated a
questionable benefit and even opposite effects415–419.
One trial with an antioxidant indicated that patients with probable AD benefitted cognitively from
the N-acetylcysteine supplement420. Trials with resveratrol and curcumin have produced either
mild positive or neutral results402,421. However, a combination of antioxidants including vitamins
C, E, α-lipoic acid and coenzyme Q3 in an RCT involving patients with mild-to-moderate stages
of AD raised the concern that there might be a faster cognitive decline despite lower levels of
selective, but not all CSF, markers of oxidative stress422.
Targeting neuroinflammation appears to be one of the most promising approaches to slowing or
preventing some forms of dementia, including AD, since it has been shown to be one of the earliest
processes related to the disease pathogenesis. Epidemiological, neuropathological and animal
studies have shown a long-term treatment with NSAIDs that inhibit cyclooxygenase (COX)
activity, either selectively (COX2) or non-selectively, and that reduce the synthesis of
prostaglandins, are associated with a reduced risk of AD

265,423–436

. However, clinical trials with

NSAIDs have produced controversial results with some studies reporting positive effects and
others indicating no significant cognitive improvement in MCI and AD425,427,437–447.
It appears that with NSAID treatment, an absence of initial cognitive symptoms and earlier
intervention were the factors defining success of the study. It is likely, that initiation of NSAIDs
27

treatment prior to major pathology development (i.e. very early stages) of the disease and in
asymptomatic phase might have a potential to prevent or slow down the progression and delay
clinical onset of AD424,425,437,439,443. Thus, NSAIDs can be viewed as a preventive measure rather
than a treatment per se. However, there are clinical reports with evidence of serious adverse
cardiovascular and cerebrovascular effects using this group of drugs irrespective of the selectivity
of the NSAID, although the COX-2 selective drugs appeared more implicated in the adverse effects
438,448–463

.

Based on these mixed results, of great importance is the question of the safety of these agents in
the general population as well as those with concurrent vascular or metabolic diseases such as
T2DM and MetS. This latter group are in a high-risk group for vascular complications and may
already have cardiovascular diagnoses and/or cerebrovascular history448,451. Further studies
carefully investigating the exact conditions of the treatment, including the timing, dosage and
duration and determining overall safety are required to understand the treatment potential of this
large class of agents. Innovative drug design to enhance delivery to the brain to allow the use of
lower doses and to minimize of adverse effects are needed.
Aspirin is another drug with COX enzyme inhibiting properties, was also shown to modulate
oxidative and inflammatory pathology preclinically464,465. However, no positive effects were seen
in clinical trials and the treatment was also associated with increased risk of cerebrovascular
events440,466.
Experimental anti-inflammatory drug treatment is being continuously examined in preclinical
research and the research yields results supportive of the anti-inflammatory hypothesis of AD risk
reduction. Novel NSAIDs, as well as drug agents form various other classes have been tested467.
Some promising treatments such as CHF 5074, a modulator of microglial activation profile
towards the M2 phenotype, have proceeded to the clinical trials for MCI. Unfortunately, this drug
did not show statistically significant cognitive improvement468,469.
Inhibitors of RAGE, which is a critical component of the inflammatory pathway, including PF04494700 and Azeliragon, were proposed as therapeutic agents for AD and again failed in clinical
trials470. Triflusal, a platelet aggregation inhibitor, has shown good results in preclinical models
and treatment delayed progression of MCI to AD in one clinical study465,471–473. The drugs targeting
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TNF-α such as etanercept infliximab have shown positive cognitive dynamics in mild – to – severe
AD cases474–479. Minocycline, a tetracycline antibiotic able to cross the BBB, has been increasingly
reported to have good anti-inflammatory and anti-oxidant effects with positive effects on amyloid
and tau-pathology in preclinical models mainly via inhibition of the NF-κB and MAPK
pathways480–483. Furthermore, this agent is associated with the white matter protection, which in
light of the early stage pathology and cognitive function relationship of white matter inflammation
to AD, is extremely relevant and favorable484,485.
In conclusion, nearly all proposed treatment strategies for AD failed in clinical trials likely due to
the use of agents at the advanced stage of the disease when pathology is too severe and likely
irreversible. Thus, it is important to focus on the early stages of the disease, shifting the focus from
advanced pathologies to that presented at the prodromal stage, a few decades before the clinical
onset, and at stage correlating with cognitive deficits due to white matter disease (i.e. WMH) and
its specific pathology486.
Moreover, in many cases dementia is not the only disease present in these patients, and other
chronic pathologies, such as vascular and metabolic diseases, contribute to the mixed pathology
underlying cognitive decline, and consequently can influence the success in treating dementia.
Many of these other chronic disorders begin in individual’s middle age and develop progressively
over time eventually manifesting in a serious condition long after the initial signs. Thus, it is
reasonable for prevention strategies to take into account the impact of coexisting disorders. It is
important to explore the potential roles of those conditions that are risk factors for dementia and
investigate mechanisms of shared pathological conditions simultaneously presenting with
dementia. Reducing risk factors for the diseases including lifestyle modification and early
prevention with drugs appears to be of great importance and should be pursued. Moreover, stable
control over comorbid disorders should be achieved to increase the positive outcome of the
treatment for dementia. A combination therapeutic approach that targets multiple links in the
disease pathophysiological chain might be beneficial and should be seriously investigated.
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1.3 Metabolic Vascular Disorders
1.3.1 Comorbidities of Alzheimer’s Disease: Focus on Metabolic Syndrome
Vascular metabolic conditions, such as T2DM and MetS, which represent risk factors for dementia
including AD, develop in midlife and very often lead to the development of serious cardio- and
cerebrovascular complications including myocardial infarction and stroke. Furthermore, these
diseases accumulate with aging and are common comorbidities of AD. Increasing attention is paid
to the interplay of AD with MetS due to the extreme prevalence of MetS in the elderly. MetS is
also a precursor condition for the major cardiovascular diseases and T2DM and is highly
modifiable in its nature.
Epidemiological and clinical studies strongly suggest the existence of an interaction between MetS
and AD and a possible synergistic or additive effect on cognitive outcomes when these pathologies
are simultaneously present14,35. Individuals with MetS show a greater risk for developing MCI and
AD later in life and AD patients tend to have a worse cognitive outcome and a faster progression
or conversion to AD when MetS is also present28,29,129,134,138,487–497. Experimental data from studies
using rodent comorbid models of overt AD and diet-induced obesity and metabolic changes yield
evidence of poor performance in cognitive tasks and increased AD-like pathology109,188,498–504. A
common gene, APOE, is implicated in the development of both AD and MetS, further suggesting
a possible link between them505.
While cerebrovascular comorbidities with AD, such as brain infarcts or strokes, are strongly and
consistently associated with amplified cognitive impairment506,507, the association between MetS
and AD appears to be less consistent. The complex interaction seems to be influenced by the age
of the study participants14,508. Younger groups with age <70 years show a greater risk of AD
development, whereas studies including older persons (>75-80 years) consistently report an
inverse association of obesity and MCI, in which there is a slower progression and a better
cognitive performance in comorbid demented subjects, suggesting a beneficial effect of the
presence of metabolic changes34,509–512.
It is possible that metabolic alterations interacting with cerebral homeostasis changes with age and
with the development of the pathological processes. In addition, it might be that the age at which
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vascular metabolic dysfunctions develop is a crucial factor which determines the effects on the
cognitive function. The number of physiological and metabolic changes and their combination
within the MetS cluster might further complicate the relationship between MetS as a whole and
AD. Some changes may be individually related to AD risk in the same or opposite way, and the
relationship may depend on the severity of the change. Further studies are needed to unravel the
interactions between the two diseases, particularly investigating the early prodromal stages of AD
where there is a greater possibility for treatment and prevention.

1.3.2 Diagnosis of Metabolic Syndrome
MetS is a cluster of components including central (i.e. abdominal) obesity, hypertension, insulin
resistance, pre-diabetes (elevated blood glucose levels and glucose intolerance), diabetes and
dyslipidemia (elevated triglycerides and reduced high-density lipoprotein (HDL) cholesterol)8,10.
Central obesity is defined by measures of BMI, waist circumference or waist/hip ratio
measurements. Criteria for MetS diagnosis vary slightly related to test-specific values and
measurements of obesity and glucose metabolism, depending on the organization, but it always
requires a combination of 3 conditions8. The most commonly used criteria from the World health
organization (WHO) proposed in 1999, requires the presence of insulin resistance with glucose
intolerance based on the 2h oral glucose tolerance test (OGTT) along with any two or more
abnormalities (i.e. high triglycerides, low HDL cholesterol, raised blood pressure or obesity).
The Third Adults Treatment Panel National Cholesterol Education Program (NCEP) ATP3 criteria
from 2005 diagnoses MetS based on the presence of any three or more components from the five
identified previously. The International Diabetes Federation (IDF) 2006 guidelines include central
obesity and the presence of two or more components. The last two organizations do not use OGTT,
but include raised fasting blood glucose or hypoglycemic treatment and additionally diagnosed
T2DM in IDF.
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1.3.3 Risk Factors of Metabolic Syndrome
Modern lifestyle plays a big role in the etiology of obesity and MetS with a significant contribution
from poor eating habits, particularly chronic consumption of high calorie Western diets
characterized by high intake of saturated fat, simple carbohydrates (especially fructose) and salt,
coupled with physical inactivity6,513–517. While environmental factors seem to be the main drivers
of the disease, genetic predisposition to intra-abdominal fat accumulation, increased BMI, obesity,
insulin resistance and dyslipidemia also contribute8,513,518. The role of parental obesity, intrauterine
environment, maternal habits, diseases affecting fetal development and the postnatal environment
are also recognized8. The development of MetS also increases with increasing age519–521.

1.3.4 Clinical Presentation and Pathophysiology of Metabolic Syndrome
Central or abdominal obesity is a core element of MetS. Obesity is a condition characterized by an
excessive fat accumulation, especially around the internal organs (visceral fat), which is a highly
metabolically active tissue contributing to systemic metabolic, vascular perturbations and
development of chronic low-grade inflammation513,515,522–524. However, metabolically normal
obese persons do not develop the syndrome, and MetS can be diagnosed without obesity, thus
emphasizing that metabolically active visceral fat rather than subcutaneous fat increase is
required518. Increased visceral adiposity is one of the major causes of insulin resistance which is
characterized by the reduced sensitivity of cells to the actions of insulin such as glucose uptake
and utilization, thus, leading to hyperglycemia and compensatory hyperinsulinemia (i.e. high blood
levels of glucose and insulin)6,525. The main tissues developing insulin insensitivity are adipose
tissue, liver and muscle. Exposure to the high levels of abdominal fat-secreted free fatty acids is
thought to play a major role in the development of insulin resistance which in turn promotes fat
accumulation creating a vicious cycle. Moreover, insulin resistance plays a major role in
development of the pathologies that constitute MetS and defines its clinical presentation515.
Insulin resistance promotes lipolysis in adipocytes resulting in elevation of free fatty acid levels
that further interferes with the lipid metabolism. Abnormalities in lipid metabolism, or
dyslipidemia, include an increase in total cholesterol, cholesterol atherogenic fractions such as
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low-density lipoprotein (LDL), very low-density lipoprotein (VLDL) particles and decrease in
antiatherogenic high- density lipoproteins (HDL) and elevated triglycerides level515.
Insulin resistance and associated hyperinsulinemia and hyperglycemia are linked to the
development of vascular insulin resistance directly associated with endothelial dysfunction,
vascular reactivity change, oxidative and inflammatory damage exacerbated by elevated
circulatory cytokines6. These changes create a prothrombotic environment which together with
atherosclerosis promoted by dyslipidemia and associated inflammation increases the risk for
cardio- and cerebrovascular diseases. These conditions along with hyperactivation of the reninangiotensin system and sympathetic nervous system by the insulin resistant state also leads to the
development of hypertension518.
Obesity is associated with increased NF-κB-mediated secretions of pro-inflammatory cytokines
including interleukins IL-1 and IL-6, TNF-α and CRP by metabolic cells. These cytokines are
triggered by excess consumption of nutrients, high caloric intake, particularly saturated free fatty
acids and simple carbohydrates (e.g. fructose, glucose), leading to increased systemic
inflammation that can affect multiple organs (primarily adipose tissue, liver, pancreas, muscle,
gastrointestinal tract and brain)524,526–531. Adipocytokines including leptin, adiponectin and resistin
secreted by adipose tissue are important regulators of energy intake, appetite, satiety, body weight,
lipid and glucose metabolism and modulators of inflammation518,532. In morbid obesity there is
leptin resistance with an increase in leptin production linked to hypertensive and pro-inflammatory
actions and decreased levels of adiponectin associated with antiatherogenic and anti-inflammatory
effects.
MetS has deleterious effects throughout the whole body leading to many complications including
cardiovascular pathology, retinopathy, nephropathy, non-alcoholic fatty liver disease, skin
conditions, problems with the reproductive system and sleep and breathing disorders515. The CNS
is not an exception and has complications, confirmed by a growing body of evidence of brain
insulin resistance and its neural consequences38,178. Chronic long-term development of these
metabolic abnormalities is 5 times more likely to manifest as T2DM. The real hidden danger of
MetS is that individuals with this condition are largely asymptomatic for a long period of time, but
have a 2-fold increase in cardiovascular disease over the next 5 -10 years and have a 2- to 4-
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increased risk of stroke, myocardial infarction and certain cancers resulting in a large contribution
to mortality518,532.

1.3.5 Cognitive Function in Metabolic Syndrome
Obesity and MetS developed during midlife are involved in the perturbation of cognitive function
and are associated with global cognitive decline16,533–536. The relationship of MetS and cognitive
function are not mediated by a single individual component, but rather several components
separately or in combination. Individuals with MetS show poorer scores on the mini-mental state
examination (MMSE) measuring general cognitive ability, Raven’s progressive matrixes (RPM)
for fluid intelligence assessment, memory assessing cognitive-affective verbal learning test
(AVLT), impaired reasoning and executive functioning (e.g. on the Wisconsin Card Sorting Test,
including working memory and attentional set shifting), decreased information processing speed
and complex attention deficits135,491,537,538. Executive functioning as well as informational
processing speed and verbal memory were the most frequently impaired cognitive domains533. As
indicated above, it is interesting that older old adults, >85 years old, showed a better cognitive
performance when metabolic components were present34.

1.3.6 Neuropathology of Metabolic Syndrome
Obesity and MetS affect CNS homeostasis through multiple mechanism although it is mainly via
neuroinflammation, insulin resistance and vascular abnormalities, with effects on both gray and
white matter539–541. The hypothalamus, especially the mediobasal region, which is a key
neuroendocrine regulator of a large number of processes in the body including thermoregulation,
appetite and body weight, is the most vulnerable brain structure to the vascular metabolic
disturbances associated with MetS531.

However, other cerebral structures such as the

hippocampus, neocortex, brainstem, amygdala, cerebellum and choroid plexus show pathological
changes during the course of the disease531. In clinical studies, obesity has been associated with
frontal and temporal brain atrophy, white matter alterations, frontal and prefrontal metabolic
changes and reduced blood flow in a large cortical area, resulting in decreased cognitive
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performance independent from the cardio- and cerebrovascular conditions534,542,543. MetS has also
been associated with a greater incidence of silent brain infarcts that also might contribute to
cognitive deficits544.
The results of animal studies with Western high-fat, high-sugar diet induced obesity and MetS
have supported the negative relation of the syndrome to learning and memory, particularly
hippocampal dependent memory. These learning and memory deficits appear to be mediated by
increased vascular and oxidative-inflammatory damage to the hippocampus, decreased neuronal
plasticity and long-term potentiation and BDNF levels

16,18,107,109,187,188,499,500,535,545–559

. Insulin

resistance, hyerinsulinemia, hyperglycemia and dyslipidemia can all affect the cerebrovasculature,
induce oxidative stress and inflammation and modulate tau and amyloid metabolism promoting
peptide accumulation, leading to cognitive impairment135,190,504,536,539,541,555,560–563.

1.3.6.1 Neuroinflammation in Metabolic Syndrome
One of the central mechanisms mediating MetS effects in the brain is neuroinflammation. The
proinflammatory JNK and IKKβ/NFkB pathway appears to be upregulated in the hypothalamus
and linked to energy imbalance, promoting obesity, as well as brain leptin and insulin resistance564–
567

. High-fat diets in animals, commonly used to model obesity-related metabolic alterations, and

increased consumption of the simple sugar fructose have been shown to increase microglial
infiltration in the hypothalamic arcuate nucleus. The microglia are thought to be attracted and
activated by circulating cytokines, immune cells, saturated fatty acid build up, hyperglycemia,
thus, initiating local inflammatory reaction and recruiting astrocytes526,527,568–570. It has been
suggested that hypothalamic reactive gliosis, cytokine release and inflammation induce local
synaptic dysfunction and neuronal damage, thus affecting outputs to the brain structures linked
with the hypothalamus including the hippocampus and amygdala. These brain regions contribute
to the disease progression inducing neurodegeneration and cognitive decline107,531,548,571.
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1.3.6.2 White Matter Changes in Metabolic Syndrome
MetS, and obesity in particular, are associated with reduced white matter volume and disrupted
microstructural integrity with both axonal and myelin alterations, especially in the corpus
callosum, cingulum, external capsule, corona radiata, internal capsule and fornix542,572–580. These
areas contribute to the development of cognitive dysfunction and in particular executive
dysfunction

318,534,581,582

. Alterations to the white matter connecting frontal and temporal, limbic

structures and prefrontal regions are observed576,577. WMH and lacunar infarcts are also found in
individuals with MetS, particularly temporoparietal regions which show an increased
vulnerability108,583–588.

1.3.7 Treatment Strategies for Metabolic Syndrome
Lifestyle modification is a very effective preventive approach to the development of MetS. It
includes changes in dietary habits, caloric restriction and regular exercise589. Pharmacological
treatment is implemented to manage individual pathological conditions in MetS when preventive
measures are not sufficient6,515,518,590. Weight loss medications include appetite suppression (e.g.
phentermine, sibutramine) and nutrient absorption reducing (e.g. orlistat) agents. Bariatric surgery
which is aimed to reduce the gastric volume is used in extreme cases of obesity in which there are
additional health complications. Dyslipidemia can be controlled with statins, fibrates, cholesterol
absorption inhibitors and bile acid sequestrants590. Angiotensin converting enzyme inhibitors and
angiotensin receptor blockers are commonly used as blood pressure regulating drugs. Glycemic
control can be achieved with the use of anti-diabetic drugs such as metformin, thiazolidinediones,
acarbose. Some of these drugs are able to act on multiple pathological units. Administration of
aspirin is commonly used to reduce risk of thrombosis and linked vascular events.
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1.4 Interaction of Alzheimer’s Disease and Metabolic Syndrome
AD and MetS share multiple pathological features, including neuroinflammation, oxidative stress,
alterations to the BBB, cerebrovasculature pathology, cerebral hypoperfusion, brain insulin
resistance, and gray and white matter abnormalities176,562,591–597. These processes are also tightly
related to the mechanisms of amyloid and tau production and degradation598.
Neuroinflammation is a key pathological event developing at the prodromal stage of AD and drives
the progression of the disease205,207,208,257,260. MetS is a chronic low-grade inflammatory disease
which primarily originates from the visceral adipose tissue

513,515,522–524

and is one of the major

causes of peripheral and brain insulin resistance which, in turn drives the clinical manifestation of
MetS which can include cognitive dysfunction6,525,529,591,599–604.
Systemic inflammation, such as that occurring in obesity and MetS, can modulate CNS
inflammatory system and this interaction can have a high impact on cognitive function504,605–608.
Resident microglia and macrophages respond to peripheral immune signals with increased
cytokine production initiating a neuroinflammatory cascade. The peripheral immune signals such
as pro-inflammatory cytokines and chemokines, can include ILs and TNF-α, and act via nondisrupted NVU and circumventricular organs that lack a BBB as well as by neural afferent
pathways609. Leukocytes, peripheral immune cells, have been shown to enter the CNS and
aggravate gliosis contributing to neuroinflammation599,610.
These observations suggest that neuroinflammation might be a potential early stage event linking
these two chronic disorders which can further modulate AD-related pathology591,611–617.
Modulation of brain amyloid metabolism in MetS has been suggested to be mediated by reduced
degradation and clearance and increased production of Aβ. The amyloid changes are associated
with effects of inflammation (i.e. TNFα), insulin (inhibition of insulin degrading enzyme), soluble
LRP and leptin resistance190,618–620. Furthermore, APP is expressed not only in the brain, but in the
peripheral tissues including adipose tissue, intestines and its expression is upregulated in
obesity32,621,622. Aβ produced on site in these peripheral tissues in increased quantities can enter
the blood circulation and can enter the brain contributing to the cerebral pathology and promoting
neuroinflammation623.

37

Systemic low-grade inflammation in MetS is associated with a high circulating levels of CRP,
lipopolysaccharide binding protein (LBP) and α1-antichymotrypsin. This low-grade inflammation
is highly correlated with cognitive impairment, particularly cognitive flexibility, working memory
and attentional set shifting (i.e. executive functioning) in obese subjects and the effects appear to
be independent from the major cerebrovascular diseases538,624–627. These effects on cognitive
performance are thought to be mediated by white matter abnormalities observed in these
subjects584,586,587,624,628. Cerebral white matter lesions are also common in AD and have been shown
to highly correlate with cognitive decline. Thus, white matter abnormalities represent another point
of interaction between these comorbidities which seems to be intimately linked to inflammatory
processes108,313–320,380.
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1.5 Rational and Objectives
AD and MetS are both serious disorders affecting a large elderly population worldwide. These
conditions coexist in the population and it is likely they interact contributing to the course and
progression of AD-pathology and cognitive decline and influence the success of experimentally
tested treatments. However, the exact underlying processes of this interaction remain
unclear14,28,29,134,138,487–489,491,493–497. Neuroinflammation, mainly driven by microglia and astrocyte
activation, is a key pathological event developing at the prodromal stage of AD and a primary
cause of disease progression207,208,257.
AD is also a white matter disease with abnormalities in major fiber tracts including glial activation.
This white matter pathology is present well before symptomatic onset of AD and highlights the
potential of cerebral white matter lesions as a new biomarker of cognitive impairment in MCI and
AD and a possible target for prevention and early therapy307,308,310,311,316.
MetS is a chronic systemic inflammatory condition and is also associated with neuroinflammation
and white matter changes, which appear to contribute to cognitive impairment319,531,538,564,624–628.
Furthermore, aging which is highly associated with white matter alterations and increased risk of
AD preceded by white matter lesions, also is associated with the development of metabolic
disorders313,317,519–521.
Research data suggests that aging, and particularly age-related brain neuroinflammatory
dysregulation288,289, may exacerbate existing metabolic, vascular and neuroinflammatory
conditions and aggravate white matter degeneration629–632. Thus, it is likely that an early interaction
between the comorbid conditions of preclinical AD and MetS is mediated though the white matter
inflammation occurring at prodromal stage of AD. This represents a critical area for research and
deserves a great attention and requires extensive investigations. In order to conduct these types of
investigations, there is a demand for comorbid preclinical animal models. Development of just
such a model was a part of this work.
In these investigations a high calorie high-fat, high sugar diet-induced MetS was combined with
an APP21 transgenic rat model of prodromal Aβ plaque-negative AD 633–637. This comorbid model
was studied to test the research hypothesis. The hypothesis is that the comorbid condition of
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preclinical AD and MetS will result in increased white matter inflammation and cognitive
dysfunction which can be prevented by anti-inflammatory treatment. The following objectives
were addressed:
1) To determine the impact of comorbid metabolic abnormalities (MetS) and increased pathogenic
APP environment on white matter neuroinflammation, specifically on microglia and astrocytes,
and on cognitive function; thus, defining possible targets for early therapeutic intervention
(Chapter 2).
2) To examine the therapeutic potential of a brain targeted anti-inflammatory agent by examining
the effect of the drug on the increased white matter inflammation and cognitive deficits in the
comorbid model of prodromal AD and MetS (Chapter 3).
3) To analyze the possible negative effects of a brain targeted anti-inflammatory agent tested as a
potential therapeutic strategy to target increased white matter inflammation (Chapter 4).
4) To identify potential biomarkers of white matter inflammation by characterizing the
relationship between the white matter inflammation and the observed systemic metabolic and
physiological parameters (Chapter 5).
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Chapter 2: Comorbidity of Prodromal Alzheimer’s Disease and Metabolic
Syndrome in the APP21 Transgenic Rat
The aim of this study was to investigate the impact of the comorbid conditions of MetS and
prodromal AD (TG for hAPP) on white matter neuroinflammation and on cognitive function
(Objective 1). The manuscript for this investigation is currently under review for Journal of
Neuroinflammation.

2.1 Introduction
Among age-related diseases, dementias are particular serious given their prevalence, severity and
progressive and incurable characteristics. Alzheimer's disease (AD) is the most commonly
diagnosed form of dementia. The accumulation of amyloid-β peptide (Aβ), produced through an
altered cleavage of amyloid precursor protein (APP), and formation of neurofibrillary tangles are
considered to be the hallmarks of AD 1. The processes associated with the development of AD
include glial activation, excessive neuroinflammation and oxidative stress, as well as vascular and
metabolic abnormalities 1,2. AD is a disease impacting both the gray and white matter of the brain.
While changes to the gray matter in the pathogenesis of AD are well known and continued to be
heavily investigated, the neuropathology of white matter abnormalities still remains not fully
understood and is mainly attributed to cerebral small vessel degeneration, inflammatory events, as
well as loss of myelin and axonal fibers 3–6. However, white matter changes have been shown to
develop very early, in prodromal phase and precede the onset of clinical symptoms of dementia,
highlighting the importance of their further investigation7,8.
The complex etiology and pathology of AD alone remains a focus of research, but increasing
attention is paid to the interplay of AD with comorbidities such as stroke and metabolic disorders
including diabetes and metabolic syndrome (MetS) 9. MetS, which is a focus of our research work,
represents a combination of conditions such as obesity, dyslipidemia, glucose intolerance, insulin
resistance and hypertension. Unhealthy lifestyle choices play a big role in etiology of MetS, with
chronic intake of high calorie Western diets rich in saturated fat and simple carbohydrates coupled
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with a sedentary lifestyle being the most common risk factors 10,11. MetS is a serious public health
issue

12

. It begins in middle age and continues to develop over time manifesting in serious

conditions such as type 2 diabetes, cardio- and cerebrovascular diseases. Moreover, it represents a
risk factor for dementia, including AD

13–16

, and often coexist with it in one individual likely

contributing to the course and progression of dementia 17.
Epidemiological and clinical studies strongly suggest the existence of an interaction between MetS
and dementia, including mild cognitive impairment (MCI) and AD. Individuals obese and
diagnosed with MetS show a greater risk for developing cognitive decline later in life 18–20 and AD
patients tend to have a poorer prognosis when MetS is also present

21

. Experimental data from

studies using rodent models of well-developed AD fed a high-fat diet yield evidence of poor
performance in cognitive tasks and increased AD-like pathology including neuroinflammation 22–
26

. In contrast to the earlier studies, our present study aimed to examine the early processes and

interactions occurring at the prodromal phase of AD using a novel transgenic model of high
cerebral amyloid levels as a predisposing environment.
Inflammation as an event associated with both dementia, including AD, and MetS has been
suggested to be one of the shared mechanisms contributing to the impaired cognition and AD-like
pathology

27–29

. In the current study, we examined the early effects of the comorbidity on the

inflammation in the white matter which is highly susceptible to pathological changes, particularly
the key cellular components of inflammatory response, microglia and astrocytes.
While there is a clear connection between metabolic diseases and AD, the exact underlying
mechanisms regarding how metabolic diseases affect mental health and contribute to the existing
neuropathology, especially at the very initial stages of their development, remain unclear. The gap
in our understanding of this interaction appears to be a limiting factor in any success in finding
effective therapeutic and preventive interventions. This highlights the importance of developing
experimental models that combine prodromal phase AD-like pathology with risk factors such as
MetS to investigate the potential of early intervention and prevention.
The present study was undertaken to better understand the relation between metabolic
abnormalities and prodromal AD dementia, particularly studying the impact on changes in white
matter inflammatory pathology and coincident cognitive deficits. The comorbidity of prodromal
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AD with MetS was examined in a novel APP21 transgenic (TG) rat model of prodromal AD 30,31
created on a Fischer 344 background which carries a human APP (hAPP) gene with Swedish and
Indiana mutations, implicated in early-onset AD. This rat has been previously shown to express
high levels of human brain APP and serum β-amyloid (Aβ1-40 and 1-42) without spontaneous Aβ
plaques deposition in brain tissue with age

32,33

. Thus, it allows us to study the early interaction

between MetS and prodromal AD-like processes in the brain in a model with AD-predisposing
conditions.
In this study we focused on the pathology of diet-induced MetS in relation to prodromal phase of
AD, specifically examining the consequences of its chronic course on the white matter
inflammation, one of the earliest and most critical events occurring in the brain in response to
insult, particularly on its key cellular players, microglia and astrocytes. In addition, we examined
the effects of diet in the prodromal AD model on behavior and cognitive function. The hypothesis
is that there would be greater white matter inflammation and cognitive deficits in the combined
model than in either condition alone.
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2.2 Methods
2.2.1 Animals
All animal handling and experimental procedures were approved by Western University Animal
Care Committee (AUP 2008-113) and were carried out in accordance with the guidelines of the
Canadian Council on Animal Care and National Institute of Health Guides for the Care and Use
of Laboratory Animals. A total of 24 male wildtype (WT) and 22 male APP21 TG Fischer 344
rats were involved in this study, and rats were assigned to experimental groups at random. APP21
TG rats overexpressed hAPP with Swedish and Indiana mutations driven by the ubiquitin-C
promoter were created via lentiviral vector method. Rats were bred in house with original breeding
pairs obtained from Drs. Yuksel Agca and Cansu Agca (University of Missouri, Colombia, MO,
USA) 30 and confirmed to be homozygous. Animals were housed in pairs under standard conditions
(12:12 light/dark cycle, at 22-24°C) and maintained on a standard rat diet provided ad libitum. At
the age of 8.5-9.5 months, half of the rats of each genotype were randomly assigned to a highcalorie Western type diet (HCD), while the other half continued on a standard diet (control diet,
CD). Diets were provided ad libitum and rats were maintained on the diets for 12 weeks. A study
timeline is shown in Figure 2-1. Body weight as well as food and drink consumption were
measured twice a week throughout the experiment. Towards the end of the experiment, there were
slight variations in the exact time for the physiological and metabolic measures since they would
interfere with the acquisition of behavioral data. Animal numbers for each experimental dietary
group were as follows: WT CD, n=12; TG CD, n=11; WT HCD, n=12; and TG HCD, n=11.

2.2.2 Diets
Rats maintained on a standard diet received chow with the following composition (in %kJ): 26
protein, 59.7 carbohydrate, and 14.3 fat with 1.52 % of saturated fatty acid (Prolab RMH 3000
5P00). The Western diet consisted of the following (in %kJ): 17 protein, 43 carbohydrate, and 40
fat with 62.4% of saturated fatty acid (D12079B, Research Diets, Inc) which included 0.21%
cholesterol. The metabolizable energy from standard and Western diet (in kJ/g) was 13.31 and
19.66, respectively. The solid food was supplemented with water in the CD group and with 20%
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corn syrup water solution in the HCD group as an additional source of calories (Bee Hive, ACH
Food Companies, Inc, USA).

2.2.3 Intraperitoneal Glucose Tolerance Test (IpGTT) and Insulin Measurement
IpGTT was performed at two weeks prior, and 11 weeks following the change in diet (Figure 21). Following a 12-h overnight fast, 100-150 microliters of blood was drawn from the saphenous
vein for determination of glucose and insulin baseline levels. A 60% glucose solution of D-(+)glucose (G 8270, Sigma-Aldrich, Inc., Saint Louis, Missouri, USA) in 0.9% saline (2g/kg) was
then injected intraperitoneally. Blood was collected from a tail vein repeatedly at 15, 30, 60, 90
and 120 minutes after the glucose load. Glucose levels (mmol/l) were measured using Freestyle
Light Blood Glucose Monitoring System (Abbott Diabetes Care Inc, Alameda, CA). Glucose
responses over time were analyzed to determine the area-under-the-curve (AUC). Fasting insulin
levels were determined in serum samples using an ELISA kit (Ultra-sensitive rat insulin ELISA
kit, Crystal Chem. Inc) according to the manufacturer’s instructions. Homeostasis model
assessment index of insulin resistance (HOMA-IR) was calculated to estimate insulin resistance
using the following formula34: HOMA-IR=(fasting glucose (mmol/l) x fasting insulin
(mmol/l)/22.5.

2.2.4 Lipid Profile Analysis
Triglycerides, total cholesterol and high-density lipoprotein (HDL) cholesterol were measured in
serum samples isolated from cardiac blood at time of euthanasia and analyzed at the Clinical
Laboratory at University Hospital (London, ON, Canada). Non- HDL cholesterol was calculated
as total cholesterol – HDL cholesterol . The cholesterol ratio (Chol:HDL ratio) was calculated by
dividing total cholesterol value by HDL cholesterol number.
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2.2.5 Blood Pressure Analysis
Systolic and diastolic arterial blood pressure were assessed three weeks before and at week 6 and
10 on the diet (Figure 2-1) via a non-invasive tail cuff method (CODA Blood Pressure System,
Kent Scientific Corp., Connecticut, USA).

2.2.6 Open Field Activity and Anxiety-like Behavior
Locomotor activity and anxiety-like behavior were tested in a square open field arena (Med
Associates Inc., St. Albans, VT, USA) over the course of 20 minutes on week 9 of the diet (Figure
2-1). Ambulatory distance and time spent in central and peripheral zones were evaluated using
Activity Monitor software, Med Associates Inc.

2.2.7 Morris Water Maze
Rats first encountered the Morris water maze test (MWM) 1 week prior to the diet onset. The
second testing (relearning) was performed 12 weeks after the diet following the same protocol, but
with a new platform location (Figure 2-1). Rats were trained to find a hidden escape platform in a
circular pool (145 cm in diameter, 58 cm in depth) filled with water, dyed with black non-toxic
acrylic paint, using extra-maze cues placed on the walls around the pool. The training protocol
consisted of 16 trials over 4 consecutive days (4 trials/day). The duration of one trial was 60 sec
with a 30-sec inter-trial period during which time the rats remained on the platform. The platform
(12cm in diameter) was placed in the middle of one of 4 virtual quadrants the pool was divided
into, and this location remained unchanged during the training phase. Start positions were
presented in a randomized order for every day of spatial acquisition. Learning progress was
assessed using time and distance required to reach the platform (actual path length) and path
efficiency (ratio of direct path length to the platform to actual path length, 1 being most efficient)
in the acquisition trials. The day after the last day of training the rats were subjected to a 30-sec
probe trial where the platform was removed from the pool and the rats were released from a novel
start position. At the end of the training and probe prior to the dietary manipulation two
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reacquisition trials in which the platform was returned to the previous position were administered
to prevent memory extinction. Performance was evaluated using such parameters as time and
distance travelled in the quadrant of a previous platform location (target quadrant) and swimming
speed. Performance was monitored using video-tracking software (ANY-maze®, Stoelting Co.,
Wood Dale, IL, USA).
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Figure 2-1. Project timeline. Rat’s age (in months) at the start (day 0) and the end (week 13) of
the study are shown in brackets. Diets were assigned on day 0 and all testing time points are in
reference to this day. Baseline measurements were completed 3 weeks prior to the start of the diet.
Morris water maze spatial training was completed on week -1 (4 days, 4 trials a day) with a probe
trial (Pr1) following on the day after. A second probe trial (Pr2) was completed on week 12 on a
diet. Learning of a new platform location started the next day following the same protocol with a
probe trial (Pr3) at the end. BP = blood pressure measurement, IpGTT = intraperitoneal glucose
tolerance test, MWM = Morris Water Maze, Pr = probe trial, OF = open field test, BC = blood
collection, TC = tissue collection, W = week.
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2.2.8 Euthanasia and Tissue Collection
Following a 12-h fasting period the rats were weighed and euthanized by a pentobarbital overdose.
Cardiac blood was collected immediately before perfusion. Epididymal fat pads were collected
and weighed. Rats were then perfused transcardially with 0.01 M phosphate buffered saline (pH
7.35) followed by 4% paraformaldehyde (PFA, pH 7.35). Brains were post-fixed in PFA overnight
and then transferred to a 30% sucrose solution until saturated fully submerged. Brains were
sectioned coronally on a cryostat into 35 μm thick sections approximately from bregma 4.70mm
to bregma -5.20mm 35, sorted into 12 series and were stored in cryoprotectant at -20°C until used
for immunohistochemistry.

2.2.9 Immunohistochemistry
Immunohistochemistry was performed on free-floating sections to visualize microglia, activated
microglia, astrocytes, neurons and synapses using rabbit polyclonal antibody against the ionized
calcium binding adaptor molecule-1 (anti-Iba-1; 1:1000; Wako Chemicals USA Inc., Richmond,
VA, USA), mouse monoclonal antibodies directed against the MHC II receptor (OX-6; 1:1000;
BD Pharmingen, Mississauga ON, Canada), glial acidic fibrillary protein (anti-GFAP; 1:2000;
Sigma-Aldrich, St Louis MO, USA), neuronal nuclei (anti-NeuN; 1:1000; EMD Millipore Corp.,
USA) and synaptophysin, a major synaptic vesicle protein, (anti- synaptophysin; 1:1000; SigmaAldrich, St Louis MO, USA), respectively. Following an overnight an incubation with the primary
antibody at 4ºC, sections were incubated with biotinylated anti-mouse or anti-rabbit secondary
antibody (1:500, Vector Laboratories, Inc. Burlingame, CA, USA) followed by incubation with
avidin-biotin complex (ABC kit, Vector Laboratories, Inc. Burlingame, CA, USA) reagent and
then developed in 0.05% 3, 3’ diaminobenzidine tetrahydrochloride (Sigma-Aldrich, St. Louis
MO, USA). Sections were then mounted on glass slides, air-dried, dehydrated, cleared in xylene
and coverslipped with DePex mounting media (DePex, BDH Chemicals, Poole, UK). Detection of
changes in white matter fiber myelination was done in sections pre-washed in 0.01M PBS mounted
on glass slides, dried overnight and stained with Luxol fast blue following the protocol described
elsewhere36.
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2.2.10 Imaging and Quantification of Immunohistochemistry
Immunohistochemically and histochemically processed brain sections were imaged at 10x
objective with a Nikon Eclipse Ni-E upright microscope with a Nikon DS Fi2 colour camera head
using NIS-Elements Imaging Software Version 4.30.02 (Nikon Instruments Inc., Melville, NY).
Brain sections stained for OX-6 and Luxol fast blue were scanned with Aperio digital entire-slide
scanner, allowing 20x magnification (Department of Pathology, Western University, London,
Ontario, Canada). Entire series of brain sections was screened for positive OX-6 signal to
determine regions of interest (ROIs) for all further analysis. Analysis and quantification were
carried out using 64-bit ImageJ software (Version 1.48u4, Wayne Rasband, National Institutes of
Health, Bethesda, MD, USA). The investigator was blinded to the identity of rats included in the
quantification analysis. Images were converted into a black-and-white 8-bit format, underwent
thresholding and were calibrated prior to taking all the measurements. Based on the location of the
positive OX-6 immunostaining being mainly in the white matter structures, the corpus callosum,
internal capsule and fimbria of the dorsal hippocampi were chosen as ROIs. A total of six regions
from three consecutive brain sections containing corpus callosum, internal capsule or fimbria were
analyzed for each animal. For the assessment of activated microglia cells (OX-6 stained) in the
corpus callosum and internal capsule, areas with positive signal were manually outlined using a
free outline tool. Integrated density, defined as a sum of the values of the pixels in the selected
area, was measured for each region and summarized into a single value per animal. To analyze
changes in general microglia population (Iba-1stained), activation of astrocytes, activated
microglia in the fimbria and myelin content, white matter tracts were manually outlined, and a
measure of the area of coverage by positive signal (percent of the total area) was noted for each
region and expressed as a weighted average. The neuronal population of the hippocampus, CA1
subregion, was visualized with NeuN immunostaining and was assessed using the NIS Elements
analysis software. In the ROI sampled from two to three coronal brain sections neuronal nuclei
were automatically counted in a selected field of 0.2 mm2 area and an average number was
generated for each animal. Synaptophysin staining was quantified in the CA1 and CA3
hippocampal subregions in a total of 8 fields per subregion, sampled from two brain sections, per
animal in the ImageJ. The area of coverage by positive signal was expressed as a weighted average.
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2.2.11 Data Analysis
Statistical analysis was performed using GraphPad Prism 6.0. Data were analyzed by performing
t-test or One-way or Two-way analysis of variance (ANOVA), followed by Tukey’s multiple
comparisons test. Data is expressed as mean ± standard error of the mean (SEM), and a p value of
≤ 0.05 was considered statistically significant.

2.3 Results
First, we performed an extensive physiological characterization of the model by analyzing body
weights, parameters of glucose and lipid metabolism and arterial blood pressure values.

2.3.1 Body Weights, Diet, Fat Accumulation, Lipid and Glucose Metabolism
Both TG and WT rats on a HCD gained weight rapidly and weighed significantly more than CD
groups as early as the first week on the diet (Figure 2-2A). Starting from week 6 on the diet, rats
from the comorbid group weighed more than the WT HCD group and this weight difference
remained significant until the end of the study. In addition, as shown in Figure 2-2B, epididymal
fat pads mass was significantly increased with HCD consumption (F(1,42)=335.9; p<0.0001), with
an even greater increase in the TG rats (genotype effect F(1,42)=11.26; p<0.0017, interaction
F(1,42)=3.769; p<0.059). Analysis of diet consumption across the 12 weeks showed a decrease in
amount of food consumed (WT CD 20±0.2, TG CD 21±0.3 vs WT HCD 9±0.2, TG HCD 11±0.4
g/day), however there was a large increase in drink consumption by rats from both HCD groups
(WT CD 23±0.7, TG CD 27±0.7 vs WT HCD 68±2.4, TG HCD 61±1.9 g/day). This resulted in a
significantly higher total energy intake in the HCD groups during the entire period of 12 weeks
(WT CD 264±3.0, TG CD 272±4.0 vs WT HCD 406±5.0, TG HCD 402±3.0 kJ/day). Based on
genetic profiles, rats had different preferences for the source of calories; TG rats favored high-fat
food, whereas WT rats had a stronger preference for carbohydrates from drink. Triglyceride levels
were significantly elevated by HCD (Figure 2-2C).
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Total cholesterol was increased in both groups on the HCD, but reached statistical significance
only in the comorbid rats compared to controls. Both TG and WT rats on the HCD had an increased
cholesterol content of atherogenic lipoprotein particles (non-HDL cholesterol; Figure 2-2D). HDL
cholesterol levels, when analyzed separately, were not different for HCD rats in comparison to the
control groups. However, the Chol:HDL ratio, a relevant clinical index, was significantly greater
in both HCD groups, indicating that these rats had a decrease in HDL cholesterol and a significant
shift towards the atherogenic Non-HDL fraction (Table 2-1).
Rats maintained on HCD did not show signs of hyperglycemia based on the fasting blood levels
of glucose (Table 2- 1). Surprisingly, a glucose intolerance pattern was observed only in WT rats
maintained on a HCD, which was characterized by a greater increase in blood glucose levels at 30
minutes after a glucose injection that remained significantly increased till the end of a 2-h period
(Figure 2-2E). This also translated into a significantly greater AUC for blood glucose. There
appeared to be no effect of diet on glucose tolerance in the TG rats and AUC was very similar to
CD group values (Table 2- 1). Fasting insulin levels were significantly higher for both WT and
TG rats from HCD groups (Figure 2-2F). Two-way ANOVA analysis revealed a significant effect
of the diet (F(1,41)=21.20; p<0.0001) in both genotypes. HOMA-IR index was significantly greater
for both WT and TG rats from hypercaloric diet groups compared to the control groups (Table 21). Nevertheless, these data suggest that HCD did not lead to the development of frank diabetes,
yet led to the manifestation of a pre-diabetic state. In contrast, the HCD had a robust effect on lipid
metabolism.

2.3.2 Blood Pressure
Systolic and diastolic blood pressure values obtained at 6 and 10 weeks of diet were not different
between the experimental groups, indicating that no animal group showed signs of hypertension
due to dietary intervention or genotype (Figure 2-3). Additional analysis of the pressure changes
with age and diet within individual groups indicated a decrease in systolic (week 6 p=0.0025; week
10 p=0.0011) and diastolic (week 10 p=0.131) pressure levels of TG HCD rats from the baseline
(week -3) levels. HCD WT group showed an increase in diastolic pressure from baseline level at
week 6 (p=0.0065), which then dropped to initial values at week 10 (p=0.0004).
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Figure 2-2. Weight gain, visceral fat accumulation, lipid and glucose metabolism. (A) Body
weight change over the course of the diets. (B) Post-mortem paired epididymal fat pad weight. (C)
Fasting triglyceride levels measured at the end of week 12 on the diets. (D) Fasting levels of total
cholesterol presented as the whole bar and its fractions: Non-HDL (upper part of a bar) and HDL
cholesterol (lower part of a bar). (E) Blood glucose levels during 2-h intraperitoneal glucose
tolerance test (IpGTT) after 11 weeks on the diets. Zero time point (0) represents fasting glucose
value obtained immediately before glucose load. (F) Fasting insulin levels measured from a blood
sample drawn at time point 0 during IpGTT. Animal numbers are as follows: WT CD (n=12), TG
CD (n=11), WT HCD (n=12), TG HCD (n=11). Values are presented as mean ± SEM. Significance
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is indicated by * between HCD and both CD groups (in d – for non-HDL cholesterol), † between
HCD groups and ‡ between TG HCD and both CD groups for total cholesterol. RM Two - way
ANOVA and One - way ANOVA, Tukey’s multiple comparisons test, p < 0.05. CD = control diet,
HCD = hypercaloric diet, HDL = high density lipoprotein, TG = transgenic, WT = wildtype.
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Table 2-1. Serum glucose-, insulin- and lipid-related measures
WT CD

TG CD

WT HCD

TG HCD

Glucose,
mmol/l (initial)

3.73±0.10

3.82±0.07

Glucose,
mmol/l (post)

3.6±0.13

3.63±0.14

3.96±0.13

3.91±0.12

AUC IpGTT
(initial)

929.98±45.91

786.08±53.51

AUC IpGTT
(post)

891.08±82.09

907.25±79.11

1568.85±172.74*†

892.44±90.58

Insulin,
pmol/ml (post)

243.1±28.60

237.9±29.16

HOMA-IR
(post)

0.19±0.03

0.17±0.03

0.56±0.09*

0.58±0.13*

Chol:HDL,
mmol/l

1.64±0.09

1.49±0.06

2.43±0.17*

2.44±0.17*

Initial – data obtained prior to the diet assignment; rats used in the study were combined by
genotype. Post – data collected after 11-12 weeks on the diets. Non-specified – data obtained at
the end of the study. All measures (except AUC IpGTT) represent fasting state values. Values are
presented as mean ± SEM. The symbols * and † indicate significance for HCD group vs both
control groups and between HCD groups respectively. One - way ANOVA, Tukey’s multiple
comparison test; p<0.05. Abbreviations: AUC – area-under-the-curve, CD – control diet, Chol –
total cholesterol, HCD – hypercaloric diet, HDL – high density lipoprotein cholesterol, HOMAIR – homeostasis model assessment index of insulin resistance, IpGTT – intraperitoneal glucose
tolerance test, TG – transgenic, WT – wildtype.
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Figure 2-3. Arterial blood pressure measured three weeks prior to and 6 and 10 weeks on
the diet. A) Systolic blood pressure levels prior to the diet onset (week -3), on week 6 and 10 on
the diet. B) Diastolic blood pressure levels on week -3, week 6 and 10 on the diet. Animal numbers
are as follows: WT CD (n=12), TG CD (n=11), WT HCD (n=12), TG HCD (n=11). Values are
presented as mean ± SEM. The symbol * indicates significance at a timepoint compared to the
baseline (week -3) within the group . Two - way ANOVA, Tukey’s multiple comparisons test,
p<0.05. CD = control diet, HCD = hypercaloric diet, TG = transgenic, WT = wildtype.
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2.3.3 Behavioral Assessment
We monitored cognitive performance using a spatial navigation version of MWM task. First
testing was done prior to the assignment of different dietary regimens to assess baseline learning
abilities of rats. The testing at the end of the study evaluated effects of the HCD-induced metabolic
dysregulation alone and in combination with AD predisposing conditions on learning and memory.

2.3.3.1 MWM and Spatial Learning Preceding Diet
At the end of the initial training period, one week prior to the start of the diet, all groups had learned
the location of the platform to the same extent (Figure 2-4A). Distance travelled in the target
quadrant during the probe trial 1 following the learning was indicative of a good memory of the
platform location (Figure 2-4B).

2.3.3.2 MWM and Spatial Relearning after Diet
Following 12 weeks on the diet, the latency to platform, path length to platform and path efficiency
were significantly improved in CD groups, but were not significantly improved in the HCD groups
(Figure 2-5A,B,D). Comorbid rats had on average shorter path lengths compared to the WT CD
and TG CD animals (p=0.0451 and p=0.0494, respectively) on day 1 of the training (Figure 2-5B).
However, when performance on individual trials within day 1 was compared, there was no
significant difference between the groups (Figure 2-5C). Furthermore, TG HCD rats started the
day 2 at the same level as the rest of the rats and continued in a comparable manner. This suggests,
that TG HCD rats encountered the platform on average faster than CD rats on the very first day of
learning the new location which could contribute to the observed day1-day4 lack of difference.
This could likely occur by chance, especially on the trial 1, or due to choosing a certain swim
strategy such as chaining, rather than represent a true spatial learning. TG rats on the HCD showed
an inconsistent learning pattern with a sudden drop in path efficiency and increase in latency and
path length to platform on the second day of the task. However, by the end of the spatial acquisition
phase all rats learned the task to the same extent as indicated by the absence of differences between
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groups in any of these measurements at day 4 of training. Learning swim speed was comparable
between the groups across days. During the probe trial (Probe 3), comorbid rats spent less time
searching in the target quadrant, while the other groups had a preference for the quadrant where
the platform was located during learning days. Tukey’s multiple comparisons test showed a
significant decrease (p<0.01; one-way ANOVA; Figure 2-5E) in time spent in the target quadrant
for the comorbid rats compared to WT control group. Swim speed did not differ between groups
(Figure 2-5F). Two-way ANOVA analysis revealed a significant effect of dietary treatment
(F(1,42)=7.384; p<0.01) and genotype (F(1,42)=4.462; p<0.05) for time travelled in the target
quadrant with no significant interaction, but the TG HCD group was significantly different from
WT CD group (p=0.0085). Altogether, these results demonstrate diet- and genotype-dependent
impairment in memory consolidation with a negative outcome in the comorbid condition.

2.3.3.3 Open Field Test
Assessment of the effects of HCD alone and in conjunction with AD pathology on locomotion and
anxiety level was done in the open field maze. Analysis of total ambulatory distance during a 20
min task did not result in any significant changes in the locomotor activity between groups (Figure
2-6A), however, there was a genotype-dependent decrease (F(1,43)=6.371; p=0.0154) in locomotor
activity of TG rats. Time spent in the central zone of the open field arena as a measure of anxietylike behavior was not affected by the diet. In contrast, the transgene significantly decreased
(F(1,42)=10.09; p<0.01) time spent in the central zone (Figure 2-6B), suggesting that TG rats were
more anxious.
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Figure 2-4. Morris water maze learning and memory test performed one week prior to the
diet onset. A) Latency to reach the platform in the 4-day training phase. B) Time spent in the
target quadrant during the probe trial following the learning phase (Pr1) expressed as percent of
total time in probe trial. Animal numbers are as follows: WT CD (n=12), TG CD (n=11), WT HCD
(n=12), TG HCD (n=11). Values are presented as mean ± SEM. Significance is indicated by *
between days 1 and 4 in all experimental groups. RM Two - way ANOVA, One - way ANOVA,
Tukey’s multiple comparisons test, p<0.05. Cd = control diet, HCD = hypercaloric diet, TG =
transgenic, WT = wildtype.
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Figure 2-5. Morris water maze relearning and probe trial for memory test after 12 weeks
on the diet. (A) Latency to platform in the 4-day training phase. (B) Mean path length to reach the
platform in the 4-day training phase. (C) Path length to platform in individual trials of each training
day. (D) Path efficiency to reach the platform during 4 days of training. (E) Time spent in the
target quadrant during the probe trial (Pr3) following relearning expressed as percent of total
distance in probe trial. (F) Swim speed in the Pr3. Animal numbers are as follows: WT CD (n=12),
TG CD (n=11), WT HCD (n=12), TG HCD (n=11). Values are presented as mean ± SEM.
Significance is indicated by ‡ between days 1 and 4 in CD groups, by * in A – between TG CD
and HCD groups, in B – between CD groups and TG HCD, in E - between TG HCD and WT CD.
RM Two - way ANOVA, One - way ANOVA, Tukey’s multiple comparisons test, p<0.05. CD =
control diet, HCD = hypercaloric diet, TG = transgenic, WT = wildtype.
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Figure 2-6. Locomotor activity and anxiety-like behavior in open filed test. (A) Total
ambulatory distance for 20 minutes and (B) percentage of time spent in central zone of an open
field arena. Animal numbers are as follows: WT CD (n=12), TG CD (n=11), WT HCD (n=12),
TG HCD (n=11). Values are presented as mean ± SEM. Significance is indicated by * for WT CD
vs TG CD and TG HCD. One - way ANOVA, Tukey’s multiple comparisons test, p<0.05. CD =
control group, HCD = hypercaloric diet, TG = transgenic, WT = wildtype.
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2.3.4 Neuroinflammation
Neuroinflammation is one of the earliest and most critical events occurring in the brain in response
to insult and plays an important role in pathogenesis of AD. Microglia are the key cellular
component of the inflammatory processes occurring in the brain and are the first ones to become
activated and proliferate in response to disturbances in cerebral homeostasis. Astrocytes play a
major role in maintaining brain health and get readily involved in inflammatory reactions. These
two types of glial cells were included in our analysis as the elements of particular interest and were
visualized using immunohistochemistry technique.

2.3.4.1 Microglia Activation
We looked for signs of microglial inflammation by scanning the entire brain from all frontal to
posterior levels. The pathology observed was located mainly in the white matter regions with very
few activated microglia cells observed in the gray matter regions such as the cortex and
hippocampus. There were no apparent differences among the groups. Microglia activation in the
white matter, detected with the OX-6 immunostaining, has been shown to undergo an age-related
increase in the TG rats compared to WT rats31. The images of the OX-6 activated microglia in
three white matter regions from the three-month-old TG animal demonstrate there is a low
activation of microglia in the young animal (Figure 2-7A), similar to that of the WT aged rat.
These images were complemented with an Iba-1 positive microglia cells from the young TG
animal (Figure 2-8A).
A detailed immunohistochemical assessment of the brain sections indicated significant changes in
white matter inflammation due to the combination of the diet and transgene. The comorbid
condition of HCD in the TG group, resulted in a large increase in OX-6 positive activated ramified
microglia in all subcortical white matter areas examined, including corpus callosum (starting as
far anterior as the forceps minor), internal capsule, anterior commissure, optic tract and fimbria of
the hippocampi. Representative images are shown in Figure 2-7A. TG HCD group had significant
microgliosis in all white matter regions compared to all other groups (Figure 2-7B). For the TG
HCD compared to the WT CD group the p value was less than 0.0001 for all regions. Within the
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TG groups the TG HCD was significant compared to the TG CD CD groups with p=0.0003 in the
corpus callosum and p=0.0002 in the internal capsule and fimbria.
This white matter microglial activation was also genotype-dependent, with APP21TG rats showing
significantly higher OX-6-positive signal in comparison to WT rats in the corpus callosum (F1,40
= 17.84; p =0.0001), internal capsule (F1,40 = 49.03; p<0.0001) and fimbria (F1,12 = 53.17;
p<0.0001). In addition, two-way ANOVA analysis showed a significant effect of diet on
microgliosis in the corpus callosum (F1,40 =22.88; p <0.0001), internal capsule (F1,40 = 22.89;
p<0.0001) and fimbria (F1,12 = 29.73; p=0.0001). There was also a significant diet-genotype
interaction on microgliosis in the internal capsule (F1,40 = 4.250; p=0.0458) and fimbria (F1,12=
12.09, p=0.0046), and almost significant interaction in the corpus callosum (F1,40 = 3.809,
p=0.0588).
Comorbid impact on total microglia within the white matter tracts was also assessed (Figure 2-8).
The comorbid TG HCD group had significantly more microglia than the WT CD group for both
the corpus callosum (p=0.0195) and the internal capsule (p=0.0013), changes not seen in the
fimbria. In the corpus callosum TG CD rats also had greater numbers of microglia than WT CD
animals (p=0.0161).
Iba-1 stained section analysis indicated a significant transgene–dependent increase in area
coverage by Iba-1 positive microglia in the corpus callosum (F1,12 = 15.13; p=0.0021), internal
capsule (F1,12 = 13.73; p=0.003) and fimbria (F1,12 = 7.684; p=0.0169; Figure 2-8B). There was an
additional effect of the diet on the microgliosis in the internal capsule (F1,12 = 12.04; p=0.0046).
Thus, comorbid rats demonstrated a large microglial activation in all white matter areas analyzed
along with an increase in microglial proliferation in the corpus callosum and internal capsule.
Additional analysis revealed transgene related effects on microglial activation and proliferation in
all white matter regions. There was a diet induced activation in all regions and proliferation in the
internal capsule.
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2.3.4.2 Astrogliosis
Area of coverage by GFAP-immunopositive astroglia expressed as a percentage of total area of
ROI was taken as a measurement of astrocyte reactivity in subcortical white matter (Figure 29A,B). For the comorbid TG HCD group the only observed increase in astrocytes was compared
to the WT HCD group in the corpus callosum (p=0.0095). In the corpus callosum even the TG CD
group had higher levels of astrocytes compared to the WT HCD (p=0.0188).

There was a transgene effect in that TG rats showed a significant increase in astrocyte density in
the corpus callosum (F1, 11=20.05, p=0.0009) and fimbria hippocampi (F1, 11=8.307, p=0.0149),
compared to WT groups.
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Figure 2-7. Activated microglia in white matter. (A) 10x photomicrographs of representative
OX-6 immunolabelled activated microglial cells in the corpus callosum, internal capsule and
fimbria hippocampi from the boxed regions indicated on the whole brain section insertion, right
hemisphere. Photographs of the activated microglia in the three white matter regions of the threemonth-old TG rat are shown in the right column. Scale bar 200µm. (B) Integrated density as a
measure of microgliosis for corpus callosum and internal capsule. Animal numbers are as follows:
WT CD (n=12), TG CD (n=11), WT HCD (n=12), TG HCD (n=11). Area coverage by a positive
signal (as a percentage of a total area of the region) as a measure of microgliosis for fimbria.
Animal numbers are n=4 in each group. Values are presented as mean ± SEM. Significance is
indicated by * between TG HCD and all other groups; by † between CD groups. One - way
ANOVA and Tukey’s multiple comparisons test, p<0.05. 3M = three-month-old TG rat, CD =
control diet, HCD = hypercaloric diet, TG = transgenic, WT = wildtype.
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Figure 2-8. Total microglia in white matter. (A) 10x photomicrographs of representative Iba-1
immunolabelled microglial cells in the corpus callosum, internal capsule and fimbria hippocampi
from the boxed regions indicated on the whole brain section insertion, right hemisphere.
Photographs of the microglia in the three white matter regions of the three-month-old TG rat are
shown in the right column. Scale bar 100µm. (B) Area coverage by a positive signal (as percentage
of a total area of a region) for corpus callosum, internal capsule and fimbria. Animal numbers are
as follows: WT CD (n=4), TG CD (n=4), WT HCD (n=4), TG HCD (n=4). Values are presented
as mean ± SEM. Significance is indicated by * for WT CD vs both TG groups in corpus callosum
and WT CD vs TG HCD in internal capsule). One - way ANOVA and Tukey’s multiple
comparisons test, p<0.05. 3M = three-month-old TG rat, CD = control diet, HCD = hypercaloric
diet, TG = transgenic, WT = wildtype.
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Figure 2-9. Reactive astrocytosis in white matter. (A) 10x photomicrographs of representative
GFAP immunolabelled astrocytes in the corpus callosum, internal capsule and fimbria
hippocampi. Scale bar 100µm. Magnified images of individual astrocytes are inserted at the
bottom right corner of image panels in A. (B) Area coverage by a positive signal (as percentage of
a total area of a region) for corpus callosum, internal capsule and fimbria. Animal numbers are as
follows: WT CD (n=4), TG CD (n=4), WT HCD (n=3), TG HCD (n=4). Values are presented as
mean ± SEM. Significance is indicated by * for WT HCD vs both TG groups in corpus callosum).
One - way ANOVA and Tukey’s multiple comparisons test, p<0.05. CD = control group, HCD =
hypercaloric diet, TG = transgenic, WT = wildtype.
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2.3.5 Neuronal density
Dorsal hippocampus, particularly the CA1 region, is a crucial structure for spatial learning and
memory and is very susceptible to the pathological processes in AD37–40. We assessed whether
there is a loss of neurons in the CA1 subregion of the hippocampus (Figure 2-10A). Counts of
NeuN positive pyramidal neurons revealed no differences in the neuronal density between
experimental groups (WT HCD vs TG HCD p=0.0816; WT CD vs TG HCD p=0.1844; Figure 210B).

2.3.5 Synaptic density
Synaptic density was analyzed in the CA1 and CA3 dorsal hippocampal subregions using
synaptophysin immunostaining to detect synaptic vesicles (Figure 2-11A). The area of coverage
by a positive signal was significantly decreased in the TG rats compared to the WT animals in both
regions (CA1 p=0.0008, F(1,20) =15.38; CA3 p=0.0001, F(1,20) =22.60; Figure 2-11B). In the TG
rats that were also on the HCD there was no additional effect of the comorbidity on the synaptic
density in any of the regions (TG CD vs TG HCD in CA1 p>0.99; in CA3 p>0.98). Rats from the
Control TG and HCD TG groups showed significantly lower synaptic density compared to the
HCD WT (p=0.0126 and 0.0148, respectively) in the CA1 region, and to the HCD WT (p=0.0153
and 0.0065, respectively) and Control WT (p=0.0342 and 0.0149, respectively) in the CA3 region.
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Figure 2-10. Neuronal counts identified by neuronal nuclear antigen (NeuN)
immunohistochemistry. (A) 20x photomicrographs of the dorsal hippocampus CA1 subregion
pyramidal neurons. Scale bar 100 um. Boxed area corresponds to a field defined for cell counts.
(B) NeuN positive cell counts in a field of area 0.2 mm2. Animal numbers are n=4 in each group.
Values are presented as mean ± SEM. Cd = control diet, HCD = hypercaloric diet, TG = transgenic,
WT = wildtype.
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Figure 2-11. Synaptic density in the hippocampus identified by synaptophysin (SYN)
immunohistochemistry. (A) 20x photomicrographs of the pyramidal neurons in the dorsal
hippocampus CA1 (top row) and CA3 (bottom row) subregions. Scale bar 50 um. Boxed area
corresponds to a field defined for quantification. (B) Synaptophysin area coverage (%) in CA1 and
CA3 regions of the hippocampus. Animal numbers are n=6 in each group. Values are presented as
mean ± SEM. Significance is indicated by * for HCD WT vs both TG groups in CA1 and for both
TG groups vs both WT groups in CA3 region. HCD = hypercaloric diet, TG = transgenic, WT =
wildtype. One - way ANOVA, Tukey’s multiple comparisons test, p<0.05.
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2.3.6 Myelination
Activated microglia were highly accumulated in the cerebral white matter of TG rats on HCD with
some more minor transgene and diet effects. To assess if signs of demyelination of the white matter
tracts were present at this level glial pathology, Luxol fast blue staining was performed (Figure 212A,B). We quantified the percentage of area coverage by a positive signal for both corpus
callosum (Figure 2-12C) and internal capsule (Figure 2-12D). There was no statistically significant
difference in myelin content between the groups and no effect of genotype or diet was detected.
Thus, increased microglial activation was not accompanied by loss of myelin at this stage.
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Figure 2-12. Myelination of white matter. 10x photomicrographs of representative brain
sections stained with Luxol fast blue containing (A) corpus callosum and (B) internal capsule, right
hemisphere. Scale bar 100µm. Area coverage by a positive signal (as percentage of a total area of
a region) for (C) corpus callosum and (D) internal capsule. Animal numbers are as follows: WT
CD (n=4), TG CD (n=4), WT HCD (n=4), TG HCD (n=4). Values are presented as mean ± SEM.
CD = control diet, HCD = hypercaloric diet, TG = transgenic, WT = wildtype.
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2.4 Discussion
The results of this investigation clearly show, for the first time, that APP21 TG predisposed to AD
rats maintained on a high fat and high carbohydrate diet not only develop considerable metabolic
perturbations, but they also exhibit marked widespread white matter microgliosis that was
accompanied by impairment on a spatial memory task compared to the performance level of
wildtype rats. However, there was no neuronal loss or decrease in synaptic density in the
hippocampus of these comorbid rats. Although there were some behavioral, synaptic and
inflammatory changes that could be attributed to the diet or the transgene alone, it was clear that
the more significant neuroinflammation and memory and learning deficits were due to the
combination of the energy-rich high fat, high carbohydrate diet and the TG condition. This is the
first demonstration of the impact of hypercaloric diet on white matter in a vulnerable aging brain
with increased levels of pathogenic hAPP. These TG rats have been previously characterized to
have dense neuronal staining for hAPP, but no evidence of plaques 30,33. This differs from previous
mouse models that assessed high-fat diet induced MetS on animals with established classical AD
events including amyloid plaque and tau pathology.
The hypercaloric diet approach was chosen to mimic a modern dietary pattern in the human
population represented by a combination of food that is high in fat and simple sugars and
carbohydrate-rich beverages 10,41. This study was not designed to examine the exact effects of the
specific source of fat or type of fatty acids or specific carbohydrates ingested in a large amount.
The intent was to examine a combined diet with a high content of both components to deliver an
excess of calories associated with induction of MetS pathology in our rat model10,41,42. We
therefore cannot extrapolate on the potential effects of high fat diet or high carbohydrate diet in
isolation.
Twelve weeks on the HCD were sufficient for the development of significant obesity and visceral
adiposity in these rats. While rats in control groups had normal rat chow as the only source of
energy, rats maintained on high-fat, high-sugar diet had an additional energy uptake from a corn
syrup drink, which resulted in a reduction of food consumption in these animals, but nonetheless
a greater total caloric intake per rat compared to rats on CD.
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The ingestion of high fat and high carbohydrate calories had effects in the periphery and markedly
altered lipid metabolism, increasing triglycerides, total cholesterol and atherogenic non-HDL
fraction in rats of both genotypes. Rats TG for hAPP were more susceptible to these changes and
had a greater degree of dyslipidemia. In contrast, WT rats were more prone to perturbations in
glucose metabolism. Such sensitivity of lipid homeostasis to a long-term consumption of high fat
diets has been shown previously 41 and has also been reported for the Fischer 344 rat strain 23,43.
However, this is the first instance where the high-fat high-sugar diet has been tested in the APP21
TG rat demonstrating a greater degree of dyslipidemia compared to the WT subjects.
Although fasting glucose levels were within a normal range for both groups on HCD, the HCD led
to the increase of fasting insulin levels suggesting the development of hyperinsulinemia and insulin
resistance in rats of both genotypes.
During a 2-h glucose tolerance test, WT rats had sustained high blood glucose levels indicating a
decreased tolerance for glucose in this group. Interestingly, HCD did not appear to induce
pronounced glucose intolerance in TG rats, at least not after the 12-week long intervention. This
physiological difference in response to excessive caloric intake could implicate mutated hAPP
gene inserted in the genome of rats and overexpressed in tissues other than brain (i.e. liver, kidney,
lung) and its possible interaction with mechanisms of metabolism. Similar to our observation,
5xFAD mice bearing 5 human familial AD mutations including APPSwe placed on a high-fat diet
for 10 weeks did not show signs of glucose intolerance in the oral version of the test compared to
WT control group 44. The presence of carbohydrate metabolism alterations has been reported in
patients with symptomatic AD, in which there are lower rates of fasting blood glucose as well as
lower glucose values in the oral glucose tolerance test 45. However, this unique phenomenon would
need further separate investigation using more sensitive methods to find out whether there is a
difference in glucose metabolism and in the role of compensatory mechanisms to overcome dietary
effects between the two genotypes, which could account for this diverse response to a glucose load
and was not in the focus of the present study.
There was no dietary effect on the blood pressure, demonstrating that a 12-week exposure to the
HCD was not long enough to develop hypertension in this rat strain. However, the non-invasive
method to measure blood pressure used in this study falls short of the accuracy of invasive
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techniques, and might be insensitivity to subtle early changes in blood pressure possibly present
at this stage.
Behavioral analysis at the end of the diet indicated an impact of the diet-induced metabolic
alterations on memory consolidation in rats with AD predisposition, however only compared to
the WT CD rats. This observation clearly has implications for human populations with a high
prevalence of obesity due to a hypercaloric Western style diet with advancing age and increasing
levels of brain amyloid

18,46

. Studies using TG AD mouse models have shown similar effects of

high-fat diet on the spatial memory domain and noted the link of these effects to the inflammatory
events44,47–49. One study showed increased microglia activation detected in vivo using positron
emission tomography, and a greater amyloid plaque load in APP/PS1 TG mouse which received a
high-fat diet and a streptozocin treatment 49. Interestingly, a triple-transgenic AD mouse on a highfat diet did not exhibit increase in amyloid plaque deposition or tau-pathology, rather a
significantly increased number of activated microglia associated with plaques in the hippocampal
region that was suggested to be the primary mediating pathology to an observed cognitive
impairment 47. Another study using a APPswe/PS1 TG mouse of AD similarly showed no effect
of the Western diet on the brain parenchymal amyloid burden, however the diet resulted in
decreased synaptic plasticity and blood brain barrier dysfunction which could contribute to the
behavioral deficits48. These changes were attributed to the systemic inflammation promoted by the
Western diet48. This is in line with studies of human brain showing a lack of correlation between
amyloid plaque burden and presence or severity of dementia symptoms50,51. This suggests that
other events contribute to manifestation and progression of cognitive decline and that
neuroinflammation including white matter microgliosis and astrogliosis can be among them52.
As the field of AD research has started to move away from the amyloid causal hypothesis, the
white matter inflammation and other white matter changes concepts have been gaining attention
and recognition as important players in cognitive impairment 3,7,53,54. White matter abnormalities
visualized as hyperintensities on MRI scans are common findings among the elderly population.
These signals increase with aging, are often present in mild cognitive impairment (MCI), AD and
patients with metabolic disorders, and have been shown to highly correlate with cognitive decline
8,55,56

. Of great interest is the clinical finding that white matter lesions tend to be present well before

symptoms of cognitive deterioration start to appear 7,8,54. This has opened a new avenue to explore
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the potential of cerebral white matter lesions as a new biomarker of cognitive impairment such as
MCI and AD dementia and a possible target for prevention and therapy.
Our results clearly indicate an increased microgliosis and microglial proliferation in the white
matter tracts of TG rats expressing pathogenic hAPP markedly aggravated by diet-induced
metabolic dysregulations in the comorbid rats. Analysis of the brain tissue has shown a widespread
inflammation of the white matter, including the corpus callosum, fimbria, internal capsule,
cingulum, anterior commissure and optic tract. This finding is of considerable interest as it
replicates the white matter pathology associated with advanced age, MCI, early AD and metabolic
disorders in the human population 3,5,6. Intriguingly, the white matter inflammation appeared to be
an early pathological event as there was no apparent loss of CA1 hippocampal neurons or
additional to the TG background decrease in synapses in the CA1 and CA3 subregions of the
hippocampus in the comorbid animals at this stage of the disease.
In the present study we also assessed myelination of two major white matter tracts, the corpus
callosum and internal capsule, which appeared to be unchanged in APP21 TG rats on the HCD.
Further analysis confirmed that the white matter microgliosis was not accompanied by signs of
myelin loss at this stage. Nevertheless, axonal damage or perturbation to oligodendrocyte health
could begin to develop and should be examined in the future studies to enhance understanding of
the white matter pathological changes.
Additional brain tissue analysis should be carried out in order to identify the nature and magnitude
of the inflammatory events as well as determine if these inflammatory events are precursors to or
consequences of potential vascular changes and other processes that might take place at this early
stage of dietary intervention and contribute to the cognitive dysfunction. However, these elements
of interest were not in the focus of the present study which aimed to address the effects of HCD
superimposed on the high amyloid background on the major glial cells, microglia and astrocyte,
activation as an indicator of neuroinflammatory process.
Clinical data, points towards an association of cerebral white matter pathology with perturbations
in executive function, processing speed and general cognition57. Widespread neuroinflammatory
responses to the HCD, primarily denoted by microgliosis and increased microglia cell activation,
seen in the white matter of TG rats may interfere with functioning of multiple cognitive domains
113

leading to a general decline and may contribute to the observed impairment in the behavioral task
performance. However, to establish a clear connection between the white matter inflammation and
cognitive impairment, more studies including neuronal health assessment, should be performed.
The spatial navigation version of the MWM used in the present study was chosen to assess learning
and memory dependent on hippocampal formation that is highly vulnerable to AD pathology.
However, it is not the most sensitive for specific testing of executive function components that
might be affected at the prodromal stage of the disease in our TG rat model. It will be necessary
to perform more sensitive tests (e.g. operant conditioning based set-shifting task) to clarify the
cognitive deficits that may be related to the observed brain white matter pathology.
The sex-dependent differences in the effect of MetS on neuroinflammation and other early
pathology of pre - AD and cognition were not tested in the current study using only male rats.
Future projects should consider including experiments conducted on female animals to address the
potential role of biological sex and endocrinological differences in the interaction of these
conditions.
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2.5 Conclusions
Our study using a TG APP21 rat on HCD, suggests the role of diet-induced metabolic alterations
as a risk factor for white matter inflammation, which is an early brain pathology in MCI and AD,
as a possible point of interaction with prodromal phase AD. Results further suggest that white
matter inflammation may lead to accelerated development of cognitive symptoms, since the white
matter microglial activation was accompanied by cognitive impairment in comorbidity condition
compared to normal rats from WT population. The other 2 groups, TG rats on the CD and WT on
the HCD did not demonstrate this significant cognitive change from the WT CD animals. Activated
inflammatory cells were mainly located in the white matter which raises a number of important
questions on the nature of events and mechanisms that trigger this specific response. The intense
white matter inflammatory response provoked by the dietary intervention in the TG rats also
suggests specific anti-inflammatory agents may be a potential treatment and preventative strategy.
Several approaches could be taken in this therapeutic direction including targeting inflammatory
cytokines or components of the arachidonic acid pathway that mediate the inflammation.
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Chapter 3: Effect of the Novel Anti-inflammatory Prodrug Ketoprofen lysine in Comorbid APP21 Transgenic Rat and Diet-induced Metabolic
Syndrome
This experiments in this chapter were designed to examine the effects of a novel brain targeted
NSAID prodrug Ketoprofen-lysine on the increased white matter microgliosis and cognitive
deficits in the comorbid model of prodromal AD and MetS (Objective 2). This manuscript has
been reviewed by all authors and is ready to be submitted for publication.

3.1 Introduction
Dementia and mild cognitive impairment (MCI), which is associated with an increased risk of
converting to dementia, represent a serious public health challenge. The progressive and incurable
characteristic of these age-related disorders is of considerable concern given their prevalence in
the human population. Alzheimer's disease (AD), the most common form of dementia, is a
neurodegenerative disease that leads to severe mental health decline. The major hallmark of the
disease is an accumulation of amyloid-β peptide (Aβ), produced through cleavage of amyloid
precursor protein (APP) and formation of neurofibrillary tangles 1. However, white matter
abnormalities and neuroinflammation are thought to be implicated in the early stages of AD
development and contribute to its progression 2–6. Analysis of brain and serum specimens of AD
patients have shown elevation of pro-inflammatory chemokines and cytokines such as IL-6, IL1β, TNF-α, TGF-β, increased expression of inflammatory genes and activation of signaling
pathways associated with inflammation (e.g. TNF-α, NF-κB, COX1, COX2), and reactive glial
activation in both grey and white matter structures6–8.
In the human elderly population MCI and AD very often co-exist with metabolic disorders such
as diabetes and metabolic syndrome (MetS). MetS can include a combination of abdominal
obesity, dyslipidemia, insulin resistance and hypertension. A chronic inflammatory state is also a
characteristic feature of the MetS 9–11. Inflammation appears to be a shared pathology with AD and
is suggested to be a point of their interaction12–14. This interaction between prodromal AD and
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MetS was recently demonstrated in our previous study of a novel human APP21 transgenic (TG)
rat model of early AD15–17 and a hypercaloric diet (HCD) designed to induce obesity and MetS.
This combination of MetS in a prodromal model of AD resulted in a larger increase in
neuroinflammation in the white matter of the comorbid animals compared to either condition
alone.
Recognition of neuroinflammation as one of the key processes in the etiopathogenesis of the
disease has opened a potential new avenue for the early treatment of dementia. Promising
candidate agents for treatment belong to the class of non-steroidal anti-inflammatory drugs
(NSAIDs)18–22, that primarily block pro-inflammatory mediators production via cyclooxygenase
(COX) enzyme inhibition23. Both COX-1 and COX-2 enzymes are thought to be involved in the
inflammatory processes24,25, and it is possible that agents from this pharmacological group with
various selectivity have the potential to modulate pathological changes and be considered for a
treatment or prevention of AD.
Several epidemiological studies have shown an associated reduced risk of AD with a long-term
treatment with NSAIDs26–30. In addition, studies using these agents for treatment in animal models
of AD have shown beneficial effects on amyloid pathology, neuronal health and cognitive
function31–36. However, clinical trials on prevention and treatment of mild cognitive impairment
and AD, have produced controversial results for NSAIDs of both selective and non-selective COX
inhibitor subclasses37. Cases describing beneficial outcome of a trial were linked to the use of nonselective NSAIDs, especially with prolonged intake20,37–40. The majority of animal studies
reporting a positive effect of the treatment have also used conventional non-selective drugs40.
Although there have been many failures in clinical trials to treat or delay the progression of
cognitive decline40–47, analysis of clinical data has indicated that the timing of the treatment
appears to be critical for any positive outcome. The studies suggest that the desired beneficial
effect can be achieved by early intervention, before symptomatic onset and at the start of or likely
before cerebral pathological changes37,48.
Thus, there appears to be strong epidemiological support for NSAIDs in the prevention of AD,
although more studies are necessary to characterize potential therapeutic effects of these agents as

121

well as to investigate the exact conditions and define the best regimen of treatment taking into
consideration some of the lessons learned from clinical trials.
In the present study we examine therapeutic potential of a novel non-steroid anti-inflammatory
prodrug, ketoprofen-lysine (KL), that was designed to specifically target the brain. This study
analyzed the effect of KL prodrug on neuroinflammation and cognitive function in the comorbid
APP21 TG rat model of prodromal AD combined with diet-induced MetS. The prodrug was
synthetized via conjugation of a non-selective NSAID ketoprofen to an amino acid l-lysine that
allows large neutral amino acid transporter (LAT1) - mediated drug transport through the blood
brain barrier. This manipulation of the drug should provide a major advantage of improved drug
delivery to the central nervous system49. Thus, the prodrug has a rapid uptake from the bloodstream
minimizing undesired systemic side effects, good brain tissue distribution and a high cell uptake
providing a targeted action.
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3.2 Methods
3.2.1 Animals
All animal handling and experimental procedures were carried out in accordance with the
guidelines of the Canadian Council on Animal Care and were approved by Western University
Animal Use Subcommittee (AUP 2014-016).
Breeding pairs of the homozygous APP21 TG Fischer 344 rat model of AD were obtained from
Drs. Cansu and Yuksel Agca (University of Missouri, Colombia, MO, USA) and were bred in
house alongside wildtype Fischer 344 rats15. We have previously characterized the combination of
this TG rat and HCD diet for the effects on cognitive function and neuroinflammation.
A total of 80 male wildtype (WT) and male APP21 TG rats were involved in this study. Single and
paired rats were housed under standard conditions (12:12 light/dark cycle, at 22-24°C) and
maintained on a standard rat diet. At the age of 10-10.5 months half of the rats of each genotype
were randomly assigned to a Western type high-caloric diet (HCD), while the other half continued
on a standard control diet (CD). Diets were provided ad libitum during the 15-week duration of
the study. A subset of animals of each genotype and each dietary group was assigned to the nonsteroidal anti-inflammatory KL prodrug treatment protocol. Animal numbers for each
experimental group were the following:
WT

TG

CD

11

9

CD-KL

10

8

HCD

11

10

HCD-KL

11

10

For histological analysis, lipid and visceral fat measurements animal numbers in non-KL groups
were the following: WT CD n=9, TG CD n=5, WT HCD n=6 and TG HCD n=6. One rat from TG
CD-KL and one from WT CD-KL group died after 1 month of drug administration.
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3.2.2 Diets
A study timeline is shown in Figure 3-1. The CD contained (in % Kcal): 26 protein, 59.7
carbohydrate, and 14.3 fat with 1.52 % of saturated fatty acid (Prolab RMH 3000 5P00). The HCD
consisted of the following (in % Kcal): 17 protein, 43 carbohydrate, 40 fat with 62.4% of saturated
fatty acid and 0.21% cholesterol (D12079B, Research Diets, Inc). The metabolizable energy
content of CD and HCD (in kcal/g) was 3.18 and 4.7, respectively. Rats were given free access to
water in CD groups and 20% corn syrup water solution in HCD groups (Bee Hive, ACH Food
Companies, Inc, USA).

3.2.3 Chronic Prodrug Treatment
KL prodrug was synthesized by Dr. Jukka Leppänen (School of Pharmacy, University of Eastern
Finland). Treatment was initiated 2 days after the dietary regimens were assigned.
The prodrug was dissolved in saline to a concentration of 30 mg/ml. This dilution allowed a single
dose to be less than 0.1 ml to make it suitable for continuous daily subcutaneous administration
for an extensive period of study (15 weeks). The treatment dose used in this study was 4.1 mg/kg
body weight, which corresponds to 2.5 mg/kg of free ketoprofen. Rodent studies on NSAIDs (e.g.
ibuprofen) treatment in AD models with detected plaque pathology commonly use a dose of 5
mg/kg. However, we were using a model of early stage AD and the treatment was prophylactic
and initiated simultaneously with metabolic disease induction. Furthermore, ketoprofen, that is
mainly used for surgical pain management in rodents, has a higher rate of adverse effects and has
been shown to produce gastrointestinal damage in rats in a commonly used therapeutic dose
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Finally, the prodrug has been engineered to easily cross the blood brain barrier. For these reasons,
we chose a dose half of what has been used for other NSAIDs.
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3.2.4 Physiological and Metabolic Assessment
3.2.4.1 Caloric Intake
Body weight, food and drink consumption were measured twice a week throughout the experiment
and caloric intake for each category was determined.

3.2.4.2 Intravenous Glucose Tolerance Test (IvGTT)
IvGTT was performed one week before the study initiation and at week 12 of the study (Figure 31). Following a 10-12-h overnight fast, a needle was inserted into the saphenous vein to draw
approximately 100-150 µl of blood for the determination of baseline glucose levels. A 50%
D(+)glucose (G 8270, Sigma-Aldrich, Inc., Saint Louis, Missouri, USA) solution in sterile water
(1g/kg body weight) was then injected in a lateral tail vein. Blood was collected from the
saphenous vein repeatedly at 5, 10, 20, 30, 40 and 50 min after the glucose load. Glucose levels
were immediately measured using Freestyle Light Blood Glucose Monitoring System (Abbott
Diabetes Care Inc, Alameda, CA).

3.2.4.3 Lipid Profile Analysis
After euthanasia cardiac whole blood samples were collected and transported to the CORE
Laboratory (University hospital, London, ON, Canada) for serum analysis of lipid metabolism that
included triglycerides, total cholesterol and high-density lipoprotein cholesterol (HDL)
measurements. Non- HDL was calculated as total cholesterol – HDL. The cholesterol ratio
(Chol:HDL ratio) was calculated by dividing total cholesterol value by HDL cholesterol number.
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3.2.4.4 Blood Pressure Analysis
Systolic and diastolic arterial blood pressure was measured using the non-invasive tail cuff method
(CODA Blood Pressure System, Kent Scientific Corp., Connecticut, USA). Rats underwent an
acclimation procedure followed by baseline level measurements two weeks before the experiment
started. Assessment of blood pressure was repeated at week 11 of the study (Figure 3-1).

3.2.5 Open Field Task
Locomotor activity and anxiety-like behavior were tested in an open field arena (45.7x45.7cm)
over the course of 20 min on week 12 of the experiment (Figure 3-1). Ambulatory time and
distance and time spent in the central zone (27.5x27.5cm) were evaluated using video-tracking
software (ANY-maze®, Stoelting Co., Wood Dale, IL, USA).

3.2.6 Morris Water Maze Task
3.2.6.1 Spatial Navigation Protocol
Rats were trained to find an escape platform submerged in a circular pool (145 cm in diameter, 58
cm in depth) using visual extra-maze cues positioned on the surrounding walls. The platform
(12cm in diameter) was placed in the middle of one of 4 quadrants the pool was conceptually
divided into and its location remained unchanged during the training phase. The training protocol
started in week 13 (Figure 3-1) consisted of 16 trials over 4 consecutive days (4 trials/day). The
duration of one trial was 60 sec with a 30-sec inter-trial period during which rats were allowed to
remain on the platform. Release positions were different for each trial of the day and their order
alternated for every other day of spatial acquisition.
At the end of the training, the rats were subjected to two 30-sec probe trials 7 days apart where the
platform was removed from the pool and the rats were released from a novel start position. Probe
1 was introduced on day 5, the day after the training. Probe 2 was performed on day 12 after the
start of the training. All sessions were monitored and recorded using video-tracking software
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(ANY-maze®, Stoelting Co., Wood Dale, IL, USA). Learning progress was assessed using latency
and path length to reach the platform for each day of training. Probe performance was evaluated
using such parameters as time and distance travelled in the quadrant where the platform had
previously been located (target zone). Swim speed was monitored at all stages of the test.

3.2.6.2 Shifting Strategy Protocol
A cognitive flexibility (strategy shifting) protocol was adapted for use in this study51–55 to assess
components of the executive function such as working memory and behavioral flexibility that were
shown to be affected in early stages of AD56–61. Immediately after Probe 2 the platform was
returned to the pool to the previous location and new rules were introduced. For this paradigm rats
received 8 trials grouped in 2 blocks of 4 trials each with a 30-sec inter-trial period within the
block and a 1 h gap in between the blocks. Rats remained on a platform during the inter-trial period.
After being familiarized with the novel protocol rats were given a 3 day shifting challenge (Figure
3-1). Platform position was fixed for each day and then changed every day, thus placing a high
demand on spatial working memory.
The first trial of each day presented information about the platform position specific for each given
day. The second trial was a retention trial where rats needed to recall the information learned in
the first trial which is required to escape the water. The following trials were used to solidify
information making the shift to a new escape location on the next day more challenging. The
difference in time and path length to platform between trials 1 and 2 were analyzed as a criterion
of working memory efficiency and flexibility. The difference in time and distance between trials
1 and 4 as well as trials 1 and 8 were used to evaluate learning ability in the new task setting. Old
platform location preference was used for assessment of the ability to abandon previously used
and now irrelevant information, i.e. persistent behaviour. For this analysis, time and distance spent
searching in the platform zone (designated a 9.5 cm proximity to the platform) of the previous day
during trial 1 were measured.
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3.2.6.3 Cued Trials
Upon the completion of the cognitive flexibility protocol, the rats were subjected to a series of 4
cued trials in the same pool (Figure 3-1). Extra-maze cues were removed to exclude their use for
spatial navigation. Instead a cue was directly mounted on top of the submerged platform that could
be seen above the water surface to indicate the platform location. The platform was placed in a
novel position each time and the start position was switched for every trial to interfere with the
spatial learning. These trials served as a control procedure to determine if there were any visual or
motivational impairments that could account for differences in learning and memory between
groups. Quantification of the path length and latency to reach the platform assessed cued learning.
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Figure 3-1. Project timeline. The age of the rats (in months) at the start (day 0) and the end of the
study (week 16) are shown in brackets. Diets were assigned and began on day 0 and all testing
time points are in reference to this day. Baseline measurements of blood pressure and glucose
tolerance were completed in the 2 weeks before the start of the diets. Morris water maze (MWM)
navigation training was completed within 4 days on week 13, with a probe trial 1 (Pr1) on the day
after training. The second probe trial (Pr2) was 7 days later, on week 14 on the diet. Immediately
after the Pr2, the cognitive flexibility (shifting) protocol was initiated, and was completed in 3
days. MWM cued trials were performed the next day after the shifting paradigm test. Ketoprofenlysine prodrug was administered subcutaneously once daily at a dose of 4.1 mg/kg starting 2 days
after day 0 and continuing to the end of the experiment. BP = blood pressure measurement, IvGTT
= intravenous glucose tolerance test, mo = month, MWM = Morris Water Maze, Pr = probe trial,
OF = open field test, BC = blood collection, TC = tissue collection, w = week.
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3.2.7 Euthanasia and Tissue Collection
At the beginning of week 16 animals were weighed and then euthanized with pentobarbital
overdose following a 12-h fasting period. Cardiac blood was collected immediately before
perfusion. Epidydimal fat pads were collected and weighed. Rats were then perfused transcardially
with 0.01M phosphate buffered saline (pH 7.35) followed by 4% paraformaldehyde (PFA, pH
7.35). The brains were post-fixed in 4% PFA overnight and then transferred to a 30% sucrose until
fully submerged. The brains were sectioned coronally on a cryostat into 30μm thick sections and
were stored in cryoprotecting solution at -20°C until they were used for immunohistochemical
procedures.

3.2.8 Immunohistochemistry
Immunohistochemical analysis was performed on free-floating sections to visualize total microglia
and activated microglia using rabbit polyclonal antibody against the ionized calcium binding
adaptor molecule-1 (anti-Iba-1; 1:1000; Wako Chemicals USA Inc., Richmond, VA, USA) and
mouse monoclonal antibody against the MHC II receptor (OX-6; 1:1000; BD Pharmingen,
Mississauga ON, Canada) respectively. After an overnight incubation with the primary antibody
at 4oC, sections were incubated with biotinylated anti-mouse secondary antibody (1:500; Vector
Laboratories, Inc. Burlingame, CA, USA) followed by incubation with avidin-biotin complex
(ABC kit, Vector Laboratories, Inc. Burlingame, CA, USA) and then developed in 0.05% 3, 3’
diaminobenzidine tetrahydrochloride (Sigma-Aldrich, St. Louis MO, USA). Sections were then
mounted on glass slides, air-dried, dehydrated, cleared in xylene and coverslipped with DePex
mounting media (DePex, BDH Chemicals, Poole, UK).

3.2.9 Imaging and Quantification of Immunohistochemistry
Immunohistochemically processed brain sections were imaged with a Nikon Eclipse Ni-E
microscope using NIS-Elements Imaging Software Version 4.30.02 (Nikon Instruments Inc.,
Melville, NY), allowing 10x magnification. Analysis and quantification were carried out using 64130

bit ImageJ software (Version 1.48u4, Wayne Rasband, National Institutes of Health, Bethesda,
MD, USA). A total of three brain sections containing anterior, mid-anterior and central-toposterior regions of the corpus callosum and three sections from the ventral hippocampal level for
the internal capsule were chosen and scanned for each animal.
Images were converted into a black-and-white 8-bit format, underwent background subtraction,
thresholding and were calibrated prior to taking measurements. Based on the white matter
pathology observed in our model previously, regions of interest (ROIs) included the entire body
(BCC) and periventricular regions (PVCC) of the corpus callosum and internal capsule in both
hemispheres and were manually outlined using a free outline tool. For the assessment of activated
microglia population total area, the area covered by a positive signal (area%) was measured for
each region and then expressed as a weighted average.

3.2.10 Data Analysis
Statistical analysis was performed using GraphPad Prism 6.0. The data was analyzed by
performing t-test, one-way or two-way analysis of variance (ANOVA), Tukey’s multiple
comparison post hoc test. Data are expressed as mean ± standard error of the mean (SEM), and a
p value of ≤0.05 was considered statistically significant.
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3.3 Results
We first performed a comprehensive physiological assessment.

3.3.1 Body Weight, Visceral Fat Accumulation and Diet Consumption
At the end of 15 weeks of dietary treatment, body weight gain from baseline was significantly
greater in all HCD groups compared to the CD groups (Figure 3-2A) as a result of a greater total
caloric intake in these animals (Figure 3-2B). Both TG and WT rats on the HCD with or without
KL prodrug treatment started to gain weight rapidly and weighed significantly more than CD
groups as early as the beginning of the 3rd week on the diet and remained significantly heavier to
the end of study. Epididymal fat pad weights, representative of visceral fat accumulation, were
significantly increased in the HCD groups compared to the control diets (F(1,62)=193.4; p<0.0001)
(Figure 3-2C). Fat accumulation also had a genotypic difference with fat deposits being larger in
the TG rats (genotype effect F(1,62)=9.606; p=0.0029).

3.3.2 Lipid and Glucose Metabolism
The HCD had a robust effect on lipid metabolism resulting in dyslipidemia (Figure 3-2D, E). Total
cholesterol was significantly increased in the comorbid animals with or without the KL prodrug
and also in WT HCD rats receiving the KL prodrug (diet effect F(1,61)=46.52; p<0.0001). A similar
pattern was seen for the non-HDL cholesterol (cholesterol content of atherogenic lipoprotein
particles). The non-HDL cholesterol was increased in the WT HCD and comorbid rats, with and
without the prodrug (F(1,60)=89.49; p<0.0001; Figure 3-2D). However, the WT HCD on the
prodrug had higher levels than the WT HCD without the drug. The Chol:HDL ratio, a relevant
clinical index, was significantly elevated by HCD (F(1,61)=65.97; p<0.0001; Table 3-1).
Triglyceride levels were significantly elevated by HCD in all groups (F(1,61)=115.1; p<0.0001;
Figure 3-2E). There was no apparent effect of KL prodrug administration on lipid metabolism with
an exception of effect on total and non-HDL cholesterol levels in WT HCD rats.
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The IvGTT results demonstrated a glucose intolerance in WT and TG groups on the HCD (Figure
3-3). This was characterized by a significantly greater blood glucose levels at individual time
points during the GTT (two-way ANOVA analysis, Tukey’s MC test). HCD groups started to
deviate significantly from the control group values as early as at 5 min after the glucose injection
(for WT HCD) and maintained high glucose levels up to 40 min post-load for WT rats and 20 min
post-load for TG rats (Figure 3-3). Interestingly, glucose levels of TG HCD rats normalized earlier
than those of the WT rats, as their glucose levels were comparable to control groups already at the
30 min time point, whereas WT HCD rats remained significantly elevated and returned to normal
only by the end of the test. The glucose intolerance was also characterized by a significantly greater
AUC for HCD experimental groups compared to the appropriate control diet groups (diet effect
F(1,76)=103.2; p<0.0001), except the TG HCD group which was only statistically different from
WT CD, but not from TG CD rats (Figure 3-2F). TG animals had a lower AUC compared to the
WT rats (genotype effect F(1,76)=12.95; p=0.0006), suggesting a better glucose uptake from the
blood stream in transgene carriers (Figure 3-2F). Rats maintained on the HCD had comparable
fasting blood glucose levels compared to CD groups that remained within the normal range (Table
3-1). This data suggests that HCD led to the development of glucose intolerance in both genotypes,
however, TG rats were significantly less prone to perturbations in glucose metabolism than WT
animals. Prodrug administration has shown no effect on glucose metabolism.

3.3.3 Blood Pressure
Systolic and diastolic blood pressure values obtained at week 11 of diets were not significantly
different between the experimental groups. Neither HCD, nor transgene presence or KL prodrug
treatment had an effect on either the systolic or diastolic pressure (Table 3-1).
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Figure 3-2. Physiological characteristics. A) Body weight gain expressed as a percentage of
baseline value. B) Average caloric intake during the 15 weeks on the diets. Drink in the HCD
groups represents energy derived from the corn syrup solution. C) Post-mortem paired epididymal
fat pad weight. D) Total serum cholesterol is presented by entire bar. High density lipoprotein
fraction (HDL) and the remaining combined non-high-density lipoproteins (non-HDL) are also
shown in each bar. E) Blood triglyceride levels. F) Area under the curve (AUC) from the IvGTT
after 12 weeks on the diets. Animal numbers for C-E are as follows: WT CD, n=9; TG CD, n=5;
WT HCD, n=6; TG HCD, n=6; WT CD-KL, n=12; TG CD-KL, n=11; WT HCD-KL, n=12; TG
HCD-KL, n=11. Animal numbers for A,B,F are as follows: WT CD, n=11; TG CD, n=9; WT
HCD, n=11; TG HCD, n=10; WT CD-KL, n=12; TG CD-KL, n=11; WT HCD-KL, n=12; TG
HCD-KL, n=11. Values are presented as mean ± SEM. * in A, B (total caloric intake), C, D (total
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cholesterol), E, F, indicates significance between HCD and CD groups. † in D, indicates
significance between individual HCD and all CD groups for the Non-HDL. † in F, indicates
significance between the TG HCD groups and the WT HCD group. ‡ in F, indicates significance
between TG HCD group and WT CD, TG CD-KL groups. One-way ANOVA and Tukey’s
multiple comparisons test p < 0.05. CD = control diet, HCD = hypercaloric diet, HDL = high
density lipoprotein, IvGTT = intravenous glucose tolerance test, KL=ketoprofen-lysine prodrug,
TG = transgenic, WT = wildtype.
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Figure 3-3. Intravenous glucose tolerance test on week 12 on the diet. Glucose curves during
the IvGTT are shown for 4 experimental groups without the Ketoprofen-lysine prodrug treatment.
* indicates significance between WT HCD and both CD groups, † between TG HCD and both CD
groups, ‡ between TG HCD and WT HCD. Animal numbers are as follows: WT CD, n=11; TG
CD, n=9; WT HCD, n=11; TG HCD, n=10. Values are presented as mean ± SEM. Two-way
ANOVA Tukey’s multiple comparisons test, p<0.05. CD = control diet, HCD = hypercaloric diet,
IvGTT=intravenous glucose tolerance test, TG = transgenic, WT = wildtype.
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Table 3-1. Physiological and metabolic characteristics obtained at the end of the study

Chol:HDL,
mmol/l
Fasting
glucose,
mmol/l
Systolic
pressure,
mmHg
Diastolic
pressure,
mmHg

TG HCD-

WT CD

WT CD-KL

TG CD

TG CD-KL

WT HCD

WT HCD-KL

TG HCD

1.19±0.25

1.27±0.13

1.32±0.05

1.26±0.05

2.05±0.31*

3.14±0.22#*

2.53±0.27*

2.34±0.22*

4.44±0.10

4.47±0.12

4.27±0.15

4.19±0.10

4.56±0.15

4.55±0.11

4.47±0.13

4.62±0.13

136.79±2.72

145.43

±2.17

137.47±2.20

136.12±1.94

138.19±3.56

137.16

±3.19

136.37±2.97

133.03±3.12

90.55±

98.16±

2.61

96.17±1.97

95.47±2.44

91.52±3.16

94.05645

±4.18

95.61±2.78

93.11±2.91

2.02

KL

Values are presented as mean ± SEM. The symbols * indicate significance for HCD groups vs appropriate CD groups, # -between WT HCD
and WT HCD - KL groups. One - way ANOVA, Tukey’s multiple comparisons test, p<0.05. Abbreviations: CD – control diet, HCD –
hypercaloric diet, TG – transgenic rats, WT – wild type, KL – ketoprofen-lysine prodrug recipients, Chol – total cholesterol, HDL – high
density lipoprotein cholesterol.
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3.3.4 Behavioral Assessment
We used two different MWM protocols to evaluate effects of comorbidity of HCD-induced MetS
with genetic predisposition to early AD and the effect of the KL prodrug treatment. These were
designed to asses spatial learning and reference memory, as well cognitive flexibility and working
memory.

3.3.4.1 MWM Spatial Learning and Memory
During the training phase, all animals significantly improved in both latency and path length to the
platform when day 1 vs day 4 performances were compared, indicating there was good learning of
the spatial version of the task in all experimental groups (Figure 3-4A). In addition, neither of these
measurements were significantly different between the groups at the end of acquisition phase (day
4). No significant difference was observed in the time or distance travelled in the quadrant of the
previous platform location (Target zone), during both probe trials (Figure 3-4B). Swim speed was
not different between the groups (Figure 3-4C). Thus, these spatial learning and memory results
demonstrate an absence of diet, genotype and drug effects on the spatial navigation ability and
reference memory of the rats.

3.3.4.2 MWM Cognitive Flexibility and Working Memory
Working memory efficiency and flexibility is demonstrated by a significant reduction in path
length and latency to reach the platform between trials 1 and 2. This can be seen in the WT and
TG CD groups. However, in comorbid rats, with or without KL prodrug treatment, this significant
reduction in path length and latency from trial 1 to 2 averaged for 3 shifting days was not present
(Figure 3-5A,C). The lack of reduction in path length from trial 1 to 2 on each day, suggests that
the combined TG HCD rats were not using working memory as efficiently as the other groups and
that the KL prodrug administration had no effect on this deficit. There was no effect of the KL
prodrug treatment as no change in the pattern was seen in any of the 4 experimental group pairs.
138

TG CD-KL and both TG HCD groups on average had a significantly shorter swims (p=0.0011 TG
HCD, p=0.0001 TG HCD-KL, p=0.0053 TG HCD-KL) and were faster (p=0.0069 TG HCD,
p<0.0001 TG HCD-KL, p=0.0083 TG HCD-KL) in locating the platform on trial 1 compared to
the WT CD rats (Figure 3-5A,C). However, further analysis of the trial 1 performance in each
separate day showed no differences between the groups. This behavior could likely occur by
chance since rats did not know the location yet or represent potential differences in swimming
strategies (i.e. chaining, scanning etc) between groups and may contribute to the smaller intertrial
differences in these groups.
The lack of improvement in the performance on the second trial in the comorbid groups could
suggest they are using a random swim strategy instead of learning the location in the first and
following trials using the spatial cues. However, when the performance in trial 1 was compared to
that of trials 4 and 8, all groups without exception achieved a significant improvement in distance
and latency even by trial 4 and all were comparable on the last trial of the day, trial 8 (Figure 35A,C). Thus, all rat groups including the comorbid rats were able to learn the location of the
platform throughout the day using rules of spatial navigation and the earlier assumption of a
random swimming strategy choice by comorbid groups is not accurate.
A potential reason for the lack of significance between trial 1 and 2 in the comorbid rats could be
a delayed learning of new task rules. Rats from comorbid groups may have more strongly adhered
to the previously learned location of the platform from the previous day and were ineffective in
switching strategies that would affect progression on the novel task. In trial 1 of each day, the
distance travelled in the platform zone of the previous day is an indicator of the domination of an
“old rule” of spatial navigation. However, all groups exhibited no difference in swimming distance
searching for the escape platform in the previous days platform zone (Figure 3-5B). Thus,
comorbid rats were able to adapt to the new protocol as well as the other groups, but not as efficient
or flexible in learning the new information presented on each day.
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3.3.4.3 MWM Cued Trial Performance
All measurements were averaged over the 4 trials of a cued test day. There were no significant
differences in latency and path length to reach the platform (Figure 3-4D) or swim speed across
all experimental groups. This suggests that all groups were able to see the cue to locate the
platform, were equally motivated and had the motor capability to escape the pool.
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Figure 3-4. Morris water maze spatial navigation task and cued trials. A) Path length to the
hidden platform during 4 days of training. B) Distance travelled in the quadrant of the previous
platform location (Target Zone) as a percentage of the total distance in the probe trials 1 and 2,
one week apart. C) Swim speed in probe trials. D) Average path length to the platform during 4
cued trials. Animal numbers are as follows: WT CD, n=11; TG CD, n=9; WT HCD, n=11; TG
HCD, n=10; WT CD-KL, n=10; TG CD-KL, n=8; WT HCD-KL, n=11; TG HCD-KL, n=10.
Values are presented as mean ± SEM. Significance is indicated by * between days 1 and 4 in all
experimental groups. One-way and two-way ANOVA, Tukey’s multiple comparisons test, p<0.05.
CD = control diet, HCD = hypercaloric diet, KL=ketoprofen-lysine prodrug, TG = transgenic, WT
= wildtype.
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Figure 3-5. Morris water maze shifting strategy task. All results are presented as an average
of 3 days of testing. A) Path length to the hidden platform in trials 1, 2 and 8. B) Distance travelled
in the previous day’s platform location for trial 1, expressed as a percentage of the total distance
travelled in the first trial. C) Latency to find the hidden platform in trials 1, 2 and 8. Animal
numbers are as follows: WT CD, n=11; TG CD, n=9; WT HCD, n=11; TG HCD, n=10; WT CDKL, n=10; TG CD-KL, n=8; WT HCD-KL, n=11; TG HCD-KL, n=10. Values are presented as
mean ± SEM. # indicates significance for trial 1 with WT CD, * indicates significance from trial
1, NS indicates not significant from trial 1. One-way ANOVA or two-way ANOVA (repeated
measurement) and Tukey’s multiple comparisons test, p<0.05. CD = control diet, HCD =
hypercaloric diet, KL=ketoprofen-lysine prodrug, TG = transgenic, WT = wildtype.
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3.3.4.4 Open Field Exploratory Activity and Anxiety-like Behavior
Analysis of the total ambulatory distance during the 20 min arena exploration indicated that TG
rats had a significantly shorter ambulatory distance than the comparable WT rats (F(1,75)=48.63;
p<0.0001; Figure 3-6A). A reduction in total ambulatory distance is an indication of decreased
spontaneous physical and exploratory activity in these animals. Furthermore, there was an overall
significant impact of the KL prodrug resulting in an increase in locomotor activity in groups
receiving the prodrug (F(1,75)=8.259; p=0.005; Figure 3-6B).
Time spent in the central zone of the open field arena expressed as a percentage of total testing
time and decrease in the central zone is a measure of anxiety-like behavior. There was no
significant group difference in the time in the arena center during the full 20 min test duration
(Figure 3-6C).
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Figure 3-6. Locomotor activity and anxiety-like behavior in the open field test on week 12 on
the diet. Total ambulatory distance A) combined in 4 groups by genotype and diet irrespective of
the prodrug treatment and B) combined by genotype and prodrug assignment. C) Percentage of
time spent in the central zone during 20 min in an open field arena for all 8 experimental groups.
Values are presented as mean ± SEM. Animal numbers are as follows: WT CD (n=11), TG CD
(n=9), WT HCD (n=11), TG HCD (n=10), WT CD-KL (n=10), TG CD-KL (n=8), WT HCD-KL
(n=11), TG HCD-KL (n=10). * in A and B, indicates significance between TG groups and WT
groups. † in B, indicates significance between WT-KL and WT-ND groups. One - way ANOVA
and Tukey’s multiple comparisons test or t-test, p<0.05. CD = control diet, HCD = hypercaloric
diet, KL=ketoprofen-lysine prodrug, TG = transgenic, WT = wildtype.
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3.3.5 Microglia Activation
We have examined and quantified OX-6 positive activated microglia cells primarily located in
white matter tracts throughout the brain, including the body of the corpus callosum (BCC), the
periventricular region of the corpus callosum (PVCC) and the internal capsule (Figure 3-7A). For
all groups of animals, WT and TG with either CD or HCD, there was no effect of the KL prodrug
on the activated microglia in any of the 3 regions measured (Figure 3-7B).
In both areas of the corpus callosum, BCC and PVCC, there was an increase in activated microglia
in the TG compared to the WT rats, irrespective of diet (F(1,17)=84.87, BCC; F(1,17)=74.13, PVCC;
p<0.0001; Figure 3-7C). For the internal capsule, the TG HCD rats had more activated microglia
than the WT CD (p=0.0024) and WT HCD (p=0.0130) (Figure 3-7C). Furthermore, in both areas
of the corpus callosum, the TG HCD had significantly more activated microglia than the TG CD,
indicating a more pronounced effect of the comorbid condition (p=0.0116, BCC; p=0.0118,
PVCC; Figures 3-7A,C).
An assessment of the total microglia proliferation within the white matter tracts using anti-Iba-1
immunohistochemistry indicated that there was no apparent change in the total microglia in the
white matter of either the corpus callosum or the internal capsule regions (Figure 3-8).
We have also observed a marked increase in the activated microglia in multiple brain regions of a
total 6 rats from all 4 experimental groups which all received a KL prodrug treatment. This
indicated a potential serious negative effect of the prodrug which was studied in a more detail in
these 6 cases and described in the Chapter 4 of this thesis.
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Figure 3-7. Activated microglia in white matter. A) The schematics show the coronal sections
at one of the levels used for analysis: Bregma 0.6 mm for the corpus callosum (on the left) and
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Bregma -2.92 mm for the internal capsule (on the right). Photomicrographs (10X) of representative
OX-6 immunolabelled activated microglial cells in the body of the corpus callosum (all
experimental groups) and internal capsule (only HCD groups on and off the prodrug treatment)
were sampled from the regions in the right hemisphere indicated by the black box on schematics.
Scale bar 100µm. B,C) Bars represent the density of the OX-6 positive microglia coverage
expressed as the percentage of a total area of the region: the body of the corpus callosum,
periventricular regions of the corpus callosum and internal capsule. B) All experimental groups
are shown; C) data presented only for 4 groups not receiving the prodrug treatment. Values are
presented as mean ± SEM. Animal numbers are as follows: WT CD (n=6), TG CD (n=5), WT
HCD (n=5), TG HCD (n=6), WT CD-KL (n=5), TG CD-KL (n=5), WT HCD-KL (n=4), TG HCDKL (n=6). * indicates significance between the TG and WT groups. † between TG HCD and TG
CD. One - way ANOVA, Tukey’s multiple comparisons test p<0.05. CD = control diet, HCD =
hypercaloric diet, KL=ketoprofen-lysine prodrug, TG = transgenic, WT = wildtype.
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Figure 3-8. Total microglia in white matter. A) The schematics show the coronal sections at one
of the levels used for analysis: Bregma 0.6 mm for the corpus callosum (on the left) and Bregma 2.92 mm for the internal capsule (on the right). 10x photomicrographs of representative Iba-1
immunolabelled microglial cells in the body of the corpus callosum and internal capsule (control
WT CD, all TG groups) were sampled from the regions in the right hemisphere indicated by the
black box on schematics. Scale bar 100µm. B) Area coverage by a positive signal (as percentage
of a total area of a region) for corpus callosum and internal capsule. Animal numbers are as
follows: WT CD (n=6), TG CD (n=5), TG HCD (n=6), WT CD-KL (n=5), TG CD-KL (n=5), TG
HCD-KL (n=6). Values are presented as mean ± SEM. CD = control diet, HCD = hypercaloric
diet, KL=ketoprofen-lysine prodrug, TG = transgenic, WT = wildtype.
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3.4 Discussion
Targeting neuroinflammation appears to be one of the most promising approaches to slowing or
preventing some forms of dementia, including AD, since it has been shown to be one of the earliest
processes related to the disease pathogenesis. Furthermore, neuroinflammation is persistent over
time and contributes to disease progression5,62. A previous study using the APP21 TG rat model of
prodromal AD in combination with diet-induced MetS supported the concept of the role of
neuroinflammation in the early onset of the disease and mild cognitive impairment. In particular,
we previously demonstrated that white matter microgliosis, in particular, may be one of the key
elements in prodromal AD-related pathology and that increased white matter inflammation may
be point of interaction between specific AD and metabolic disease.
A consideration of previous results along with accumulated evidence from epidemiology and
supportive data from clinical and other animal research, suggests that anti-inflammatory agents
may be potential treatment candidates to interrupt this neuroinflammatory interaction caused by a
combination of amyloid and high fat, high sugar diet. In the present study we investigated the
potential therapeutic effect of a novel non-steroidal anti-inflammatory prodrug, Ketoprofen-lysine,
in the APP21 TG rat model of prodromal AD with HCD–induced MetS. As in our previous
investigation, we did observe changes to metabolism characteristic of the MetS syndrome
development (obesity, increased adiposity, dyslipidemia, glucose intolerance). We also observed
again increased white matter microglial activation that was accompanied by working memory
impairment, based on the MWM cognitive flexibility test, in the comorbid TG HCD group after
15 weeks of the HCD consumption. However, the results of this investigation did not demonstrate
any obvious beneficial effect on the white matter inflammation and cognitive deficits associated
with the chronic KL prodrug treatment.
The metabolic and physiological profile in the current investigation was consistent with our
previous study. Chronic HCD consumption in WT and TG led to the development of obesity and
markedly altered lipid metabolism. Previously, using an intraperitoneal GTT (IpGTT), we
observed a genotypic difference in the response of glucose metabolism. Even with HCD exposure
the TG rats were able to maintain glucose tolerance, while WT rats had greatly elevated glucose
levels that did not normalize even at the end of the 2h of testing. In the present investigation, we
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used an intravenous glucose challenge demonstrating that both TG HCD and WT HCD rats
developed glucose intolerance.
Interestingly, the WT HCD rats again showed the highest blood glucose concentration at each time
point during the test resulting in a greater AUC compared to the TG HCD rats in the present study.
The lack of development of glucose intolerance in the previous study in which TG HCD rats did
not show an increase in AUC compared to the control groups when using an IpGTT may, in fact,
be an artefact of the different route of glucose delivery between two versions of the test. In the
IpGTT, the glucose passes from the peritoneal cavity to the systemic circulation entering the liver
first. In the intravenous administration it bypasses the liver allowing a direct assessment of the
glucose disposal and effects of acute insulin release.
Alternatively, the mutated hAPP in our APP21 TG rats is overexpressed in several peripheral
tissues including liver and this APP might interact with the mechanisms of glucose metabolism
leading to the observed differences between the WT and TG animals. Similarly, the absence of
glucose intolerance with the oral GTT have been reported in a transgenic 5xFAD mice also
expressing a mutant APPSwe, compared to the WT group63. Clinically, both lower oral GTT and
fasting glucose values were observed in an AD patient cohort64. These data suggest a potential
implication of APP in the glucose metabolism regulation, findings that require additional
investigation.
The KL prodrug administration did not affect any of the metabolic outcomes measured. There is
evidence in the literature of beneficial effects of NSAIDs on glucose and lipid metabolism that
could provide an advantage for their use in a patient population with metabolic disorders65.
However, these effects are thought to be dose-dependent. In the present investigation, the treatment
of the ketoprofen was administered at a relatively low dose since the ketoprofen was delivered in
a prodrug form which allows faster delivery to and greater fraction entered in the brain. This low
dose with a direct action in the brain would minimize the systemic exposure and effects observed
by others.
We have previously shown the comorbid rats had impaired memory consolidation on the MWM
re-learning task. In the present study, we aimed to assess working memory and cognitive
flexibility, the processes that show an early decline in AD. The comorbid, TG HCD, rats
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demonstrated preserved spatial learning ability and they did not maintain a preference for the
previous days escape location during the first trial of shifting strategy version of the MWM task.
However, the comorbid animals showed no improvement from trial 1 to 2 in the shifting strategy
testing. These results suggest the comorbid groups may have a slower information processing
speed and working memory impairment, leading to the slower switch to the changed escape
location, i.e. cognitive inflexibility.
Executive behavioral deficits have been observed in these APP21 TG rats with advanced age (19
month old) compared to the WT rats when tested on a strategy shifting MWM task similar to that
of the present investigation

55

. Furthermore, another study investigated behavioral flexibility in

comorbid stroke and early AD in 13 month old APP21 TG rat model and have shown impairments
in strategy change efficiency. This impairment in the comorbid stroke and APP TG rats was based
on an operant set-shifting task which allows for a more specific and broad assessment of the
executive function66. The testing in our study was done in 13.5 month old animals and we did not
detect impairments in the APP21 TG rats in the control diet group using the MWM adapted
protocol. This MWM protocol lacks sensitivity comparing to the operant-based set-shifting task.
Nevertheless, the animals with metabolic disturbances due to the HCD in the TG animals resulted
in working memory dysfunction even with the MWM protocol. Thus, our results support our
previous demonstration of cognitive impairment in HCD and APP TG comorbid animals.
However, as indicated, above, the KL prodrug administration did not prevent this behavioral
deficit in the comorbid rats (TG on the HCD).
In the present experiments, locomotor activity tested in the open field was lower in the transgene
carriers. This result is consistent with previously observed behavioral differences in this animal
model55 and in APP transgenic mouse models of AD67,68. Interestingly, KL prodrug treatment
appeared to increase exploratory activity overall among all experimental groups, with a more
pronounced effect in the WT rats. This could be due to peripheral pain-relieving action of
ketoprofen which could alleviate the discomfort associated with obesity and increased load on
joints in HCD groups, however, this effect was observed in all diet groups, including rats on
CD69,70. Furthermore, a rapid delivery of active ketoprofen in the prodrug form to the brain likely
minimized ketoprofen systemic effects including analgesic effect. This further suggests there
might be a direct central analgesic effect of the drug that is not attributable to prevention of any
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increases in neuroinflammation due to the transgene or the HCD70,71. How the ketoprofen effects
the brain to produce this increase in exploratory behavior requires further exploration.
In the present study, microglial activation in the white matter indicated increased
neuroinflammation in TG animals compared to WT and in comorbid animals with MetS and hAPP
compared to TG animals alone. A previous investigation has shown that the APP21 TG rats
demonstrate a significant increase in the OX-6 positive microglia in the corpus callosum compared
to the WT from 12 and 15 months of age55. Thus, the present investigation indicates that the HCD
can markedly aggravate the age-related white matter pathology in the TG rats. These results are
consistent with our previous study characterizing this combined disease model in which the
comorbid group (TG HCD) had a significant increase in microglial activation in white matter
tracts, including the corpus callosum and internal capsule. However, the present results indicate
that the anti-inflammatory KL prodrug treatment was not able to reduce the microglial activation
in the white matter in the comorbid group. Furthermore, 2 lethal cases and 6 cases of pronounced
microgliosis indicated a potential serious negative prodrug effects questioning safety of this agent.
One limitation to this study that needs be mentioned is that there was no vehicle-treated group to
control for the effects of chronic injections as a stress factor. This study was primarily aimed to
investigate the potential of the prodrug treatment to decrease white matter microglial activation,
thus, only KL treatment was done. However, it is necessary to perform a follow-up salinecontrolled experiments as well as dose-response studies to fully assess the treatment potential.
The hypothesis for this study was that the KL prodrug would ameliorate the white matter
inflammation and the cognitive deficits in the comorbid animals. The results are very clear that
there is no significant impact of the drug on these measures. Factors potentially influencing the
effect of the drug in our model could include timing of the treatment initiation, duration, dosage
and properties of the active compound ketoprofen 72. Potential changes in expression or function
of the LAT-1 transporter in our transgenic prodromal AD model and/or HCD consumption and the
establishment of metabolic dysregulation could also affect pharmacokinetics of the prodrug and
its potency. Clinical trials have also indicated that NSAIDs might be ineffective when sufficient
pathology already exists at the start leading eventually to disease progression and establishment of
symptoms without regard to the treatment. Therefore, clinical studies suggest that an early
intervention occurring prior to overt pathological changes35,37,48 or at the very early stages of the
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disease is necessary for beneficial effects48,73. It may be that in or study, the rats by 10 months of
age have already developed pathologies driving or contributing to white matter inflammation that
could not be rescued or reversed by the KL prodrug administered in the current dose and timeframe
for delivery. The inherent pathologies in our animals may be progressing with increasing age that
by itself could contribute to the previously described phenomenon of decreased protection of
drugs37 through dyshomeostasis in immune and vascular systems. In addition, these pathological
processes can be further aggravated by transgene presence in our prodromal AD rat model and
even more by the altered metabolic condition, and both of these conditions that can further sustain
inflammatory process and affect treatment results. Therefore, further experimentation should be
done to establish the timeframe of the development of neuropathological changes to determine the
earliest point for successful intervention. Moreover, these studies should be accompanied by the
safety testing of the treating agents.
Our model of prodromal AD has demonstrated inflammation primarily affecting white matter.
White matter is a structure that is highly susceptible to damage and white matter pathology appears
to be one of the earliest signs in diseases including AD and MetS and precedes cognitive
decline2,3,6,74–76. Thus, it might be important to consider potential re-directing of the treatment
strategy towards targeted protection of the white matter rather than focusing simply on general
suppression of inflammation. This would require a detailed analysis of underlying white matter
lesions and the timeline of their development. Furthermore, it might not be effective, and in fact it
is likely insufficient, to target only one out of many processes of the complex pathogenesis in the
progression of MCI and AD. Therefore, future research directions might also include an integration
of anti-inflammatory treatment into a combined therapy that accounts for multiple key players in
the disease development to increase success of the treatment and obtain the maximal beneficial
effect.

153

3.5 References
1.

Querfurth, H.W. LaFerla, F. M. Mechanisms of disease. Alzheimer’s disease. N Engl J Med 362, 329–344
(2010).

2.

Lee, S. et al. White matter hyperintensities are a core feature of Alzheimer’s disease: Evidence from the
Dominantly Inherited Alzheimer Network. Annu. Neurol. 79, 929–939 (2016).

3.

Brickman, A. M. et al. Reconsidering harbingers of dementia: Progression of parietal lobe white matter
hyperintensities predicts Alzheimer’s disease incidence. Neurobiol. Aging 36, 27–32 (2015).

4.

Brickman, A. M. Contemplating Alzheimer’s Disease and the Contribution of White Matter Hyperintensities.
Curr. Neurol. Neurosci. Rep. 13, (2013).

5.

Heneka, M. T. et al. Neuroinflammation in Alzheimer’s disease. Lancet Neurol. 14, 388–405 (2015).

6.

Raj, D. et al. Increased white matter inflammation in aging- and Alzheimer’s disease brain. Front. Mol. Neurosci.
10, 1–18 (2017).

7.

Akiyama, H. et al. Inflammation and Alzheimer ’s disease. 21, (2000).

8.

Loring, J. F., Wen, X., Lee, J. M., Seilhamer, J. & Somogyi, R. A gene expression profile of Alzheimer ’ s
disease. DNA Cell Biol. 20, 683–695 (2001).

9.

Bastard, J. et al. Recent advances in the relationship between obesity , inflammation , and insulin resistance. Eur
Cytokine Netw. 17, 4–12 (2006).

10. Gregor, M. F. & Hotamisligil, G. S. Inflammatory Mechanisms in Obesity. Annu. Rev. Immunol. 29, 415–445
(2011).
11. Dandona, P., Aljada, A. & Bandyopadhyay, A. Inflammation: The link between insulin resistance, obesity and
diabetes. Trends Immunol. 25, 4–7 (2004).
12. De Felice, F. G. & Ferreira, S. T. Inflammation, defective insulin signaling, and mitochondrial dysfunction as
common molecular denominators connecting type 2 diabetes to Alzheimer Disease. Diabetes 63, 2262–2272
(2014).
13. Misiak, B., Leszek, J. & Kiejna, A. Metabolic syndrome, mild cognitive impairment and Alzheimer’s diseaseThe emerging role of systemic low-grade inflammation and adiposity. Brain Res. Bull. 89, 144–149 (2012).
14. Walker, J. M. & Harrison, F. E. Shared neuropathological characteristics of obesity, type 2 diabetes and
Alzheimer’s disease: Impacts on cognitive decline. Nutrients 7, 7332–7357 (2015).
15. Agca, C. et al. Development of transgenic rats producing human β-amyloid precursor protein as a model for
Alzheimer’s disease: transgene and endogenous APP genes are regulated tissue-specifically. BMC Neurosci. 9,
1–13 (2008).
16. Silverberg, G. D. et al. Kaolin-induced chronic hydrocephalus accelerates amyloid deposition and vascular
disease in transgenic rats expressing high levels of human APP. Fluids Barriers CNS 12 (1), (2015).
17. Rosen, R. F. et al. Exogenous seeding of cerebral β-amyloid in βAPP -transgenic rats. J Neurochem 120, 660–
666 (2012).
18. Asanuma, M., Nishibayashi-Asanuma, S., Miyazaki, I., Kohno, M. & Ogawa, N. Neuroprotective effects of nonsteroidal anti-inflammatory drugs by direct scavenging of nitric oxide radicals. J. Neurochem. 76, 1895–904
(2001).
19. McGeer, P. L., Schulzer, M. & McGeer, E. G. Arthritis and anti-inflammatory agents as possible protective
factors for Alzheimer’s disease: A review of 17 epidemiologic studies. Neurology 47, 425–432 (1996).
20. McGeer, P. L. & McGeer, E. G. NSAIDs and Alzheimer disease: Epidemiological, animal model and clinical
studies. Neurobiol. Aging 28, 639–647 (2007).
21. Townsend, K. P. Novel therapeutic opportunities for Alzheimer’s disease: focus on nonsteroidal antiinflammatory drugs. FASEB J. 19, 1592–1601 (2005).
22. McGeer, P. L., Guo, J. P., Lee, M., Kennedy, K. & McGeer, E. G. Alzheimer’s Disease Can Be Spared by

154

Nonsteroidal Anti-Inflammatory Drugs. J. Alzheimer’s Dis. 62, 1–4 (2017).
23. Vane, J. R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat. New Biol.
231, 232–235 (1971).
24. Gasparini, L., Ongini, E. & Wenk, G. Non-steroidal anti-inflammatory drugs (NSAIDs) in Alzheimer’s disease:
Old and new mechanisms of action. J. Neurochem. 91, 521–536 (2004).
25. Graham, S. H., & Hickey, R. W. Cyclooxygenases in Central Nervous System Diseases. Arch. Neurol. 60, 628–
630 (2003).
26. Stewart, W. F., Kawas, C., Corrada, M. & Metter, E. J. Risk of Alzheimer’s disease and duration of NSAID use.
Neurology 48, 626–632 (1997).
27. Anthony, J. C. et al. Reduced prevalence of AD in users of NSAIDS and H2 receptor antagonists: The Cache
County study. Neurology 54, 2066–2071 (2000).
28. Veld, B. A. n’ T. et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer ’ s disease. N. Engl. J.
Med. 345, 1515–1521 (2001).
29. Vlad, S. C., Miller, D. R., Kowall, N. W. & Felson, D. T. Protective effects of NSAIDs on the development of
Alzheimer disease. Neurology 70, 1672–1677 (2008).
30. Zhang, C., Wang, Y., Wang, D., Zhang, J. & Zhang, F. NSAID exposure and risk of Alzheimer’s disease: An
updated meta-analysis from cohort studies. Front. Aging Neurosci. 10, 1–9 (2018).
31. Lim, G. P. et al. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer’s
disease. J. Neurosci. 20, 5709–5714 (2000).
32. Jantzen, P. T. et al. Microglial activation and beta -amyloid deposit reduction caused by a nitric oxide-releasing
nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. J. Neurosci.
22, 2246–54 (2002).
33. Yan, Q. et al. Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model
of Alzheimer’s disease. J. Neurosci. 23, 7504–7509 (2003).
34. Wilkinson, B. L. et al. Ibuprofen attenuates oxidative damage through NOX2 inhibition in Alzheimer’s disease.
Neurobiol. Aging 33, 197.e21-197.e32 (2012).
35. Varvel, N. H. et al. NSAIDs Prevent, But Do Not Reverse, Neuronal Cell Cycle Re-entry in Alzheimer’s Disease
Mouse Models. Cell Cycle 119, 1–46 (2009).
36. Zara, S. et al. Ibuprofen and lipoic acid codrug 1 control Alzheimer’s disease progression by down-regulating
protein kinase C ??-mediated metalloproteinase 2 and 9 levels in ??-amyloid infused Alzheimer’s disease rat
model. Brain Res. 1412, 79–87 (2011).
37. Imbimbo, B. P., Solfrizzi, V. & Panza, F. Are NSAIDs useful to treat Alzheimer’s disease or mild cognitive
impairment? Front. Aging Neurosci. 2, 1–14 (2010).
38. Breitner, J. C. & Baker, L. D. Extended results of the Alzheimer disease anti-inflammatory prevention trial
(ADAPT). Alzheimer’s Dement. 7, 402–411 (2011).
39. Breitner, J. C. S. et al. Risk of dementia and AD with prior exposure to NSAIDs in an elderly community-based
cohort. Neurology 72, 1899–1905 (2009).
40. Cole, G. M. & Frautschy, S. A. Mechanisms of Action of Non-Steroidal Anti-Inflammatory Drugs for the
Prevention of Alzheimer’s Disease. CNS Neurol Disord Drug Targets 9, 140–148 (2010).
41. Aisen, P. S. et al. Effects of Rofecoxib or Naproxen vs Placebo on Alzheimer Disease Progression. Jama 289,
2819 (2003).
42. Thal, L. J. et al. A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment.
Neuropsychopharmacology 30, 1204–1215 (2005).
43. Aisen, P. S. et al. Rofecoxib in patients with mild cognitive impairment: Further analyses of data from a
randomized, double-blind, trial. Curr. Alzheimer Res. 5, 73–82 (2008).
44. Soininen, H., West, C., Robbins, J. & Niculescu, L. Long-term efficacy and safety of celecoxib in Alzheimer’s

155

disease. Dement. Geriatr. Cogn. Disord. 23, 8–21 (2006).
45. Lyketsos, C. G. et al. Naproxen and celecoxib do not prevent AD in early results from a randomized controlled
trial. Neurology 68, 1800–1808 (2007).
46. Alzheimer’s Disease Anti-inflammatory Prevention Trial Research Group. Results of a follow-up study to the
randomized Alzheimer’s Disease Anti-inflammatory Prevention Trial (ADAPT). Alzheimers. Dement. 9, 714–
23 (2013).
47. Martin, B. Cognitive function over time in the Alzheimer’s disease anti-inflammatory prevention trial : results
of a randomized, controlled trial of naxopren and celecoxib. 65, 896–905 (2008).
48. Hauss-Wegrzyniak, B., Vraniak, P. & Wenk, G. L. The effects of a novel NSAID on chronic neuroinflammation
are age dependent. Neurobiol. Aging 20, 305–313 (1999).
49. Gynther, M. et al. Brain uptake of ketoprofen-lysine prodrug in rats. Int. J. Pharm. 399, 121–128 (2010).
50. Shientag, L. J., Wheeler, S. M., Garlick, D. S. & Maranda, L. S. A therapeutic dose of ketoprofen causes acute
gastrointestinal bleeding, erosions, and ulcers in rats. J. Am. Assoc. Lab. Anim. Sci. 51, 832–41 (2012).
51. Bizon, J. L. et al. Spatial reference and working memory across the lifespan of male Fischer 344 rats. Neurobiol.
Aging 30, 646–655 (2009).
52. Bizon, J. L., Foster, T. C., Alexander, G. E. & Glisky, E. L. Characterizing cognitive aging of working memory
and executive function in animal models. Front. Aging Neurosci. 4, 1–14 (2012).
53. McDonald, R. J., King, A. L., Foong, N., Rizos, Z. & Hong, N. S. Neurotoxic lesions of the medial prefrontal
cortex or medial striatum impair multiple-location place learning in the water task: Evidence for neural structures
with complementary roles in behavioural flexibility. Exp. Brain Res. 187, 419–427 (2008).
54. Weishaupt, N., Riccio, P., Dobbs, T., Hachinski, V. C. & Whitehead, S. N. Characterization of behaviour and
remote degeneration following thalamic stroke in the rat. Int. J. Mol. Sci. 16, 13921–13936 (2015).
55. Weishaupt, N. et al. APP21 transgenic rats develop age-dependent cognitive impairment and microglia
accumulation within white matter tracts. J. Neuroinflammation 15, 1–12 (2018).
56. Cloutier, S., Chertkow, H., Kergoat, M. & Gauthier, S. Patterns of cognitive decline prior to dementia in persons
with Mild Cognitive Impairment. J 47, 901–913 (2015).
57. Sgaramella, T. M. et al. Executive deficits appearing in the initial stage of Alzheimer’s Disease. Brain Cogn 46,
264–268 (2001).
58. Backman, L., Jones, S., Berger, A., Laukka, E. J. & Small, B. J. Cognitive impairment in preclinical Alzheimer
’ s Disease : a meta-analysis. Neuropsychology 19, 520–531 (2005).
59. Baddeley, A., Bressi, S., Sala, S. Della, Logie, R. & Spinnler, H. The decline of working memory in Alzheimer’s
disease. Brain 114, 2521–2542 (1991).
60. Binetti, G. et al. Executive dysfunction in early Alzheimer ’ s disease. J. Neurol. Neurosurg. Psychiatry 60, 91–
93 (1996).
61. Baudic, S. et al. Executive function deficits in early Alzheimer ’ s disease and their relations with episodic
memory. Arch. Clin. Neurophsycology 21, 15–21 (2006).
62. Mandrekar, S. & Landreth, G. E. Microglia and inflammation in Alzheimer’s disease. CNS Neurol Disord Drug
Targets 9, 156–167 (2010).
63. Lin, B. et al. High-fat-diet intake enhances cerebral amyloid angiopathy and cognitive impairment in a mouse
model of alzheimer’s disease, independently of metabolic disorders. J. Am. Heart Assoc. 5, 1–17 (2016).
64. Adolfsson, R., Bucht, G., Lithner, F. & Winblad, B. Hypoglycemia in Alzheimer’s disease. Acta Med Scand 208,
387–388 (1980).
65. Bellucci, P. N., González Bagnes, M. F., Di Girolamo, G. & González, C. D. Potential Effects of Nonsteroidal
Anti-Inflammatory Drugs in the Prevention and Treatment of Type 2 Diabetes Mellitus. J. Pharm. Pract. 30,
549–556 (2017).
66. Levit, A. et al. Behavioural inflexibility in a comorbid rat model of striatal ischemic injury and mutant hAPP

156

overexpression. Behav. Brain Res. 333, 267–275 (2017).
67. Schneider, F., Baldauf, K., Wetzel, W. & Reymann, K. G. Behavioral and EEG changes in male 5xFAD mice.
Physiol. Behav. 135, 25–33 (2014).
68. Lalonde, R., Fukuchi, K. & Strazeielle, C. APP transgenic mice for modelling behavioral and psychological
symptoms of dementia (BPSD). Neurosci. Biobehav. Rev. 36, 1357–1375 (2013).
69. Ferreira, S. H. Peripheral Analgesia: mechanism of the analgrsic action of aspirin like drugs and opiateantagonists. Br.J. clin Pharmac 10, 237S-244S (1980).
70. Cashman, J. The mechanisms of action of NSAIDs in analgesia. Drugs 52, 13–23 (1996).
71. Luan, Y., Wang, D., Yu, Q. & Chai, X. Action of β -endorphin and nonsteroidal anti-infl ammatory drugs , and
the possible effects of nonsteroidal anti-infl ammatory drugs on β -endorphin. J. Clin. Anesth. 37, 123–128
(2017).
72. Sastre, M. & Gentleman, S. M. NSAIDs: How they work and their prospects as therapeutics in Alzheimer’s
disease. Front. Aging Neurosci. 2, 1–6 (2010).
73. Cole, G. M. & Frautschy, S. A. Mechanisms of action of non-steroidal anti-inflammatory drugs for the prevention
of Alzheimer’s disease. CNS Neurol. Disord. Drug Targets 9, 140–8 (2010).
74. Prins, N., Van, D., den Heijer, T. & Al, E. Cerebral white matter lesions and the risk of dementia. Arch. Neurol.
61, 1531–1534 (2004).
75. Reijmer, Y. D. et al. Microstructural white matter abnormalities and cognitive functioning in type 2 diabetes: A
diffusion tensor imaging study. Diabetes Care 36, 137–144 (2013).
76. Reijmer, Y. D., Leemans, A., Brundel, M., Kappelle, L. J. & Biessels, G. J. Disruption of the cerebral white
matter network is related to slowing of information processing speed in patients with type 2 diabetes. Diabetes
62, 2112–2115 (2013).

157

Chapter 4: Negative Impact of Ketoprofen-lysine Treatment on Cerebral
Pathology and Cognition in a Comorbid APP21 Transgenic Rat and Diet induced Metabolic Syndrome
This chapter presents the analysis of a subset of animals from the previous investigation that
received the prodrug that developed a large amount of neuroinflammation (Objective 3). The
negative effects on neuropathology and behavior associated with the long-term prophylactic
prodrug treatment in a subset of rats are described. Full description of the methodology of this
study is presented in Chapter 3 and the current chapter includes only highlights and additional
methods used for the extended pathological examination. This manuscript has been reviewed by
all authors and is ready to be submitted for publication.

4.1 Introduction
Alzheimer's disease (AD), a common cause of dementia, is a progressive incurable
neurodegenerative disease that leads to a severe mental health decline. Neuroinflammatory
processes occupy an important place in the pathogenesis of AD, developing at the very early stages
of the disease and contributing to the progression1–5. Obesity and metabolic syndrome (MetS),
whose development is greatly associated with the intake of high-fat, -sugar hypercaloric diet
(HCD), represent risk factors for dementia including AD later in life. A chronic inflammatory state
is also a characteristic feature of these disorders6–8 and has been suggested to be a point of
interaction between AD and metabolic diseases9–12.
Epidemiological studies have shown a long-term treatment with non-steroidal anti-inflammatory
drugs (NSAIDs) is associated with reduced risk of AD14,15,24,25,16–23. Particularly, this association
is thought to be mediated through the inhibition of cyclooxygenase (COX) enzymes COX-1 and
COX-2 and blockage of downstream pro-inflammatory mediators production13, which are
involved in the inflammatory processes critical to the AD development and progression1,26–29.
However, clinical trials on NSAIDs have produced controversial results30, leading to the need for
further studies investigating treatment potential of this class of agents.
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We previously conducted a 12-week study on the effects of diet-induced metabolic disturbances
on neuroinflammation and cognition in a novel human APP21 transgenic (TG) rat model of early
AD48–50. The results demonstrated an intense white matter inflammatory response accompanied by
a poor cognitive performance in the comorbid condition, suggesting inflammation might be one of
the key players in early AD and highlighting a potential for an anti-inflammatory treatment
strategy.
We subsequently conducted another study designed to examine the therapeutic effect of a novel
prodrug ketoprofen-lysine (KL)51, a conjugate of NSAID ketoprofen and amino acid lysine,
specifically targeting the brain. This study examined the impact of KL on white matter microgliosis
and cognition in the comorbid model of early stage AD and diet-induced MetS. We hypothesized
that chronic prophylactic treatment with a novel KL prodrug which was initiated at the prodromal
AD stage simultaneously with the dietary switch for MetS induction and therefore administered at
a half-treatment for this drug class dose, will prevent increased white matter inflammation and the
concomitant cognitive impairment in the comorbid AD and MetS. Long-term prophylactic
treatment failed to stop accumulation of white matter microglia activation induced by comorbidity.
However, there was an additional phenomenon that needs to be reported since it has considerable
implications for the potential use of brain targeted NSAIDs. In all groups receiving the prodrug
there was a subset of rats that demonstrated a dramatic increase in pathologic neuroinflammation
in the neocortex and subcortical structures accompanied by a negative impact on spatial working
memory and cognitive flexibility.
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4.2 Methods
The complete study design with detailed methods section is described elsewhere.
Male Fischer 344 wildtype (WT) and TG carrying human amyloid-β precursor protein gene
(hAPP) with Swedish and Indiana mutations (APP21)48 rats 10-10.5 months of age were
maintained on either a control diet (CD; Prolab RMH 3000 5P00) or the hypercaloric diet (HCD;
D12079B, Research Diets, Inc) supplemented with 20% corn syrup water solution. A total of 21
WT and 18 APP21 TG rats received the KL prodrug in once daily subcutaneous injections in a
dose of 4.1 mg/kg body weight, which corresponds to 2.5mg/kg of free ketoprofen, for a full
duration of the study (15 weeks).
Tissue processing and immunohistochemistry were performed to visualize total, activated
microglia and astrocytes as described previously. Additional staining was done to visualize
neurons using mouse monoclonal primary antibody against neuronal nuclei protein (anti-NeuN;
1:1000; Millipore Corp; USA). Systolic and diastolic arterial blood pressure was measured using
the non-invasive tail cuff method (CODA Blood Pressure System, Kent Scientific Corp.,
Connecticut, USA) at week 11 of the study. Spatial learning abilities, working memory and
cognitive flexibility were evaluated using the Morris water maze task (MWM) at weeks 13-15 on
the diet as described in the original study. Data is reported as mean with the standard error of the
mean (SEM). Differences in the 2-way ANOVA followed by Tukey MC test or t-test were
considered statistically significant where p≤0.05.
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4.3 Results
In total there were 39 animals receiving the KL prodrug. These animals included 10 WT CD, 8
TG CD, 11 WT HCD and 10 TG HCD. The first indication that there may be a problem with the
drug treatment was the death of two rats receiving the KL prodrug, one each from the WT CD and
TG CD group. These animals were found dead in their home cages after one month of drug
administration. Previously, in these MetS studies alone, we have used a total 126 rats in these types
of experiments that do not involve any kind of surgery or invasive treatment and we have not had
any animals succumb. Unfortunately, the brains were not saved for histological analysis due to
undetermined time after spontaneous death.

4.3.1 Neuroinflammation
One of the hypotheses for the overall experiment was that there would be increased white matter
inflammation in the TG rats on the HCD and that the KL prodrug would ameliorate this
inflammation. When we performed immunohistochemical analysis of OX-6 activated microglia,
it revealed the expected white matter inflammation in the comorbid AD and MetS animals,
however there was also a widespread microgliosis in 6 animals on the KL prodrug (Figures 4-1,2).
Areas of OX-6 microgliosis have also shown an increase in the Iba-1 reactivity of microglial cell
population (Figures 4-1,2). These animals were not localized to any one group, but were in all 4
experimental groups irrespective of the presence of the transgene or the HCD (Figures 4-1,2).
The only common element is that all of these animals with extensive neuroinflammation were
exclusively from animals receiving the KL prodrug and included both genotypes and dietary
regimens: WT CD, n=1; TG CD, n=1; WT HCD, n=2; TG HCD, n=2. In all animals, there were
highly activated OX-6 positive microglia cells clustered together in large areas spreading across
both gray and white matter. Images of the activated microglia are shown for representative animals
from each group in Figures 4-1,2. This was a striking finding since this type of neuroinflammation
had never been observed in any (126 rats) of the previous animals in these studies. We particularly
did not expect this in those that are part of the control groups. We previously observed only
localized white matter inflammation increase in comorbid animals that were TG and on the HCD.
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The areas of neuroinflammation included the neocortex, thalamus, hippocampus, striatum,
amygdala, septal nuclei, hypothalamus, spreading into the adjacent white matter (Figures 4-1,2).
Morphologically, the microglia cells exhibited enlarged irregular soma with shortened thickened
processes and an increase in the number of processes (Figure 4-1).
These brains were also stained for GFAP. Analysis of the brain sections has shown an increase in
GFAP-immunoreactivity of cells in the areas of microgliosis (Figures 4-1,2). These hypertrophic
GFAP+ astrocytes exhibited thickening of their processes as well as an increase in the number and
length of the processes (Figure 4-1).
Staining for NeuN was done to obtain an indication of the numbers of neurons in these areas (boxed
fields on Figures 4-1,2). Neuronal density expressed as NeuN positive cell automated counts,
indicated there was a consistent relative decrease in the numbers of neurons in the regions of
microglial activation compared to corresponding areas of a control brain from a rat not receiving
the drug (Figure 4-3).
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Figure 4-1. Widespread microgliosis and reactive astrocytosis in Ketoprofen-lysine prodrug
recipients in groups on the control diet. 2x photomicrographs of representative brain regions
from coronal sections at the levels indicated by the Bregma (mm) with immunolabelled OX-6, Iba1 activated microglia and GFAP astroglia. Scale bar 500µm. Boxed regions refer to areas selected
for neuronal cell counting. Magnified images obtained at 10x magnification show morphology of
microglia and astrocytes in the core of the affected region. Scale bar 100 µm. CC = corpus
callosum, CD = control diet, fmiCC = forceps minor of corpus callosum, KL = ketoprofen-lysine
prodrug, LH = left hemisphere, LV = lateral ventricle, M = motor cortex, RH = right hemisphere,
TG = transgenic, WT = wildtype.
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Figure 4-2. Widespread microgliosis and reactive astrocytosis in Ketoprofen-lysine prodrug
recipients in groups on the hypercaloric diet. 2x photomicrographs of representative brain
regions from coronal sections at the levels indicated by the Bregma (mm) with immunolabelled
OX-6, Iba-1 activated microglia and GFAP astroglia. Scale bar 500µm. Boxed regions refer to
areas selected for neuronal cell counting. 3V = 3rd ventricle, CD = control diet, IC = internal
capsule, KL = ketoprofen-lysine prodrug, LH = left hemisphere, LV = lateral ventricle, RH = right
hemisphere, TG = transgenic, WT = wildtype.
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Figure 4-3. Neuronal density in areas of extensive neuroinflammation in Ketoprofen-lysine
prodrug recipients. Neuronal counts (NeuN+ cells) in affected brain areas of representatives from
WT CD, TG CD, WT HCD and TG HCD animals in comparison to control brain of untreated WT
animal on CD. Amyg = amygdala, CD = control diet, CPu = caudate putamen, HCD = hypercaloric
diet, KL = ketoprofen-lysine prodrug, Prim SS Cortex = primary somatosensory cortex, SeptNu =
septal nuclei, TG = transgenic, WT = wildtype.
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4.3.2 Behavioral deficits
To assess the impact of KL prodrug induced neuroinflammation on cognitive performance we
performed an additional analysis of behavioural data dividing rats in two groups: a group that was
not receiving the prodrug (ND, n=41) and group receiving the KL prodrug that exhibited
widespread neuroinflammation (DI, n=6). Both of these groups contained rats from the
combination of dietary protocols and genotypes.
The analysis of spatial learning in the MWM demonstrated that both ND and DI rats had significant
improvement in the time to reach the hidden platform by the end of the training (Figure 4-4A),
indicating that spatial learning ability was not compromised in the DI animals. In addition, these
two groups were similar in motor ability since swim speed did not differ between groups in any of
the probe trials (Figure 4-4B).
In the 3-day MWM shifting strategy protocol with the platform location changing every day the
average time to find the hidden platform in the first trial of the day was not different between the
groups. However, the time to recall the newly learned platform location and reach the platform in
trial 2 was significantly longer in DI group compared to the ND group (p=0.027; Figure 4-4C).
Thus, the improvement in the time on trial 2 compared to trial 1 was only significant in ND group
indicating the KL prodrug reduced cognitive flexibility due to working memory impairments.
Furthermore, analysis of the performance in trials 2-4 showed that DI rats were significantly slower
in learning the platform position within each day (p=0.02; Figure 4-4D). Finally, the latency to
reach the platform in trial 5, after a one-hour break, was significantly longer in DI rats (Figure 44E), suggesting there are difficulties in retaining information during the break. Altogether, these
results demonstrate negative effects of detrimental neuroinflammatory pathology on the spatial
reference and working memory and cognitive flexibility of the rats.
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Figure 4-4. Behavioral performance of Ketoprofen-lysine prodrug recipients with extensive
neuroinflammation. Rats divided in two groups: those not receiving prodrug (ND) and those with
prodrug and with extensive gray matter inflammation (DI). Each group combines both dietary
protocols and genotypes. Spatial navigation MWM. A) Latency to the hidden platform as a
measure of learning progress over 4 days of training. B) Swim speed during probe trials one week
apart performed right after the spatial training. Shifting strategy MWM protocol for spatial working
memory and cognitive flexibility assessment. C) Average time to find the platform in trials 1 and
2 of the day as working memory efficiency criteria. D) Average latency during trials 2-4 within
the day as working memory and cognitive flexibility measure. E) Latency to reach the platform in
trial 5, after a one-hour break in testing day, as a measure of spatial reference memory. Trial bar
in C-E) represents an average of trial time across 3 days of shifting strategy MWM task. Values
are presented as mean ± SEM. Significance is indicated by * between different time points within
the group and by # - between groups. t- test, 2-way ANOVA Tukey post-hoc test (in A), p≤0.05.
CD = control diet, HC = hypercaloric diet, KL = ketoprofen-lysine prodrug, MWM = Morris water
maze, TG = transgenic, WT = wildtype.
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4.3.3 Blood pressure
Systolic and diastolic arterial blood pressure levels assessed at week 11 of diets were not different
between the rats on the prodrug treatment that developed extensive neuroinflammation and nontreated rats, DI and ND experimental groups respectively (Figure 4-5).
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Figure 4-5. Systolic and diastolic arterial blood pressure of Ketoprofen-lysine prodrug
recipients with extensive neuroinflammation. Rats divided in two groups: those not receiving
prodrug (ND) and those with prodrug and extensive inflammation (DI) Each group includes those
rats both dietary protocols and genotypes. Values are presented as mean ± SEM.
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4.4 Discussion
The original study aimed to investigate therapeutic effect of a novel non-steroidal antiinflammatory KL prodrug to treat the negative effects of the combination of early AD-like
pathology and a high fat, high sugar hypercaloric diet. In two separate studies this combination
has been demonstrated to induce localized white matter inflammation and cognitive deficits. The
investigation that included the impact of the KL prodrug on the activated microglia in the white
matter and the behavior indicated no significant reduction in the white matter pathology or the
cognitive deficits. However, of the 39 animals receiving the KL prodrug 2 died unexpectedly, and
6 developed widespread neuroinflammation and neuronal degeneration, irrespective of the
experimental group. This widespread pathology also impacted behavioral performance when
compared to untreated rats. Although this phenomenon was observed in a relatively small number
or animals (total of 8 out of 39), the magnitude of the pathology and that fact this did not show up
in any other animals (41 rats) not receiving the KL prodrug in this study or a previous study, such
a pronounced deleterious effect that appears to be KL prodrug dependent, is important to report in
light of the clinical push to use NSAIDs to treat early symptoms of AD.
The rats receiving the KL prodrug developed massive cerebral inflammation, including both
microgliosis and astrocytosis that affected large regions of the cerebral cortex, basal ganglia,
thalamus, hippocampus, hypothalamus and adjacent white matter. Analysis of cells positive for a
neuronal marker showed neuronal loss in areas corresponding to the regions of neuroinflammation.
Treatment has also appeared to lead to a lethal outcome in two cases after one month of KL prodrug
treatment.
Spatial learning tested in the MWM navigation task, in which the hidden platform remained in the
same position over 4 days, remained intact. However, the MWM shifting strategy, or cognitive
flexibility task, adapted for use in this study52–56 to assess the executive function components, in
which the platform was moved to a novel position for each of the 3 testing days, revealed
significant deficits in spatial working memory and challenged learning ability under the novel task
rules and changing environment indicating a cognitive inflexibility in these rats.
To our knowledge such negative effects of NSAIDs have not been reported by other animal studies
in the literature to date. However, there are clinical reports with evidence of adverse cardiovascular
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and cerebrovascular effects using this group of drugs57–65. These effects include fatal and non-fatal
heart failure, myocardial infarction, ischemic and hemorrhagic stroke, and transitory ischemic
attack. An increased risk for serious vascular complications with the NSAIDs treatment has been
registered for the general population63,66 and specifically for NSAID use in osteoarthritis65 and
rheumatoid arthritis62 patient cohorts as well as individuals with a family history of AD63. The
adverse effects depended on dose and duration factors and were especially worse for long
treatments at high doses.
Potential underlying mechanisms leading to the development of the adverse effects with NSAID
use include vascular damage including due to oxidative stress, a shift towards a prothrombotic
state due to lack of or insufficient blockage of COX-1 dependent platelet aggregation and elevation
of blood pressure that might result into cerebrovascular event42,58,59,62. There are 3 characteristics
of ketoprofen that suggest the treatment agent in our study might have a prothrombotic effect and
result in the adverse cardio- and cerebrovascular events. First, ketoprofen exerts a reversible
inhibition of COX-1 pathway compared to other NSAIDs that have a more permanent COX-1
inhibition67. Secondly, it has a relatively weak affinity for COX-2 expression59,64. COX-2 is
increased in the vasculature and is associated with vasoconstriction in an inflammatory
environment such as that seen in metabolic disorders68. Thirdly, ketoprofen has a half-life less than
12h69,70. The treatment protocol of a once daily injection that we used and this dosage chosen could
produce insufficient antithrombotic action in the long term.
Ketoprofen itself may have a tendency for a higher degree of adverse effects. Blood pressure levels
measured via tail-cuff method were not different in the KL treated rats and does not appear to add
to the pathological events observed in the present study. However, aging, AD and MetS are
associated with the vascular pathology and it is, therefore, possible that cerebrovascular
derangements are present in our model and the actions of the KL prodrug could intersect with or
even further aggravate preexisting pathologies, resulting in cerebral insults seen in our animals.
Further investigation of the vascular status in our model would be needed to make conclusions on
this assumption.
In light of this, of great importance is a question of the safety of these agents in a population with
concurrent chronic diseases such as diabetes and MetS as studied in our model. These are
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individuals who are in a high-risk group for vascular complications and may already have
cardiovascular diagnoses and/or cerebrovascular history. Presence of these conditions can
potentially increase the risk of these side effects even more, leading to recurrent cardio- or
cerebrovascular insults57,71.
What is most critical about the KL prodrug we used in this investigation is the alteration in the
molecular structure, adding the amino acid lysine, to enhance uptake by the brain via LAT1mediated transport. Although this may seem like a logical approach to generate more efficacious
anti-inflammatory agents to combat the earliest neuroinflammatory pathological events, it may, in
fact be very counterproductive if other NSAIDs manipulated in a similar manner to ketoprofen
also generate this type of brain pathology. The toxicity could result from particular NSAIDs itself,
i.e. ketoprofen in our study, or could be attributed specifically to the lysine addition. Additional
experimental studies need to be done to understand the clinical risks associated with the use of
NSAIDs for the treatment of mild cognitive impairment and the slowing or prevention of dementia.

One of the limitations to this study is that there were no vehicle control groups in the current
experimentation. Our primary goal was to assess whether the novel prodrug could reduce the white
matter inflammation in our comorbid model. However, saline control experiment should be carried
out to examine possible effects of chronic injection stress and their contribution to the
neuropathology and behavioral performance.
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Chapter 5: Relationship between White Matter Inflammation and
Metabolic and Physiological Parameters in a Comorbid APP21 Rat Model
of Prodromal Alzheimer’s Disease and Metabolic Syndrome
This chapter describes the relationships between the white matter inflammation and systemic
metabolic and physiological parameters using the combined data from the two studies described
in the Chapters 2 and 3 of this thesis. The relationships between behavioral performance and white
matter inflammation are also described. The methods section of this chapter contains only
highlights of the tests used for metabolic and behavioral measurements described in detail in the
previous chapters. This aim of this study is to identify potential biomarkers of white matter
inflammation (Objective 4). This manuscript has not yet been submitted for publication.

5.1 Introduction
Dementia represents one of the biggest global public health challenges these days. Alzheimer's
disease (AD) is the most commonly diagnosed type of dementia and is a progressive, irreversible,
and currently, incurable disease1. Extensive search for the treatment of AD has not yet yielded the
desired results and research from both pre-clinical and clinical fields is continued. In addition to
the search for treatment of AD, there has been an increase in studies examining biomarkers of the
disease that would aid in early identification of the disease pathology2–5. Timely and accurate
diagnosis of AD is essential for early intervention and better prognosis and remains a great
challenge and most likely one of the major contributors accounting for the failure of clinical trials
for potential treatments. However, identified biomarkers have a limited use in the clinical
examination yet and bear significance primarily for research purposes6–9. Current biomarkers
proposed for the diagnosis of AD include changes in brain inflammatory cells, changes in
perfusion and metabolism on positron emission tomography, structural changes using MRI,
changes in cytokine, tau and amyloid protein levels in blood and cerebrospinal fluid2,10–12. Most
of these parameters are not easily obtained and the techniques are not widely available in hospitals
and clinics. In addition, they are expensive and require complex technical set up.
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Markers of neuroinflammation, or the inflammatory process in the brain, are of special interest.
Neuroinflammation, mainly regulated by microglia and astrocytes, is one of the features of
pathological processes that occur in metabolic disorders in the elderly, including obesity and
metabolic syndrome (MetS)

13,14

. Neuroinflammation

is also a common process in

neurodegenerative diseases, including AD in which it is thought to be implicated at early stages of
the development and progression of the disease 15–18.
White matter pathology, including inflammatory changes, appears to be a promising candidate for
early treatment and prevention. White matter abnormalities are often visualized as hyperintensities
(WMH) on MRI scans in individuals from the elderly population and are thought to be
characterized by excessive neuroinflammation and glial activation as well as by loss of myelin and
axonal fibers, however, the particular pathology and chronological events might differ with the
specific disease19–21. These abnormalities increase with aging, are often present in the prodromal
phase of AD 22,23, mild cognitive impairment (MCI)24 and in patients with MetS 25, and have been
shown to highly correlate with cognitive decline and, moreover, occur well before symptoms of
cognitive deterioration become evident 22,26.
Potential biomarkers of these WMH include increased blood insulin levels and hypertension,
which represent individual components of MetS27. Blood IL-8 levels were found to be associated
with the WMH particularly in AD pointing to a potential inflammatory basis of this pathology28.
The presence of WMH, however, might indicate more advanced changes to the white matter, thus,
investigation into the early pathological events, such as white matter inflammation, and their
markers is needed.
Neuroinflammation, as a feature of both AD and MetS, and represents a risk factor for MCI and
AD, and also appears to be a shared pathology between these disorders. AD and MetS are often
coexisting in human population and neuroinflammation is suggested to be a point of their
interaction 29,30. This interaction between pre-AD and MetS was recently demonstrated in our study
of a novel human amyloid precursor protein (hAPP) transgenic (TG) rat model of early AD
(APP21) and a hypercaloric diet (HCD) induced obesity and MetS. The combination of prodromal
AD and MetS resulted in a larger increase in neuroinflammation, specifically in the white matter
throughout the entire brain primarily driven by OX-6+ activated microglia of the comorbid animals
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compared to either condition alone. This increase in white matter neuroinflammation was
accompanied by spatial reference memory impairment in the comorbid group compared to the
control animals and occurred in the absence of neuronal loss in the hippocampus suggesting that
white matter neuroinflammation in particular could be one of the early brain pathologies
contributing to cognitive deficits observed in MCI and dementia, including AD cases.
The results summarized above suggest the importance of finding potential biomarkers of the
neuroinflammatory process, including those specific to the white matter, to identify a population
at risk for dementia and to be able to intervene and prevent further development of cognitive
decline. Thus, an examination of the relationship between changes in metabolism and/or
physiological markers associated with MetS and early signs of white matter inflammation in a
prodromal AD model could be an important first step in developing an understanding of potential
biomarkers for AD pathology at specific stages.
In this study, we performed an analysis of the relationships between systemic blood based
metabolic changes and physiological parameters with activation markers of the key brain
inflammatory cells, microglia and astrocytes, in the white matter. This would enable the
identification of potential measurable indicators, biomarkers or precursors to brain pathogenic
white matter inflammatory processes. Using the measures collected from our pre-clinical model,
we focused on those which are easy to obtain in the clinical setting. We also analyzed the
relationship between behavioral performance and white matter inflammation.
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5.2 Methods
5.2.1 Animals and Diets
All animal handling and experimental procedures were approved by Western University Animal
Care Committee (AUP 2008-113, 2014-016) and were carried out in accordance with the
guidelines of the Canadian Council on Animal Care and National Institute of Health Guides for
the Care and Use of Laboratory Animals.
These results were drawn from 2 cohorts of animals. The first comprised a total of 24 male
wildtype (WT) and 22 APP21 TG Fischer 344 rats 8.5-9 months old at the start of experiment
involved in a study of the characterization of the comorbid model of pre-AD and MetS. Additional
animals were included in the analysis from a second study investigating the therapeutic effect of
the anti-inflammatory prodrug using the same model of Mets and pre-AD and involved a total of
15 male WT and 11 TG rats 10-10.5 months of age. Rats were bred in house with original breeding
pairs obtained from Drs. Yuksel Agca and Cansu Agca (University of Missouri, Colombia, MO,
USA) and confirmed to be homozygous

31,32

. Animals were housed in pairs under standard

conditions (12:12 light/dark cycle, at 22-24°C). A subset of rats of each genotype was randomly
assigned to a high-calorie Western type diet (D12079B, Research Diets, Inc) supplemented with
20% corn syrup drink (HCD), while the other half continued on a standard diet (control diet, CD;
Prolab RMH 3000 5P00). Diets were provided ad libitum and rats were maintained on the diets
for 12 - 15 weeks.
For this correlational analysis, rats from both studies were combined for the same parameter with
an exception of glucose and insulin metabolism measures with the following numbers for each
experimental group: WT CD n=21, TG CD n=16, WT HCD n=18, TG HCD n=17.

5.2.2 Physiological and Metabolic Measurements
Detailed methodology can be found in the original studies. Briefly, the body weight at the end of
the experiment was recorded and epididymal fat pads were collected and weighed at the time of
euthanasia. The latter was used as a measure of visceral adiposity. Glucose metabolism was
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assessed using the glucose tolerance test (GTT) at 11-12 week following the change in diets, with
either the intraperitoneal (Ip; IpGTT) or intravenous (Iv; IvGTT) version of the test. Fasting serum
insulin levels were determined and the homeostasis model assessment index (HOMA-IR) of
insulin resistance was calculated for a subset of rats 33. Fasting serum lipid profile analysis included
measurements of triglycerides, total cholesterol, calculations of non - high density lipoprotein
(non-HDL) cholesterol and cholesterol ratio (Chol:HDL ratio; total cholesterol/ HDL cholesterol)
which is an “atherogenic” index used clinically to assess cardiovascular risks34.

5.2.3 Behavioral Testing
The Morris Water Maze test (MWM), in which rats were trained over 4 days to find a hidden
escape platform in a circular pool using extra-maze cues and then tested in a probe trial with no
platform, was used to assess spatial navigation and reference memory. In the first study, rats were
exposed to initial training before the dietary assignment, then underwent re-learning of the novel
platform location at the end of experiment with a probe trial following a day after. In the second
study rats received training only at the end of dietary treatment which was again followed by a
probe trial. Spatial reference memory was evaluated during the probe trial using time and distance
spent searching for a platform in the target zone where it used to be located expressed as a
percentage of the total probe swim. Rats from the second study were then challenged with a
modified 3-day shifting strategy task in which platform location was changed every other day and
spatial working memory (cognitive flexibility) was assessed using differences in time and distance
(i.e. path length) to reach the platform in trials 1 and 2 of the task 35,36.

5.2.4 Immunohistochemistry
Following a 12-h fasting period all the rats were euthanized by a pentobarbital overdose and
sequentially perfused with phosphate buffered saline and 4% paraformaldehyde (PFA). Coronal
sections of 30-35 μm thickness were immunohistochemically processed to visualize activated
microglia and astrocytes using monoclonal antibodies directed against the MHC II receptor (OX6; 1:1000; BD Pharmingen, Mississauga ON, Canada) and glial acidic fibrillary protein (anti182

GFAP; 1:2000; Sigma-Aldrich, St Louis MO, USA), respectively. Areas of interest included the
entire body (BCC) and periventricular regions (PVCC) of the corpus callosum as well as the
internal capsule (IC) in both hemispheres. Area coverage by a positive signal (area%) was
measured for each region in the Image J software and expressed as a weighted average. Detailed
protocols are described elsewhere.

5.2.5 Data Analysis
Statistical analysis was performed using IBM SPSS software. Statistical analysis was done on the
entire set of data including all rats, on the data sets separated based on either genotype or diet and
on individual experimental groups. Data for each measured parameter was first screened for
outliers using 2SD±mean rule. All measures were checked for normality using the Shapiro-Wilk
test. For the interregional white matter inflammation correlation, a partial correlation analysis was
performed on the entire dataset controlling for diet and genotype. Statistical significance was set
at a p value of ≤ 0.05.
Firstly, correlations were computed for each behavioral outcome and white matter inflammatory
marker to assess the relationship between the cognitive performance and cerebral pathology.
Bivariate correlation matrix was created next to define potential predictors (independent variables)
of the white matter inflammatory cellular pathology (dependent variable) from the measured
peripheral outcomes to be included in the regression model. Independent variables that were
making significant contributions to the explanation of the variance of the dependent variable were
selected based on the correlation coefficient significance. Individual linear regressions were
performed with each independent variable to model its relationship with dependent variable, the
white matter inflammatory parameter. Single input models were compared between each other to
identify a better model. Multiple linear regression analysis was next performed with low or noncorrelated independent variables to establish whether any model including more than one
independent variable explains the variance of the dependent variable better and improves over
models with a single entered component. Assumptions for linear regression were checked for each
model: linearity of relationship between independent variable and dependent variable using
scatterplots; independence, normality of distribution, linearity and homoscedasticity of residuals
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using normal probability plot, standardized predicted values over standardized residuals
scatterplot, Durbin-Watson test; multicollinearity using VIF, tolerance values, coefficients from
bivariate correlation matrix. Models were compared by number of parameters including F statistics
of overall significance of the model (p value), standard error estimate, t value, standardized
coefficients (β) and adjusted R2.
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5.3 Results
5.3.1 White matter inflammation relationships
Microglia activation throughout the brain of individual rats assessed using OX-6 immunomarker
was highly positively correlated across examined white matter regions: BCC and PVCC
Spearman’s rho=0.982, p<0.0001; BCC and IC rho=0.813, p<0.0001; IC and PVCC rho=0.810,
p<0.0001. This relationship held true while controlling for genotype and diet (Table 5-1). In the
individual groups, the BCC region activated microglia coverage was highly correlated with PVCC
(r>0.9, p<0.0001) and IC (r>0.78) for all groups except WT CD, that did not show any significant
relationship with the IC region inflammation. All groups with an exception of control rats on the
CD had a PVCC-IC significant positive correlation (r>0.65, p<0.009).
Astrocyte reactivity in the BCC measured by GFAP(+) signal area coverage (%) of the region
positively correlated with the OX-6 activated microglia coverage in the BCC in the entire dataset
(rho=0.36, p=0.004). When genotype and diet were entered as controlling factors, the correlation
lost significance. Thus, this relationship was due to both inflammation makers correlated with the
particular genotype and diet. Individual experimental group analysis revealed that the correlation
between these two inflammatory markers in the BCC region was significant only in the comorbid,
TG HCD, group (r=0.517, p=0.04).
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Table 5-1. Correlation of microglia activation in the cerebral white matter
BCC
BCC

-

PVCC

Internal capsule

0.974

0.835

<1.2e-38

3.067e-018

PVCC

-

0.819
2.064e-016

Strong positive correlation suggests that activation of white matter microglia increased globally
throughout individual rat brains for both wildtype and transgenic rats on either control or
hypercaloric diet. Pearson’s coefficient (r) and corresponding p values are shown for correlations
of OX-6+ microglia (area%) between ROIs. Partial correlation was performed controlling for
genotype and diet; n=66. BCC − corpus callosum body, PVCC − corpus callosum periventricular
sub-regions, ROI − region of interest.
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5.3.2 Behavioral performance and white matter inflammation relationships
Linear regression analysis was performed to test whether the spatial reference memory probed in
the MWM at the end of study in each of the protocols was related to the white matter microglial
activation level. The relationships with the target zone swim parameters were analyzed. The
combined dataset showed a negative relationship between OX-6 microglia coverage in IC and the
distance travelled in the target zone out of the total probe swim path (r=-0.368, p=0.015,
F(1.42)=6.427, R2=0.114) in the re-learning paradigm. This suggests a better behavioral
performance (i.e. better spatial memory), as represented by the greater distance travelled searching
in the target zone of the pool, is associated with a lower white matter microglial activation in the
IC region. This relationship was not observed within either individual genotype subsets or
individual experimental groups, however it appeared in the HCD subset and maintained the
directionality and strength of significance (r=-0.53, F(1.19)=7.427, p=0.013, R2=0.281). Astrocyte
reactivity in the white matter was not associated with any parameter of the cognitive function.
Analysis of the groups also indicated specific relationships between behavior and
neuroinflammation. Time spent searching in the target zone, expressed as a percentage of the total
probe trial time, was strongly inversely correlated with microglial activation in the BCC for TG
HCD. This suggests there is a poorer cognitive performance on the test with increase in microglial
activation in the BCC (Table 5-2). This was observed in the second study subgroup (n=6) of rats
for which this was a first ever encounter with the maze. In this rat group, a significant negative
linear relationship was also found between OX6-positive microglia area coverage in the BCC and
shifting strategy task performance. Thus, comorbid rats tended to have a smaller intertrial
difference in the swim path, a smaller improvement, that suggested they were less cognitively
flexible, when the activation level of the microglia in the BCC was higher (Table 5-2). In contrast
to these results, TG CD rats (n=4) showed a very strong positive correlation (r=0.96, F(1.)=35.193,
p=0.01, R2=0.895), suggesting a greater performance associated with the greater inflammation in
the white matter of the corpus callosum.
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Table 5-2. Relationship of the behavioral performance in the MWM of TG HCD rats with OX6 microglial activation in the BCC
Pearson’s r

Adjusted R2

MWM shifting Δ distance*

-0.836

0.624

0.038

9.315

MWM target zone time (%,s)*

-0.897

0.756

0.015

16.467

p

F

MWM − Morris water maze; TG HCD − transgenic rats on the hypercaloric diet (comorbid group);
* results of the second study only (n=6); shifting Δ distance – 3- day average difference in distance
(path length) to reach the hidden platform between trials 2 and 1 with a greater value indicating a
better cognitive performance.
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5.3.3 Metabolic, physiological parameters and white matter microgliosis relationships
Correlations and linearity of the relationship of OX-6 positive activated microglia coverage in each
of the three different white matter regions (BCC, PVCC, IC) were done individually for each
measurement and included an examination of the whole dataset as well as genotype, diet and
specific group analyses (Table 5-3).
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Table 5-3. Metabolic measures and white matter microgliosis correlations
Genotype

Diet

Body weight

Visceral Fat

Total
Cholesterol

Entire Dataset
BCC
β=0.513
F(1,64)=22.839
p<.0001
R2=0.263

β=0.341
F(1,64)=5.711
p=0.005
R2=0.102

β=0.376
F(1,64)=10.558
p<0.0001
R2=0.244

β=0.494
F(1,64)=22.701
p=0.002
R2=0.128

β=0.293
F(1,62)=5.824
p=0.019
R2=0.071

β=0.543
F(1,64)=26.695
p<0.0001
R2=0.294

β=0.363
F(1,64)=9.708
p=0.003
R2=0.132

β=0.398
F(1,64)=12.045
p=0.001
R2=0.158

β=0.516
F(1,64)=23.184
p<0.0001
R2=0.266

β=0.334
F(1,62)=7.803
p=0.007
R2=0.112

β=0.31
F(1,62)=6.579
p=0.013
R2=0.096

β=0.004
F(1,63)=8.38
p=0.005
R2=0.117

β=0.436
F(1,63)=14.78
p<0.0001
R2=0.19

β=0.282
F(1,61)=5.279
p=0.025
R2=0.08

β=0.256
F(1,61)=4.266
p=0.043
R2=0.05

PVCC

β=0.352
F(1,63)=34.227
p<0.0001
R2=0.352
Presence of Transgene (TG rat dataset)
BCC
β=0.396
F(1,30)=5.58
p=0.025
R2 =0.129
IC

PVCC

IC

HCD Dataset
BCC
β=0.547
F(1,31)=13.255,

β=0.463
F(1,30)=8.166
p=0.008
R2=0.188

Triglycerides

Non-HDL
Cholesterol

Chol:HDL

AUC GTT

β=0.482
F(1,30)=9.072
p=0.005
R2 =0.207
β=0.534
F(1,30)=11.937
p=0.002
R2 =0.261
β=0.37
F(1,29)=4.59
p=0.041
R2 =0.107
β=0.109
F(1,31)=6.038

(Iv) β=-0.802
F(1,9)=16.192
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Fasting
Insulin;
HOMA-IR

p=0.001
R2=0.3
Genotype

p=0.02
R2=0.136
Diet

Body weight

Visceral Fat

p=0.003
R2=0.603
Total
Cholesterol

Triglycerides

Non-HDL
Cholesterol

Chol:HDL

AUC GTT

PVCC

β=0.611
F(1,32)=19.06
p=0.008
R2=0.373

β=0.506
F(1,32)=11.038
p=0.002
R2=0.233

(Ip) β= -0.442
F(1,21)=5.088
p=0.035
R2=0.157

IC

β=0.588
F(1,31)=16.391
p<0.0001
R2=0.325

β=0.105
F(1,31)=7.553
p=0.002
R2=0.233

(Iv) β=-0.726
F(1,9)=10.049
p=0.011
R2=0.475

Fasting
Insulin;
HOMA-IR

(Ip) β=-0.464
F(1,20)=5.491
p=0.03
R2=0.176
Co-morbid TG HCD Dataset
BCC

β= -0.522
F(1,13)=5.711
p=0.033,
R2=0.252

β= -0.623
F(1,13)=8.226
p=0.013
R2=0.34

β= -0.637
F(1,13)=8.895
p=0.011
R2=0.361

β= -0.64
F(1,13)=9.015
p=0.01
R2=0.364

β= -0.639
F(1,14)=9.679
p=0.008
R2=0.367

β= -0.671
F(1,7)=5.718
p=0.048
R2 =0.371
HOMA-IR
β= -0.681
F(1,7)=6.069
p=0.043
R2=0.388

PVCC

β= -0.638
F(1,14)=9.604
p=0.008
R2=0.365

β= -0.635
F(1,14)=9.47
p=0.008
R2=0.361

β= -0.658
F(1,15)=11.465
p=0.004
R2=0.396

β= -0.744
F(1,8)=9.911
p=0.014
R2 =0.198
HOMA-IR
β= -0.743
F(1,8)=9.87
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p=0.014
R2=0.496
Genotype

Diet

Body weight

Visceral Fat

Total
Cholesterol

Triglycerides

Non-HDL
Cholesterol

Chol:HDL

TG CD Dataset
IC

AUC GTT

Fasting
Insulin;
HOMA-IR

(Iv) β= -0.619
F(1,3)=14.315
p=0.032
R2=0.306

β= -0.814
F(1,8)=15.722
p=0.004
R2 =0.621
HOMA-IR
β= -0.76
F(1,8)=10.92
p=0.011
R2=0.524

WT rat Dataset
BCC

β=0.559
F(1,30)=13.651
p=0.001
R2=0.29

β=0.516
F(1,30)=10.87
p=0.003
R2=0.242

β=0.561
F(1,30)=13.791
p=0.001
R2=0.292

β=0.425
F(1,30)=6.605
p=0.015
R2=0.153

β=0.439
F(1,30)=7.177
p=0.012
R2=0.166

β=0.544
F(1,30)=13.302
p=0.001
R2=0.284

PVCC

β=0.517
F(1,30)=10.922
p=0.002
R2=0.242

β=0.479
F(1,30)=8.955
p=0.005
R2=0.204

β=0.523
F(1,30)=11.279
p=0.002
R2=0.249

β=0.544
F(1,30)=5.548
p=0.025
R2=0.128

β=0.43
F(1,30)=6.816
p=0.014
R2=0.158

β=0.544
F(1,30)=12.587
p=0.001
R2=0.272

IC

β=0.585
F(1,30)=15.648
p<0.0001
R2=0.321

β=0.493
F(1,30)=9.612
p=0.004
R2=0.243

β=0.502
F(1,30)=10.104
p=0.003
R2=0.227

β=0.439
F(1,30)=7.147
p=0.012
R2=0.165

β=0.377
F(1,30)=4.974
p=0.033
R2=0.114

β=0.382
F(1,30)=5.122
p=0.031
R2=0.117

(Ip) β=0.531
F(1,30)=7.462
p=0.013
R2=0.244

Only significant correlations at a significance level of <0.05 are shown for OX-6+ activated microglia (area% coverage of the white matter region) in the
corpus callosum (BCC, PVCC) and IC. Transgene in this context is human amyloid precursor protein with Swedish and Indiana mutations. β −
standardized coefficient (Pearson’s R), R2 − adjusted R2. BCC − corpus callosum body, CD − control diet, PVCC − corpus callosum periventricular subregions, HCD − hypercaloric diet, HOMA-IR − homeostasis model assessment index of insulin resistance, IC − internal capsule, Ip − intraperitoneal
glucose tolerance test, Iv − intravenous glucose tolerance test, TG − transgenic rat, WT − wildtype.
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5.3.3.1 Corpus callosum
When the entire dataset was used, there were several factors that were significant predictors of the
BCC microglial activation. These included genotype (β=0.513, R2=0.263); visceral fat
accumulation (β=0.494, R2=0.128; 5-1A); and diet (β=0.341, R2=0.102). Final body weight was a
less strong predictor (β=0.376, R2=0.244). Total cholesterol levels had a weak, yet significant
positive association and the lowest prediction power (β=0.293, R2=0.071). When visceral fat mass
and genotype were considered together, both genotype and visceral fat were significant predictors
of microglial activation in the BCC (β=0.401 fat and β=0.425 genotype) and together they
strengthened the regression model (F(2,62)=22.452, p<0.0001, R2=0.398).
The data set was then split in two groups based the presence of transgene (WT or TG) for one set
and based on the diet (CD and HCD) for another analysis. The regression analysis indicated
visceral fat accumulation was the strongest significant predictor in both genotypes (Figure 5-1B)
and correlated in a positive manner in the HCD rat subset (Figure 5-1C). Genotype remained a
significant predictor of BCC neuroinflammation in both dietary datasets. Additionally, weaker
correlations that were also significant were detected for body weight, non-HDL cholesterol,
triglycerides and for the GTT, including area under the curve (AUC) for glucose levels using the
IpGTT in the WT subset and AUC using the IvGTT method in the HCD group.
Thus, genotype was strongly associated with the microglia activation in the BCC in every dataset.
Among the measured parameters, visceral fat mass was associated with a greater BCC microglia
activation irrespective of the genotypic characteristics, however was predictive of it only in the
HCD environment.
Analysis of the entire dataset indicated significant predictors of the PVCC microglial activation
included genotype (β=0.543, R2=0.294); visceral fat mass (β=0.516, R2=0.266; Figure 5-1D); body
weight (β=0.398, R2=0.158); and diet (β=0.363, R2=0.132). Weaker, but significant, relationships
were also seen with total cholesterol and non-HDL cholesterol levels. When visceral fat mass and
genotype were both included in the regression model, it improved and both genotype and fat were
still significant individual predictors (β=0.417 fat and β=0.451 genotype, F(2,62)=26.787, p<0.0001,
R2 =0.442).
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In the WT data sample, cholesterol ratio, visceral fat (Figure 5-1E), body weight, diet as well as
non-HDL cholesterol and triglycerides each had a significant contribution to the variance of the
microglial neuroinflammation. The strongest association with microglial activation was with the
Chol:HDL ratio, which had a better prediction capacity (β=0.544, R2=0.272) than body fat
(β=0.523, R2=0.249). The strongest relationship with the OX-6 microglial activation in the PVCC
region in the TG rat sample was found with the body fat mass (β=0.534, R 2=0.261; Figure 5-1E).
In both HCD and CD environments genotype was the strongest factor significantly related to the
inflammation in the PVCC. In addition, the amount of visceral fat was the next strong predictor
after the genotype in the HCD subset mass (β=0.506, R2=0.233; Figure 5-1F), followed by the
AUC in the IpGTT.

5.3.3.2 Internal capsule
Microglia activation in the IC region was associated with the genotype as the strongest factor for
the entire rat dataset (β=0.352, R2=0.352) as well as both dietary subgroups (CD β=0.681,
F(1,31)=24.433, p<0.0001, R2=0.463; HCD β=0.588, R2=0.325). For metabolic measures visceral
fat showed the strongest relationship with neuroinflammation in the entire dataset (β=0.436,
R2=0.19; Figure 5-1G) and HCD subset (β=0.105, R2=0.233; Figure 5-1I). Body weight and diet
showed much weaker, yet significant correlation in the whole sample regression analysis. Total
cholesterol and non-HDL fraction were also positively but weakly correlated to the inflammation.
Multiple regression model which included both genotype and fat mass showed an increased
precision with both variables contributing significantly to the variation in the inflammation
(R2=0.45; β=0.321 fat and 0.523 genotype, F(2,62)=25.383, p<0.0001). Visceral fat was
significantly correlated with the IC activated microglial coverage in both genotypes with a stronger
relationship of the fat amount in WT rats (Figure 5-1F). Additional correlations indicated that diet
was the strongest predictor (β=0.585, R2=0.32), while Chol:HDL ratio, body weight, non-HDL
cholesterol and triglycerides which were the weakest and poorly explained the variance of
inflammatory outcome in the WT rat subset. In the HCD subset the measure of AUC in IvGTT or
AUC in IpGTT were identified as having a negative correlation with IC microgliosis (AUC IvGTT,
β=-0.726, R2=0.475; AUC IpGTT, β=-0.464, R2=0.176).
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Thus, transgene presence and HCD was associated with the greater microglia activation in the
corpus callosum, both in the body and periventricular regions, and the IC. Greater visceral fat mass
was associated with a greater microglia activation in all three white matter regions analysed
irrespective of the genotypic characteristics, however was predictive of it only in the HCD
environment.

5.3.3.3 Relationships in individual experimental groups
Group-wise linear regressions on the BCC activated microglia coverage identified candidate
parameters only in the comorbid (TG HCD) group.
Figure 5-2 indicates there was a strong negative correlation with final body weight (β=-0.522,
p=0.033); fasting total cholesterol levels (β=-0.623, p=0.013); triglycerides (β=-0.637, p=0.011);
non-HDL cholesterol (β=-0.64, p=0.01); Chol:HDL (β=-0.639, p=0.008) and fasting insulin levels
(β=-0.671, p=0.048).
Linear regression analysis indicated that a lower Chol:HDL ratio was the best predictor of
increases in the BCC microglial activation level in the comorbid rats (β=-0.639, R2=0.367). This
was also true for the PVCC brain region for which Chol:HDL ratio model produced a strong
negative relationship (β=-0.658, R2=0.396).
For inflammation in the IC, group-wise linear regressions indicated a relationship with fasting
insulin (β=-0.814, R2=0.621); HOMA-IR (β=-0.76, R2=0.524); and AUC IvGTT (β=-0.619,
R2=0.306) in the TG CD group.
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Figure 5-1. Relationships between visceral fat accumulation and white matter activated
microglia. Visceral fat pads mass indicated as fat pad weight and OX-6+ activated microglia
coverage expressed as percent of the total area of the white matter structure in A-C) BCC; D-F)
PVCC; G-I) IC regions. Significant linear relationships were found for the datasets: A) entire set
(R2=0.128, p=0.002); B) TG (R2=0.207, p=0.005) and WT (R2=0.292, p=0.001); C) HCD
(R2=0.136, p=0.02); D) entire set (R2=0.266, p<0.0001); E) TG (R2=0.261, p=0.002) and WT
(R2=0.249, p=0.002); F) HCD (R2=0.233, p=0.002); G) entire set (R2=0.19, p<0.0001); H) TG
(R2=0.107, p=0.041) and WT (R2=0.227, p=0.003); I) HCD (R2=0.233, p=0.002). Black and
colored solid lines on each graph show linear regression line. Dotted lines indicate 95% confidence
interval of linear regression. BCC = body of the corpus callosum, PVCC = periventricular regions
of the corpus callosum, IC = internal capsule regions.
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Figure 5-2. Relationships in the comorbid group between metabolic measures and microglia
activation in the corpus callosum. Significant relationships between BCC OX-6 activated
microglia coverage expressed as percent of the total region’s area and A) end of experiment body
weight (R2=0.252, p=0.033), B) serum fasting total cholesterol (R2=0.34, p=0.013), C) non-HDL
cholesterol (R2=0.364, p=0.01), D) Chol:HDL ratio (total cholesterol/HDL cholesterol);
(R2=0.367, p=0.008), E) triglycerides (R2=0.361, p=0.011), F) fasting insulin levels (R2=0.371,
p=0.048). The results are from the co-morbid model of transgenic rats on the hypercaloric diet (TG
HCD). BCC = body of the corpus callosum, Chol = cholesterol, HDL = high density lipoprotein
cholesterol. R2 = adjusted R2.
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5.3.4 Metabolic, physiological measures and white matter astrocyte reactivity relationships
Correlations and linearity of relationship of the GFAP activated astrocytes in the BCC and IC
regions were done individually for each measurement and included whole dataset, genotype, diet
and individual group analyses.
Astrocyte reactivity in the BCC was related to the genotype when analyzing the entire dataset
(β=0.292, F(1,60)=5.591, p=0.021, R2=0.085). Astrocytosis in the corpus callosum was inversely
related only to the glucose metabolism, AUC IvGTT, in the data subsets from CD (β=-0.743,
F(1,9)=11.101, p=0.009, R2=0.503) and TG (β=-0.754, F(1,9)=11.852, p=0.007, R2=0.520) rat groups
(Figure 5-3A).
Reactive astrocytosis in the IC was inversely associated with the glucose metabolism, AUC Ip
GTT, in the entire group of all rats (β =-0.625, F(1,13)=8.351, p=0.013, R2=0.391), WT (β=-0.813,
F(1,5)=9.750, p=0.026, R2=0.593) and HCD subsets (β=-0.792, F(1,5)=8.343, p=0.034, R2=0.628);
(Figure 5-3B). The WT rat subset had negative significant, but weak relationships with body
weight, visceral fat and Chol:HDL ratio.
The TG CD group showed a strong inverse association between the AUC IvGTT and GFAP BCC
coverage (β =-0.976, F(1,2)=40.682, p=0.024, R2=0.93).
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Figure 5-3. Relationships between glucose tolerance and reactive astrocytes in the body of
the corpus callosum and internal capsule. Glucose tolerance presented as glucose AUC in the
GTT with greater AUC numbers corresponding to low glucose tolerance. GFAP+ reactive
astrocyte coverage expressed as percent of the total area of A-C) body of the corpus callosum and
D-F) internal capsule regions. Significant relationships between glucose intolerance and astrocyte
reactivity are shown for the datasets: A) TG CD individual group (β =-0.976, p=0.024, R2=0.93);
B) TG combined set (β=-0.754, p=0.007, R2=0.520); C) CD combined set (β=-0.743, p=0.009,
R2=0.503); D) entire set (β =-0.625, p=0.013, R2=0.391); E) WT combined set (β=-0.813,
p=0.026, R2=0.593); F) HCD combined set (β=-0.792, p=0.034, R2=0.628). AUC = area under
the curve, CD = control diet, GTT = glucose tolerance test using intravenous (IvGTT) or
intraperitoneal (IpGTT) method, HCD = hypercaloric diet, TG = transgenic, WT = wildtype. Solid
lines on each graph represent linear regression lines. Dotted lines indicate 95% confidence interval
of linear regression. R2 = adjusted R2.
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5.4 Discussion
This investigation was directed toward identifying potential markers of the cerebral white matter
inflammation in prodromal AD by studying associations between metabolic parameters and
cerebral white matter activated microglia and astrocytosis in APP21 TG and MetS rat models,
alone or in combination.
First it was determined whether there is any association between the neuroinflammatory markers
and outcomes of behavioral tests utilized to assess spatial reference and working memory. White
matter activated microglia, but not astrocyte reactivity, showed correlations with the cognitive
performance. The general trend was indicative of an inverse correlation, i.e. a better cognitive task
performance was associated with a lower white matter microglial activation. Interestingly, specific
group analysis revealed differences in directionality of the relationship. The comorbid rats, TG on
the HCD, followed the general trend. Unlike the general trend of an inverse correlation, the TG
CD group had a very strong positive correlation, suggesting a greater performance associated with
the greater neuroinflammation. These observations, however, should be treated with caution as the
analysis was limited by the low sample size since the behavioral protocols were different for the
two cohorts of animals.
Linear regression examined the relationship of metabolic measures with microgliosis and
astrocytosis in the corpus callosum and internal capsule. Microgliosis was strongly associated with
the amount of visceral fat and lipid metabolism, whereas astrocytes reactivity was correlated with
glucose metabolism. In addition, genotype appeared to be the leading predictor in the degree of
neuroinflammation in every region, in this case the transgene was the hAPP with Swedish and
Indiana mutations associated with early familial AD (APP21). These animals have high APP and
amyloid beta proteins in the brain31,37 and develop increased white matter microglial activation
with aging and with the HCD in our studies36.
The most profound metabolic predictor of an increase in microglia activation in both white matter
regions was greater visceral fat mass. The association between visceral adiposity and WMH have
also been observed in humans 38–40. This seems to be in line with the notion of obesity as a systemic
low-grade inflammatory condition and increased visceral fat accumulation as an active proinflammatory secreting tissue influencing inflammatory status in the brain41,42. The amount of
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visceral fat together with the transgene demonstrated the greatest contribution to the white matter
microglial activation.
Correlations with lipid profile parameters, including total cholesterol, atherogenic fraction and
triglycerides levels indicated these parameters were also possible contributors to the amount of
microgliosis, although not to the same extent as visceral fat, body weight or genotype. In the
combined datasets, hyperlipidemia was significantly associated with higher levels of microglia
activation in the white matter, a phenomenon which is associated with AD pathogenesis. This data
fits one of the existing patterns observed in epidemiological studies which related high levels of
total cholesterol, LDL-cholesterol and triglycerides, low HDL levels in mid-life with the greater
risk of AD development43–45.
There appeared to be different associations when the individual set of comorbid rats was compared
to the combined dataset. This relationship was inversed in the TG HCD group, suggesting a
negative association between blood lipids and white matter microgliosis in comorbidity condition.
Such negative relationship between lipid profile and WMH load, although not significant, was
noted in a sample of cognitively normal middle-aged subjects with a family history of AD, the
majority of whom also had MetS 27.
The strongest predictor of the OX-6 activated microglia accumulation in the corpus callosum for
the comorbid rat sample was Chol:HDL ratio, which represents the ratio of two main cholesterol
fractions, HDL and atherogenic non-HDL. A higher lipid ratio, which is observed in metabolic
disorders, and is generally related to a greater risk for cardiovascular disease and dementia, was
associated with lower levels of white matter microgliosis in comorbid group. Analysis of the lipid
profile of our comorbid rats have indicated that these rats had blood levels of the HDL cholesterol,
similar to that of CD rats. However, total cholesterol and the Chol:HDL ratio was significantly
greater compared to controls, which suggests that the increase in the ratio was due to the greater
non-HDL fraction.
The literature provides evidence of the cholesterol paradox in the AD relationship46–50. The
inconsistency of results regarding cholesterol association with AD points to a differential
association with respect to the age of subjects and possibly even the stage of the disease. High
blood total cholesterol and non-HDL cholesterol fractions are associated with decreased risk of
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AD, particularly in the subjects of a greater age, whereas the opposite relationship is seen in middle
age51–53. This could be due to observed declines in cholesterol along with higher energy demands
of the brain with increased age54. Moreover, lower serum cholesterol levels were observed in AD
patients a decade prior to the clinical onset, suggesting lower cholesterol levels are associated with
the prodromal stage of the disease55.
With respect to the white matter, axonal myelin sheaths are highly enriched by lipids and loss of
membrane cholesterol and gangliosides along with myelin degradation and low biosynthesis all
have been associated with aging and AD pathology56–59. It is possible, that increased cholesterol
levels might counterbalance these effects. Thus, the analysis of the association between MRIdetected white matter lesions and cardiovascular risk factors in the elderly participants of the
Cardiovascular Health Study, showed a significant progression of the white matter lesions over
time in participants with high HDL and low LDL blood cholesterol levels as well as with the use
of statins60. In another study dyslipidemia (high triglycerides and low HDL cholesterol levels)
were found to be positively associated with healthy white matter microstructure in generally
healthy adults61.
Furthermore, animal studies have shown the dual role of high dietary cholesterol pointing to antiinflammatory effects, including promotion of M2 “anti-inflammatory” microglia phenotype and
higher IL-4 and IL-6 levels, of higher lipid levels in the aging brain62. This could relate the higher
total cholesterol and non-HDL levels with the lower white matter microglial activation in the
prodromal AD model in our study.
The genetic background of our TG rats, specifically hAPP with Swedish and Indiana mutations,
could also contribute to the observed relationship with lipid metabolites in our model since APP
plays a role in cholesterol metabolism63,64. One study have shown that human astrocytes
homozygous for APP Swedish mutation lead to disrupted cholesterol metabolism in the brain, in
particular low intracellular cholesterol levels, impaired lipoprotein endocytosis and LDL receptor
function were seen65. These changes might contribute to AD pathology such as white matter
degeneration. APP is widely expressed as in the brain so in peripheral tissues. It is possible that
mutated forms might also have effects on peripheral lipid homeostasis, which are yet to be
investigated.
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The effects of the mid-life hypercholesterolemia, dyslipidemia and associated increased levels of
oxidized cholesterol forms (oxysterols) might be particularly detrimental to the white matter
health, including myelin synthesis and breakdown regulated by glia, and thus predispose to AD
pathology later in life. Oxysterols which are able to cross the blood-brain barrier were determined
as a potential links between diet and obesity-related dyslipidemia and AD pathogenesis including
via their contribution to neuroinflammatory and amyloidogenic events 66–78. Treatments that lower
cholesterol, i.e. statins, may help protect vulnerable white matter during the mid-life period, but
can be detrimental in advanced aging and fully developed AD and thus have no effect on the
slowing down the progression of the disease in the clinical trials54.
Interestingly, lower astrocyte reactivity, corresponding to a lower inflammation, was observed
with a greater glucose AUC in the GTT, i.e. glucose intolerance likely related to insulin resistance.
This is somewhat contradictory to what is usually expected since a greater insulin resistance is
associated with poorer brain health. However, in our study the TG rats did not develop pronounced
glucose intolerance compared to WT rats on the HCD. Similarly, patients with AD have been
shown to have lower rates of fasting blood glucose as well as lower glucose values in the oral
glucose tolerance test 79.
There are some limitations to be considered for this investigation. Firstly, the data samples
obtained from the two animal studies were not large. This factor could decrease the precision and
power some of the relationships, such as related to the glucose and insulin metabolism parameters
and in specific subsets. Secondly, we have considered only a limited number of factors that could
contribute to the brain inflammatory pathology. There might be other measures that better explain
the variation in the white matter inflammation and which could greatly improve the prediction of
the defined models. Thirdly, there were only two cellular markers of the neuroinflammation
analysed in the current study based on the data derived from our initial experiments. However,
other white matter pathological processes, including for example oligodendrocyte health, axonal
degeneration, myelination level and vascular status that could occur at the prodromal stage of the
disease, could have a better correlation with systemic metabolic parameters and provide a better
explanation of the cognitive performance. Finally, microglia and astrocyte immunohistochemical
detection was limited to examination of a single marker of each type of cell. Other markers of
activation of these cells should be considered.
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In summary this study highlights the potential of visceral fat accumulation and lipid metabolism
components such as cholesterol ratio, to be markers of activation of microglia in the white matter
in a prodromal AD model. Astrocyte reactivity, another inflammatory factor, was associated with
the glucose metabolism and insulin resistance. More studies investigating the association between
metabolic measures found in the blood and specific brain pathology associated with the prodromal
stage of AD and MCI should be pursued to clarify potential relationships and their usefulness as
minimally invasive biomarkers in various age groups. Comorbid conditions including chronic
metabolic and vascular diseases, gender, genetic variations and attributes of certain ethnic groups
may modulate these relationships, thus requiring even more extensive investigations in this area.

204

5.5 References
1.

Querfurth, H.W. LaFerla, F. M. Mechanisms of disease. Alzheimer’s disease. N Engl J Med 362, 329–344
(2010).

2.

Counts, S. E., Ikonomovic, M. D., Mercado, N. & Vega, I. E. Biomarkers for the Early Detection and Progression
of Alzheimer ’ s Disease. Neurotherapeutics 35–53 (2017). doi:10.1007/s13311-016-0481-z

3.

Hampel, H. et al. Core candidate neurochemical and imaging biomarkers of Alzheimer ’ s disease. Alzheimer’s
Dement. 4, 38–48 (2008).

4.

Sabbagh, M. N., Daniel, L. L. & Jiong, F. Increasing precision of clinical diagnosis of Alzheimer ’ s disease
using a combined algorithm incorporating clinical and novel biomarker data. Neurol. Ther. 6, 83–95 (2017).

5.

Dubois, B. et al. Advancing research diagnostic criteria for Alzheimer ’s disease: the IWG-2 criteria. Lancet
Neurol. 13, 614–29 (2014).

6.

Gauthier, S., Patterson, C., Chertkow, H., Gordon, M. & Herrmann, N. Recommendations of the 4th Canadian
Consensus Conference on the Diagnosis and Treatment of Dementia ( CCCDTD4 ). Can. Geriatr. J. 15, 120–
126 (2012).

7.

Albert, M. S. et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations
from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for
Alzheimer’s disease. Alzheimer’s Dement. 7, 270–279 (2011).

8.

Herukka, S. et al. Recommendations for cerebrospinal fluid Alzheimer ’ s disease biomarkers in the diagnostic
evaluation of mild cognitive impairment. Alzheimer’s Dement. 13, 285–295 (2017).

9.

Mckhann, G. M. et al. The diagnosis of dementia due to Alzheimer ’ s disease : Recommendations from the
National Institute on Aging-Alzheimer ’ s Association workgroups on diagnostic guidelines for Alzheimer ’ s
disease. Alzheimer’s Dement. 7, 263–269 (2011).

10. Huynh, R. A., Mohan, C., Huynh, R. A. & Mohan, C. Alzheimer ’ s disease : biomarkers in the genome , blood
, and cerebrospinal fluid. Front. Neurol. 8, 1–15 (2017).
11. Fiandaca, M. S., Zhong, X., Cheema, A. K. & Orquiza, M. H. Plasma 24-metabolite panel predicts preclinical
transition to clinical stages of Alzheimer ’ s disease. Front. Neurol. 6, 1–13 (2015).
12. Zetterberg, H. Applying fluid biomarkers to Alzheimer ’ s disease. Am J Physiol Cell Physiol 313, C3–C10
(2017).
13. Gregor, M. F. & Hotamisligil, G. S. Inflammatory Mechanisms in Obesity. Annu. Rev. Immunol. 29, 415–445
(2011).
14. Miller, A. A. & Spencer, S. J. Obesity and neuroinflammation: A pathway to cognitive impairment. Brain. Behav.
Immun. 42, 10–21 (2014).
15. Raj, D. et al. Increased white matter inflammation in aging- and Alzheimer’s disease brain. Front. Mol. Neurosci.

205

10, 1–18 (2017).
16. Akiyama, H. et al. Inflammation and Alzheimer ’s disease. 21, (2000).
17. Heneka, M. T. et al. Neuroinflammation in Alzheimer’s disease. Lancet Neurol. 14, 388–405 (2015).
18. Mandrekar, S. & Landreth, G. E. Microglia and inflammation in Alzheimer’s disease. CNS Neurol Disord Drug
Targets 9, 156–167 (2010).
19. Wardlaw, J. M., Valdés Hernández, M. C. & Muñoz-Maniega, S. What are white matter hyperintensities made
of? Relevance to vascular cognitive impairment. J. Am. Heart Assoc. 4, 001140 (2015).
20. Simpson, J. E. et al. Microglial activation in white matter lesions and nonlesional white matter of ageing brains.
Neuropathol. Appl. Neurobiol. 33, 670–683 (2007).
21. Simpson, J. E. et al. White matter lesions in an unselected cohort of the elderly: astrocytic, microglial and
oligodendrocyte precursor cell responses. Neuropathol. Appl. Neurobiol. 33, 410–419 (2007).
22. Lee, S. et al. White matter hyperintensities are a core feature of Alzheimer’s disease: Evidence from the
Dominantly Inherited Alzheimer Network. Annu. Neurol. 79, 929–939 (2016).
23. Brickman, A. M. et al. Reconsidering harbingers of dementia: Progression of parietal lobe white matter
hyperintensities predicts Alzheimer’s disease incidence. Neurobiol. Aging 36, 27–32 (2015).
24. Boyle, P. A. et al. White matter hyperintensities, incident mild cognitive impairment, and cognitive decline in
old age. Ann. Clin. Transl. Neurol. 3, 791–800 (2016).
25. Yates, K., Sweat, V., Yau, P., Turchiano, M. & Convit, A. Impact of metabolic syndrome on cognition and brain:
A selceted review of the Litterature. Arter. Tromb. Vasc. Biol. 32, 2060–2067 (2012).
26. Prins, N., Van, D., den Heijer, T. & Al, E. Cerebral white matter lesions and the risk of dementia. Arch. Neurol.
61, 1531–1534 (2004).
27. Hawkins, K. A. et al. Hyperinsulinemia and elevated systolic blood pressure independently predict white matter
hyperintensities with associated cognitive decrement in the middle-aged offspring of dementia patients. Metab.
Brain Dis. 32, 849–857 (2017).
28. Zhu, Y. et al. Serum IL-8 is a marker of white-matter hyperintensities in patients with Alzheimer’s disease.
Alzheimer’s Dement. Diagnosis, Assess. Dis. Monit. 7, 41–47 (2017).
29. Walker, J. M. & Harrison, F. E. Shared neuropathological characteristics of obesity, type 2 diabetes and
Alzheimer’s disease: Impacts on cognitive decline. Nutrients 7, 7332–7357 (2015).
30. Misiak, B., Leszek, J. & Kiejna, A. Metabolic syndrome, mild cognitive impairment and Alzheimer’s diseaseThe emerging role of systemic low-grade inflammation and adiposity. Brain Res. Bull. 89, 144–149 (2012).
31. Agca, C. et al. Development of transgenic rats producing human β-amyloid precursor protein as a model for
Alzheimer’s disease: transgene and endogenous APP genes are regulated tissue-specifically. BMC Neurosci. 9,
1–13 (2008).

206

32. Rosen, R. F. et al. Exogenous seeding of cerebral β-amyloid in βAPP -transgenic rats. J Neurochem 120, 660–
666 (2012).
33. Antunes, L. C., Elkfury, J. L., Jornada, M. N., Foletto, K. C. & Bertoluci, M. C. Validation of HOMA-IR in a
model of insulin-resistance induced by a high-fat diet in Wistar rats. Arch. Endocrinol. Metab. 60, 138–142
(2016).
34. Millian, J. et al. Lipoprotein ratios : Physiological significance and clinical usefulness in cardiovascular
prevention. Vasc. Health Risk Manag. 5, 757–765 (2009).
35. Bizon, J. L., Foster, T. C., Alexander, G. E. & Glisky, E. L. Characterizing cognitive aging of working memory
and executive function in animal models. Front. Aging Neurosci. 4, 1–14 (2012).
36. Weishaupt, N. et al. APP21 transgenic rats develop age-dependent cognitive impairment and microglia
accumulation within white matter tracts. J. Neuroinflammation 15, 1–12 (2018).
37. Klakotskaia, D. et al. Memory deficiency, cerebral amyloid angiopathy, and amyloid-β plaques in APP+PS1
double transgenic rat model of Alzheimer’s disease. PLoS One 13, 1–16 (2018).
38. Kim, K. W., Seo, H., Kwak, M. S. & Kim, D. Visceral obesity is associated with white matter hyperintensity and
lacunar infarct. Int. J. Obes. 41, 683–688 (2017).
39. Pasha, E. P. et al. Visceral adiposity predicts subclinical white matter hyperintensities in middle-aged adults.
Obes. Res. Clin. Pract. 11, 177–187 (2017).
40. Lampe, L. et al. Visceral obesity relates to deep white matter hyperintensities via inflammation. Ann Neurol 85,
194–203 (2019).
41. Greenberg, A. S. & Obin, M. S. Obesity and the role of adipose tissue in inflammation and metabolism. Am J
Clin Nutr 83, 461S – 465 (2006).
42. Guillemot-Legris, O. & Muccioli, G. G. Obesity-Induced Neuroinflammation: Beyond the Hypothalamus.
Trends Neurosci. 40, 237–253 (2017).
43. Kivipelto, M. et al. Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease.
Arch Neurol 62, 1556–1560 (2005).
44. Tolppanen, A.-M., Solomon, A., Soininen, H. & Kivipelto, M. Midlife vascular risk fctors and Alzheimer’s
disease: evidence from epidemiological studies. J. Alzheimer’s Dis. 32, 531–540 (2012).
45. Nägga, K. et al. Increased midlife triglycerides predict brain β-amyloid and tau pathology 20 years later.
Neurology 0, 10.1212/WNL.0000000000004749 (2017).
46. Rojo, L., Sjöberg, M., Hernández, P., Zambrano, C. & Maccioni, R. Roles of cholesterol and lipids in the
etiopathogenesis of Alzheimer’s disease. J. Biomed. Biotechnol. 2006, 1–17 (2006).
47. Vance, J. E. Dysregulation of cholesterol balance in the brain : contribution to neurodegenerative diseases. Dis.
Model. Mech. 5, 746–755 (2012).

207

48. Van Vliet, P. Cholesterol and late-life cognitive decline. J. Alzheimer’s Dis. 30, (2012).
49. Reitz, C. Dyslipidemia and the Risk of Alzheimer’s Disease. Curr Atheroscler Rep. 15, 1–14 (2014).
50. Wood, W. G., Li, L., Müller, W. E. & Eckert, G. P. Cholesterol as a causative factor in Alzheimer Disease: a
debatable hypothesis. J Neurochem 129, 559–572 (2014).
51. Reitz, C. et al. Association of higher levels of high-density lipoprotein cholesterol in elderly individuals and
lower risk of late-onset Alzheimer Disease. Arch Neurol 67, 1491–1497 (2010).
52. Reitz, C., Tang, M.-X., Luchsinger, J. & Mayeux, R. Relation of plasma lipids to Alzheimer disease and vascular
dementia. Arch Neurol 61, 705–714 (2004).
53. Mielke, M. M., Zandi, P. P., Sjögren, M., Gustafson, D. & Östling, S. High total cholesterol levels in late life
associated with a reduced risk. Neurology 64, 1689–1695 (2005).
54. Mcguinness, B., Craig, D., Bullock, R. & Passmore, P. Statins for the prevention of dementia. Cochrane
Database Syst. Rev. 1–48 (2016). doi:10.1002/14651858.CD003160.pub3.www.cochranelibrary.com
55. Stewart, R., White, L. R., Xue, Q.-L. & Launer, L. J. Twenty-six–year change in total cholesterol levels and
incident dementia. Arch Neurol 64, 103–107 (2007).
56. Bartzokis, G. Age-related myelin breakdown : a developmental model of cognitive decline and Alzheimer ’ s
disease. 25, 5–18 (2004).
57. Roher, A. E. et al. Increased Aβ peptides and reduced cholesterol and myelin proteins characterize white matter
degeneration in Alzheimer’s disease. Biochemistry 41, 11080–11090 (2002).
58. Svennerholm, I. & Gottfries, C. Membrane lipids , selectively diminished in Alzheimer brains , suggest synapse
loss as a primary event in early-onset form ( type I ) and demyelination in late-onset form ( type II ). J Neuroch
62, 1039–1047 (1994).
59. Caughlin, S. et al. Membrane-lipid homeostasis in a prodromal rat model of Alzheimer’s disease: Characteristic
profiles in ganglioside distributions during aging detected using MALDI imaging mass spectrometry. Biochim.
Biophys. Acta - Gen. Subj. 1862, 1327–1338 (2018).
60. Longstreth, W. T. et al. Incidence , manifestations , and predictors of worsening white matter on serial cranial
magnetic resonance imaging in elderly. The Cardiovascular health study. Stroke 36, 56–61 (2005).
61. Verstynen, T. D. et al. Competing physiological pathways link individual differences in weight and abdominal
adiposity to white matter microstructure. Neuroimage 79, 129–137 (2013).
62. Chen, Y., Yin, M., Cao, X., Hu, G. & Xiao, M. Pro- and anti-inflammatory effects of high cholesterol diet on
aged brain. Aging Dis. 9, 374–390 (2018).
63. Grösgen, S., Grimm, M. O. W., Frieß, P. & Hartmann, T. Role of amyloid beta in lipid homeostasis. Biochim.
Biophys. Acta 1801, 966–974 (2010).
64. Grimm, M. O. W. et al. Regulation of cholesterol and sphingomyelin metabolism by amyloid- β and presenilin.

208

Nat. Cell Biol. 7, 1118–1123 (2005).
65. Fong, L. K. et al. Full-length amyloid precursor protein regulates lipoprotein metabolism and amyloid- ␤
clearance in human astrocytes. J Biol Chem 293, 11341–11357 (2018).
66. Gamba, P. et al. The link between altered cholesterol metabolism and Alzheimer ’ s disease. Ann N.Y. Acad. Sci.
1259, 54–64 (2012).
67. Gamba, P. et al. Oxidized cholesterol as the driving force behind the development of Alzheimer’s disease. Front.
Aging Neurosci. 7, 1–21 (2015).
68. Wooten, J. S. et al. The influence of an obesogenic diet on oxysterol metabolism in C57BL/6J mice. Cholesterol
2014, (2014).
69. Guillemot-Legris, O. et al. High-fat diet feeding differentially affects the development of inflammation in the
central nervous system. J. Neuroinflammation 13, 1–11 (2016).
70. Mutemberezi, V. et al. Oxysterol levels and metabolism in the course of neuroinflammation: Insights from in
vitro and in vivo models. J. Neuroinflammation 15, 1–16 (2018).
71. Gamba, P. et al. Up-regulation of b-amyloidogenesis in neuron-like human cells by both 24- and 27hydroxycholesterol: protective effect of N-acetyl-cysteine. Aging Cell 13, 561–572 (2014).
72. Gamba, P. et al. Interaction between 24-hydroxycholesterol, oxidative stress, and amyloid-β in amplifying
neuronal damage in Alzheimer’s disease: three partners in crime. Aging Cell 10, 403–417 (2011).
73. Papassotiropoulos, A. et al. 24S-hydroxycholesterol in cerebrospinal fluid is elevated in early stages of dementia.
J. Psychiatr. Res. 36, 27–32 (2002).
74. Popp, J. et al. Cerebral and extracerebral cholesterol metabolism and CSF markers of Alzheimer ’ s disease.
Biochem. Pharmacol. 86, 37–42 (2013).
75. Björkhem, I., Cedazo-Minguez, A., Leoni, V. & Meaney, S. Oxysterols and neurodegenerative diseases. Mol.
Aspects Med. 30, 171–179 (2009).
76. Shafaati, M. et al. Marked accumulation of 27-hydroxycholesterol in the brains of Alzheimer ’ s patients with
the Swedish APP 670 / 671 mutation. J. Lipid Res. 52, 1004–1010 (2011).
77. Zhang, X. et al. Increased levels of 27-hydroxycholesterol induced by dietary cholesterol in brain contribute to
learning and memory impairment in rats. Mol Nutr Food Res 62, 1–10 (2018).
78. Bjorkhem, I. Crossing the barrier : oxysterols as cholesterol transporters and metabolic modulators in the brain.
J ournal Intern. Med. 260, 493–508 (2006).
79. Adolfsson, R., Bucht, G., Lithner, F. & Winblad, B. Hypoglycemia in Alzheimer’s disease. Acta Med Scand 208,
387–388 (1980).

209

210

Chapter 6: Discussion
6.1 Summary of Results
The studies constituting this thesis were undertaken to enhance our understanding of the interaction
between metabolic vascular condition and pathogenic environment of the early prodromal stage of
AD. Specifically, the studies aimed to investigate the effects of such interaction on the white matter
inflammation and the impact on the cognitive outcome, and to determine the potential of
manipulating inflammation with a novel brain-targeted NSAID to prevent pathological and
cognitive changes. A high calorie high-fat, high-sugar diet-induced MetS in the APP21 TG rat
model of prodromal AD was used to test the research hypothesis that the comorbid condition will
result in increased white matter inflammation and cognitive dysfunction which can be prevented
by anti-inflammatory treatment. The following objectives were addressed:
1)

To determine the impact of comorbid MetS and increased pathogenic APP environment on

white matter inflammation, specifically on microglia and astrocytes, and the effect on cognitive
function; thus, defining possible targets for early therapeutic intervention (Chapter 2)
2)

To examine the therapeutic potential of a novel anti-inflammatory agent by analyzing its

effect on white matter inflammation and cognition in the comorbid model of prodromal AD and
MetS (Chapter 3)
3)

To analyze the possible negative effects of a brain targeted anti-inflammatory agent tested

as a potential therapeutic strategy to target increased white matter inflammation (Chapter 4).
4)

To identify potential biomarkers of white matter inflammation by characterizing the

relationship between white matter inflammation and systemic metabolic and physiological
parameters (Chapter 5).
In support of the hypothesis, the comorbid rats demonstrated increased white matter microglia, but
not astrocyte, activation, which was accompanied by spatial reference and working memory
deficits and cognitive inflexibility (Chapters 2 and 3). TG rats on the HCD were the only group
demonstrating spatial reference memory consolidation deficit compared to control group of the
wild type rats suggesting that intense white matter inflammatory response to the presence of
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metabolic alterations could be promoting and accelerating the development of this type of
cognitive decline (Chapter 2). These results highlighted that white matter inflammation could be
a potential treatment target.
Experiments to demonstrate that an anti-inflammatory agent is a potential therapeutic approach,
did not find support in our studies. The chronic treatment with a novel NSAID KL prodrug did not
prevent the potentiating effect of the MetS on the white matter inflammation and cognitive
dysfunction at the prodromal AD phase (Chapter 3). Moreover, the use of this particular prodrug
was associated with detrimental effects in several animals on cognition and cerebral homeostasis
expressed as substantial inflammatory pathology involving both microgliosis and reactive
astrocytosis in large regions of gray and white matter of the cerebral cortex and subcortical
structures (Chapter 4). Additional analysis indicated that white matter inflammation, specifically
white matter activated microglia, is found to negatively correlate with cognitive performance. A
general trend of a better cognitive task performance was associated with a lower white matter
microglial activation (Chapter 5).
The data overall supports the need for further studies to clarify the potential of an antiinflammatory treatment. However, this research should carefully choose the types of agents and
consider timing as well as determine the best therapeutic window. In the meantime, identifying
biomarkers for white matter inflammation is important as it could have implications for diagnosis,
treatment and prevention.
The attempt to find potential biomarkers of this pathology indicated that the presence of the
mutated form of APP and amount of fat accumulated around internal organs is highly positively
correlated with white matter microgliosis. Blood lipid metabolism components including total
cholesterol, atherogenic fraction, triglycerides levels and Chol:HDL ratio were also contributors
to the amount of microgliosis. In particular, the comorbid condition has shown a negative
association of white matter inflammation with the lipid profile, while the entire rat sample and WT
dataset had a positive relation. These results indicate there are complex relationships between
blood and physiological parameters and white matter microglial activation, which are complicated
by the coincidence of metabolic and early AD pathologies. Thus, biomarker research should
consider the presence of comorbidities that might affect the relationship between metabolic
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measures and cerebral pathologies and therefore have an effect on interpretation and subsequent
clinical application of the biomarker.

6.2 Comorbid Model of Prodromal Alzheimer’s Disease and Metabolic Syndrome
MetS is a chronic disorder highly prevalent among the elderly which is associated with increased
risk for and is a common comorbidity of MCI and AD1–6. It is thought that these diseases interact
with each other and might have synergistic effect on cerebral homeostasis and cognitive
function7,8. The exact basis of such interaction has not been conclusively defined yet. Analysis of
pathogenetic commonalities indicates that inflammation and white matter lesions might be the
events linking the two conditions, specifically at the early prodromal stages of AD.
To investigate this idea we developed a preclinical model of this comorbidity in the TG rat
overexpressing pathogenic hAPP, implicated in human FAD, which shows increased production
of APP and Aβ levels and yet no plaque and NFT pathology9,10. Thus, these TG rats model the
early stage of disease pathology.
Obesity and MetS in rodents are often induced via dietary manipulation and include high-fat or
high-carbohydrate hypercaloric diets with a various composition and macronutrient percent
content11–13. In our studies we combined high fat, rich in saturated fat and cholesterol, food with a
corn syrup drink, rich in simple carbohydrates, that together resulted in increased caloric value to
closely mimic the genesis of obesity in human populations with unhealthy dietary habits11,14.
Twelve to fifteen weeks on this HCD led to successful development of MetS in our rats. In
particular, the following components developed: obesity, hypertriglyceridemia, increase in levels
of total and atherogenic non-HDL cholesterol, shift towards greater Chol:HDL ratio, insulin
resistance, hyperinsulinemia and glucose intolerance15. Comorbid rats showed greater
dyslipidemia and only modest glucose intolerance compared to the WT rats. This smaller reduction
in glucose tolerance compared to the WT rats is similar to observed in AD patients and could be
related to peripheral pathogenic hAPP effects on regulation of glucose metabolism16,17. Rats of
both genotype on the HCD also had increased visceral adiposity which was greater in TG rats,
suggesting establishment of pro-inflammatory environment in these animals18–22. In our animals,
HCD did not induce hypertension, a parameter that is important component of the syndrome.
Behavioral analysis using MWM variations showed modest cognitive changes in spatial reference
memory consolidation, spatial working memory and ability to rapidly adjust to the environmental
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changes (i.e. cognitive flexibility) driven exclusively by HCD consumption in the TG rats with
AD predisposition. This suggests there is a potentiating effect of comorbidity on cognitive deficits.
This

cognitive profile demonstrated by MWM closely resembles executive dysfunction,

processing speed and general cognition deficits seen in humans with white matter lesions who are
obese, have MetS or are in the initial phase of AD23–34.
Other investigations have shown that the APP21 TG rats used in our studies develop executive
dysfunction with increased age compared to WT animals supporting the clinical relevance of this
model35,36. In our studies, a non-specific and less rigorous MWM protocol to test executive domain
was used and the TG rats alone did not develop executive dysfunction. However, executive
dysfunction was shown in the comorbid animals there is a potentiating effect on behavioral
deficits.
Brain analysis identified predominant widespread white matter microgliosis and reactive
astrocytosis in TG rats, which was not accompanied by evident demyelination. MetS combined
with the prodromal AD environment significantly increased the white matter microgliosis
compared to TG condition alone, although there was no additional increase in astrocyte reactivity
or change to myelination level. In addition, the numbers of neurons in the hippocampus were not
found to be affected in TG rats compared to WTs35. There was also no apparent hippocampal
neuronal loss in the comorbid animals. While there was a decrease in hippocampal synaptic density
in TG rats compared to WTs, it was not further aggravated by the presence of metabolic syndrome
in the comorbid rats. Thus, the HCD was efficient in modeling MetS traits similar to that observed
in humans and indicated possible effects of comorbidity on physiology and metabolism which
might be relevant and important for clinical consideration. Moreover, the combined model
indicated synergistic effects of comorbidity on neuroinflammation, specifically white matter
inflammation demonstrated by increased microglia activation, and behavioral deficits suggesting
a potential link between the AD and MetS and white matter inflammation might be underlying
mechanism potentiating the effect of comorbidity on cognitive deficits.
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6.3 White Matter Inflammation
The Fischer 344 rat strain used in these studies have shown to be especially prone to white matter
alterations, specifically development and progression of widespread inflammation, with increased
aging, similar to what is seen in humans as they age 35,37–42. APP21 TG rats created on the Fischer
344 background have previously been shown to develop accelerated microglia activation in white
matter compared to the WT rats of this strain35. This phenomenon was also observed in our animals
as described in this thesis.
The regions of microglial activation included the corpus callosum, particularly the anterior part
starting at the forceps minor and more found in the periventricular areas, fimbria, internal capsule,
cingulum, anterior commissure, hippocampal commissure and optic tract. The predominance of
white matter changes in the anterior region of the corpus callosum is similar to the pattern seen in
human aging and the early phase of AD, changes that support the retrogenesis hypothesis of white
matter disruption due to local events prior to neurodegenerative changes43–47.
Significantly more activated microglial cells were observed in the corpus callosum, internal
capsule and fimbria hippocampi of TG rats compared to WT rats in our studies. HCD-induced
MetS collectively was also associated with significant increase of white matter microgliosis.
However, it was the comorbid rats of prodromal AD and MetS that demonstrated the most marked
increase in white matter microglial activation in all three regions compared to all other groups,
indicating a synergistic response of the two diseases.
Although the TG animals demonstrated an increase in astrocyte reactivity, there was not an
additional increase induced by the comorbid condition with the HCD-induced MetS. This could
be due to microgliosis in the white matter being a very early pathological change preceding
reactive astrocytosis or alternatively a specific form of response to this comorbidity with obesity
and metabolic changes48.
Rats of both genotype on the HCD also had increased visceral adiposity which was even greater
in TG rats on the diet, suggesting the establishment of pro-inflammatory environment in these
animals. The enhanced white matter inflammation in the comorbid rats which also had the highest
amount of visceral fat supports the idea of systemic inflammation in MetS contributing to and
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promoting the brain inflammatory processes and in this case, specifically the white matter
microglial response21. Furthermore, as only the comorbid rats showed cognitive impairments this
supports the association of high systemic inflammatory status due to increased visceral adiposity
with cognitive dysfunction in obese individuals18–22,49–52.
There was no apparent hippocampal neuronal loss in the comorbid rats suggesting that white
matter pathology, specifically inflammation, is associated with the behavioral deficits and explain
the observed profile in this model. These findings of changes in white matter inflammation and
cognitive impairment, are also supported by the analyses that demonstrated an inverse correlation
between white matter activated microglia and cognitive performance in total rat sample and
especially in the comorbid animals. A better cognitive task performance is associated with lower
white matter microglial activation.
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6.4 Anti-inflammatory Treatment
Consistent evidence from the literature and the present results, of the involvement and critical role
of neuroinflammation in MCI and AD, from prodrome to end stage, strongly suggests that
modulation of inflammation is a promising approach to disease prevention or slowing53,54.
Epidemiological studies also support this idea, particularly the use of NSAIDs for blocking
inflammation via COX enzyme inhibition associated with reduced prostaglandin, thromboxane
and prostacyclin production55. Some clinical trials appear to support the efficacy of antiinflammatories in MCI and AD, whereas others show no benefit of NSAID use in control of disease
progression56.
These drugs are largely effective at the systemic level and have limited ability to cross BBB. The
transport and availability of active free drug in the CNS site of action is very limited, particularly
due to their extensive binding to plasma proteins in systemic circulation57,58. Modification of drug
structure can lead to favorable changes in its properties leading to enhanced transport into the CNS
and increased concentration of biologically active compound in the brain.
A novel engineered non-steroidal anti-inflammatory prodrug, KL, showed the ability to cross the
BBB via LAT-1 transporter, achieve a good brain tissue distribution and drug release in the brain59.
We have tested this brain targeted prodrug in the comorbid rat model and found that the long-term
prophylactic treatment initiated at the time of dietary intervention at a half-therapeutic dose for
this class of drug, did not reduce the enhanced white matter microglial activation and did not have
an effect on the behavioral deficits. However, the chronic prodrug administration was associated
with two lethal cases and development of widespread neuroinflammation and neuronal
degeneration accompanied by cognitive deficits in several rats irrespective of the experimental
group.
Literature analysis showed that some studies reported an increased risk of adverse cardio- and also
cerebrovascular events in patients taking NSAIDs that may have been happening in our animals
on the prodrug60–68. The lack of positive effects of the drug on the pathology and behavioral
deficits, and the presence of possible direct negative pathological effects could be related to the
treatment protocol, such as the dose, time of initiation and also the prodrug properties used in our
study. The pathological APP environment in the TG rats combined with metabolic abnormalities
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could alter transporter-mediated influx of the prodrug in the CNS. Clinical data suggest the timing
of drug application is the most critical condition for the success of anti-inflammatory
treatment56,69–71.
White matter inflammation, similar to what was developed in our model, is thought to be the
earliest pathology seen in AD. It is possible that white matter damage due to inflammation or other
events leading to or contributing to increased microgliosis in our TG model has been present for
some time even at the start of pharmacological intervention, even though there is no classical
plaque or NFT pathology. Thus, the prodrug was unable to prevent or reduce the enhanced
pathology in the comorbid animals using the drug administration protocol in these studies.
Prolonged exposure to the high concentration in the brain of free ketoprofen could lead to brain
damage seen in our rats. This could be linked to insufficient inhibition of negative COX effects
(e.g. pro-thrombotic, vasoconstrictive) in the current protocol61,62,65,72,73. Alternatively, these
effects might be related to the inhibition of COX enzyme activity in general which aside from the
pro-inflammatory and neurodegenerative action are involved in neuroprotection mediated by
certain prostaglandins, docosanoids, resolvins and neuroprotectins. Beneficial effects of COX
include regulation of synaptic activity and plasticity, hippocampal long-term potentiation,
neurovascular coupling and cerebral blood flow, neuronal survival, anti-thrombotic and even antiinflammatory properties (e.g. modulation of leukocyte trafficking, downregulation of cytokines
expression in glia) 74–80.
Under pathological conditions the equilibrium maintained by COX is disrupted, and effects are
initially shifted towards the inflammatory which could eventually turn into neurodegeneration.
Nevertheless, it is possible that there are still some protective effects in place to counteract
compromised homeostasis and diminishing them pharmacologically needs to be approached
cautiously.
The data overall supports the need in further studies to clarify the potential of anti-inflammatory
treatment in preventing and slowing down white matter inflammation associated with AD and
cognitive deficits. Initiation of treatment as well as the therapeutic window are critical conditions
for the success of drug therapy and should be established by future experiments. These parameters
could vary with the presence of concurrent chronic conditions, such as metabolic vascular
218

disorders, that might show an accelerated rate of development of brain pathology, be prone to
complications associated with the NSAID treatment and also impact pharmacokinetics and
dynamics of drugs60,81.
Caution should be exercised with the drug synthesis of brain-targeted NSAIDs in the race for a
better CNS penetration. This could in fact potentiate adverse effects, rather than increase the
benefits of the treatment. It might also be that some systemic effects of NSAIDs would be
beneficial such as lowering systemic inflammation present in obesity and MetS, which could
decrease pro-inflammatory signaling to the brain and therefore CNS immunity activation, i.e.
microgliosis. It is also possible to consider various NSAIDs and alternative drug agents with a
different mechanism of action that will not diminish COX-mediated beneficial effects.
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6.5 Biomarkers
Success of the treatment appears to depend on the pathological stage it is initiated at. Early
intervention might grant beneficial effects by acting on the prodromal pathology such as white
matter inflammation. It is important to investigate potential biomarkers of the cerebral white matter
inflammation that may have relevance for disease treatment. Currently, white matter lesions that
has been linked to cognitive dysfunction can be detected on conventional MRI as hyperintensities
or atrophy. However, these lesions might already be too advanced and not quite useful from a
therapeutic intervention point of view82–84. Early inflammatory pathology might already be present
even when the white matter appears normal on MRI. The DTI MRI method is more sensitive and
could provide an insight into structural white matter changes associated with pathological changes
to myelin and axons85–89. PET imaging can provide information specific to microglial activation90–
95

. More easily obtainable and affordable markers such as blood derived substances and

physiological measures present a more favorable approach and should be studied.
The experiments described in this thesis examined associations between blood metabolic and
physiological parameters and cerebral white matter activated microglia and astrocytosis using a
preclinical rat model that included a model of comorbid hAPP TG and MetS. The amount of
visceral fat was a very strong predictor of microgliosis and better explained its variance than body
weight. Lipid metabolism components showed more complicated relations. While entire
heterogenous rat sample including both diets and genotypes showed a weak positive association,
comorbid rats demonstrated a negative relationship with every component. Chol:HDL ratio
appeared to be the strongest contributor to the variations in microglia activity.
Epidemiological data does not provide a single directional relationship between blood lipids and
AD, suggesting potential effects at different disease stages. The epidemiology data actually
suggests a beneficial role of increased cholesterol levels for the brain under pathological
conditions96–98.
There was a strong genotypic relationship to the amount of activated white matter microglia. The
TG APP variant with Swedish and Indiana mutations associated with early FAD correlated with
greater microglial activation. Thus, comorbid conditions with AD, such as metabolic vascular
diseases including MetS and T2DM, and potentially the stage of the disease appear to complicate
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and can significantly modulate the associations between the markers and specific pathology. Age,
gender, ethnicity and genetics may further contribute to the relationship of certain markers with
AD or MCI pathologies. Thus, biomarker research should consider the presence of comorbidities
that might have a direct effect on the interpretation and subsequent clinical application of the
biomarker.
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6.6 Limitations
The TG rat model of AD bears the hAPP gene mutations which are causally linked to the early
onset autosomal dominant FAD99. However, genome studies revealed that variants of these gene
are implicated in the sporadic LOAD as well100,101. The clinical profile of these two types of AD
are very alike. Although there might be different mechanisms driving the disease development,
these forms are very similar pathologically. Particularly, white matter lesions commonly seen in
LOAD are also attributed to the onset of FAD type82,102,103. Thus, this rat model offers valuable
opportunities for the investigation of the roles of white matter pathology and white matter
microglia activation in a common form of AD pathogenesis and cognitive decline. This model is
also relevant to age-related pathology and vascular dementia.
The dietary approach of modeling obesity and MetS provides a great advantage since it closely
mimics human habits. These models create a complex in vivo environment to study diseases and
their interaction in more realistic conditions. However, dietary composition for experimentation is
not standardized and varies greatly in fat, sugar and protein amounts which introduces a certain
variability to the systemic and brain pathology that might introduce variable responses in different
species and strains104,105. Similarly, the duration of feeding might impact the development of
pathologies.
In these studies, the diet was provided for 12-15 weeks and was enough to model obesity and
related dyslipidemia, insulin resistance and glucose intolerance characteristic of a pre-diabetic
condition. However, the animals did not develop frank T2DM with fasting hyperglycemia. Blood
pressure elevation was not evident in the HCD rats compared to control animals. Blood pressure
was measured with a non-invasive technique which does not absolutely exclude a possibility of
subtle early changes that might be developing at this stage, that could have been detected using
sensitive invasive methods. Nevertheless, our model demonstrated characteristic features of MetS
in a particular combination that appear relatively early in the course of the disease, and this
provided us the opportunity to study early interaction with AD predisposition.
Behavioral testing done in our model utilized MWM task to assess spatial learning and memory,
as well as working memory and behavioral flexibility, which are all related to the health of the
white matter. However, MWM is not the most sensitive or specific task for assessment of executive
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function. Operant conditioning based set-shifting would be a much more appropriate test for this
purpose36. However, this test requires a considerable food restriction period for motivational
purposes prior to training and uses sugar pellets as a reward during the testing and the testing
period might be a several weeks long. This significantly complicates the integration of the task in
its original form into our studies when our animals are on the diet-induced pathology regimen. In
fact, there is evidence of pathology reduction and reversibility with caloric restriction and diet
modulation11,106–109.
Analysis of the cerebral pathology was focused on the white matter changes, particularly gliamediated inflammation. Microglia and astrocyte activation, which indicates a pro-inflammatory
environment, were detected by immunohistochemistry using a single antibody for each type of
cell, OX-6 for MHC II (M1 pro-inflammatory phenotype) and anti-GFAP, respectively110–112.
Although these markers may have some limitations, they have a good selectivity, are associated
with increased activation of cells in a pro-inflammatory condition, including aging, and are
commonly used40,113–119.
Quantification methods included integrated density defined as a sum of pixels in the area and area
coverage by antigen positive cells, which were analyzed on converted to black and white images,
and allowed assessment of the cell activation level by the number of antigen-expressing cells,
rather than the antigen expression level in cells. Additionally, the number of Iba-1 stained
microglia cells was used to assess the changes in the total microglia numbers. These
complementary microglia staining analysis indicated that comorbidity was specifically associated
with an increase in activation of cells and not due to an increase in their number. GFAP staining
does allow a conclusive answer to whether increased transgene-dependent astrocytic response was
due to an increase in individual cell reactivity or increased number of cells.
We did not detect neuronal loss or additional to transgene-related synaptic density decrease in the
hippocampal region by immunohistochemical staining suggesting depletion of neurons or
synapses in the hippocampus is not responsible for the cognitive profile of the comorbid rats. It is
likely that white matter microglial activation and/or other white matter pathology underlies these
disturbances. However, this does not exclude the possibility that some functional and
morphological neuronal changes could begin to develop at a later time. It is more likely that
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synaptic dysfunction associated with the microglia hyperactivation and white matter damage could
contribute to the cognitive impairments48,120.
The conclusions of the NSAID prodrug treatment ineffectiveness were based on a single treatment
protocol. This protocol used a half-dose of a common therapeutic dose. This was considered
sufficient since it was initiated at the time of dietary change and was viewed as a prophylactic
measure. It is possible that this dose, the frequency of injections, the duration and the time of
initiation at that particular age could be insufficient to modify the observed pathological microglia
activation. Earlier intervention in younger rats could potentially provide some benefit.
Additional studies with brain targeted anti-inflammatory drugs need to be pursued and should rely
on a determination of the white matter inflammation time course. However, a large increase in
brain inflammation observed in several prodrug-recipients suggests there may be a safety concern
for the brain-targeted agent even with the moderate dose delivered daily and a higher therapeutic
dose may not be feasible. However, a vehicle-controlled study should be performed to rule out the
possible effects of the chronic stress due to injections on the brain and behavior and determine the
unique negative effect of the drug treatment.
Correlational studies utilized a limited data sample which likely affected precision and power of
associations, particularly between behavior and glucose metabolism and microgliosis. A limited
number of measures were tested for relationship with white matter pathology. Nevertheless,
observations of differential patterns seen in the whole rat sample and the comorbid group showed
significant correlations and may be relevant to the humans.
Finally, these studies used only male rats 8.5-10.5 months of age at the start of experiments. There
could be sex differences in the response to the diet and in the interaction with AD early pathology,
which are important and should be investigated.
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6.7 Future directions
The studies presented in this dissertation represent the basis for future experiments. The
pathological and cognitive presentation of the MetS may slightly vary reflecting the diversity of
components comprising the syndrome in a particular case seen among both humans and animals.
Each of the metabolic and physiological changes in MetS may contribute to CNS pathology and
AD-related changes either individually or as a combination. Thus, it might be important to study
various phenotypes to observe both short-term and long-term progression of pathological events
to unravel the dynamics of changes in the CNS, including white matter glia activation and function.
Also, in the light of importance of understanding the early pathology, studies on the time course
of white matter microglia activation could be carried out with initiation of the experiment at a
younger age.
The use of more specific and sensitive behavioral methods is required to adequately characterize
the changes in cognitive function in the comorbid condition and the effects of the treatment. These
behavioral methods need to be first adapted for use in diet-induced metabolic disease models.
The detection of astrocytes and microglia was done using a single antigen expressed by activated
cells in a pro-inflammatory condition. Greater specificity and more information could be achieved
by using other markers of activated cells that may indirectly identify potential triggering events
for changes in amyloid, APP or myelin debris. Such molecules of interest related to microglia
function during inflammation to be considered are TREM-2, LRP, complement system receptors,
galectin-3, Mac-1,2, TSPO121–125.
While post-mortem tissue analysis is highly detailed and informative, PET and DTI MRI
techniques can provide an advantage of indicating in vivo pathology detection and to trace the
changes and progression over time. Glial activation, a marker of neuroinflammation, can also be
detected using PET and might significantly advance our understanding of pathology when
incorporated in preclinical studies126–129. Cerebral pro-inflammatory status analysis could further
be complemented by CSF or blood cytokine level determination.
Brain tissue should be further analyzed in a greater detail using available immunohistochemical
and imaging methods in order to identify the nature and magnitude of the inflammatory events as
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well as to determine if the white matter microglia activation is a precursor to or a consequence of
potential vascular changes and other processes. These other processes include myelin and/or
axonal damage and loss, oligodendrocyte dysfunction and death, are potential events that might
take place at this early stage of dietary intervention and contribute to the cognitive dysfunction130–
136

. The white matter damage or excessive microglia activation appearing at this early stage could

affect synaptic function and number137,138. The comorbid model which addresses the early AD
disease pathology demonstrated subtle cognitive changes. Synaptic pathology might be associated
with these cognitive deficits and could be investigated using various methods that include
immunohistochemistry, electron microscopy, PET imaging and electrophysiology139–143.
These processes associated with microglia activation such as vascular, axonal, myelin, synaptic
pathologies could be better correlated with cognitive decline and have a stronger association with
the blood and physiological parameters associated with MetS which could further be used as
peripheral biomarkers. Moreover, these studies on other associated pathologies and processes
could define other potential therapeutic targets and strategies directed towards white matter
protection.
NSAIDs are an intensively studied class of drugs for MCI and AD treatment. They inhibit COX
activity and downstream production of eicosanoids and docosanoids modulating both proinflammatory and innate neuroprotective mechanisms144. Additionally, blockage of COX
pathways might increase arachidonic acid which is also a substrate for lipoxynase (LOX) enzymes,
such as 5-LOX and 12/15-LOX145. This could result in an elevated release of leukotrienes
contributing to inflammation, oxidative stress and neuronal injury and modulation of tau and
amyloid pathways146,147.
Obesity, particularly when induced by hypercaloric high-fat/sugar diets, might change the brain
lipid profile and membrane composition such as increase arachidonic acid production148. Another
derivative of membrane phospholipids metabolism is lysophosphatidic acid (LPA) involved in
promotion of insulin resistance and AD-specific pathology via enhancement of tau
phosphorylation and APP processing by β-secretase into Aβ peptide, and glia activation149–152.
LPA production is increased in obesity and AD153,154. AD is also associated with the increased
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ATX gene expression, coding enzyme autotoxin involved in synthesis of LPA155,156. Comorbid
conditions may aggravate these pathways.
Thus, inhibitors of LOX and production or action of leukotrienes and LPA could be an alternative
to NSAIDs drug choice with beneficial effects for its use in comorbid patients and should be
investigated157–160. One of the drugs that inhibits 5-LOX leukotriene production and alleviates
inflammation is minocycline, a tetracycline antibiotic used for treatment of infection

161,162

.

Research data suggests a strong anti-inflammatory potential of this drug mediated by a direct
action on microglia and interference with microglia T-cell communication48,163–166. This might be
a favourable strategy for AD and especially comorbidity with MetS as it specifically targets
microglia, which appear to have a major role in the disease neuropathology and white matter
inflammation in particular. Minocycline and derivatives might block excessive glia activation by
the systemic inflammatory signalling48,111,166–168.
Blocking or suppressing pro-inflammatory cytokine (e.g. TNF-α) action via receptor binding
modulation is also a promising strategy79,169–174. Etanercept (Enbrel) which is a recombinant
receptor for TNF-α cytokine, one of the major key players in AD primarily secreted by microglia
cells, showed benefit in preclinical and clinical cases175–178. Monoclonal antibodies to TNF-α,
MAbs, is a second group of treatment candidates175,176,179–181. Minocycline which was discussed
earlier has also been shown to have an anti-TNF-α effect172,174. Nevertheless, TNF-α also has
physiological functions which could be disrupted with drugs targeting this cytokine172,173. Direct
inhibition of TNF-α receptors might be beneficial or detrimental depending on a cell type, receptor
type and disease stage, thus more careful studies and more targeted and selective therapy should
be developed182–184.
In addition to pharmacological treatments, lifestyle changes are a readily available way of
interfering with the disease development. Reduction and reversibility of the neuropathology has
been observed with caloric restriction and diet modulation11,106–109,185. The efficacy of this
approach on decreasing white matter microglia activity, including in the comorbid model, should
also be studied either independently or in combination with the drug method. Moreover, poor diet
and lack of exercise are risk factors for metabolic conditions, MCI and dementia. Thus,
modification of lifestyle at an early age could reduce the incidence of metabolic vascular disorders
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and possibly prevent cognitive decline with aging. It is likely that a therapeutic plan combining
pharmacological methods targeting several key pathological events and non-pharmacological
measures might provide successful prevention or control over the MetS, diabetes and dementia.
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6.9 Conclusions
The studies constituting this thesis support the initial hypothesis that comorbidity of pathogenic
hAPP TG model of prodromal AD with MetS increases white matter inflammation, as
demonstrated by microglia activation, and this comorbidity leads to cognitive deficits. TG CD rats
developed some increased white matter activation compared to that in the WT group but did not
show cognitive changes. Pathogenic hAPP also increased the total number of microglia cells.
Comorbidity further exacerbated microglia activation, but not proliferation in TG HCD rats
compared to TG normal rats and resulted in significant behavioral deficits. White matter
microgliosis was further associated with the visceral fat accumulation which supports the idea of
contribution of systemic inflammation to the cerebral glia activation.
While there was a genotype-dependent increase in the astrocyte reactivity in TG rats, the comorbid
condition did not have an impact on this pathology as there was no additional increase in activation
of these cells. Thus, it appears that comorbidity with diet-induced MetS exacerbated exclusively
white matter microgliosis which suggests this is the key element of prodromal AD-related
pathology and it may be the point of interaction between these diseases and related to the cognitive
health. This pathological linking event might be an extremely important target for intervention
allowing early modulation of the disease pathogenesis and disruption of detrimental synergistic
effects of concurrent diseases.
While the use of a particular brain-targeted NSAID prodrug in a single protocol did not provide
support for the anti-inflammatory intervention, it highlighted several important points for
consideration including the importance of when treatment is started, potential serious adverse
effects and the need for investigations of alternative drug agents. Thus, this APP21 TG rat model
combined with the diet-provoked metabolic alterations is an important and clinically relevant
model for studying early pathology in AD, early biomarkers and relationship with the metabolic
vascular diseases. Furthermore, it is an important arena for testing pharmacological and
nonpharmacological treatments and preventive measures that target the pathological link between
these diseases, particularly white matter microgliosis, with the goal of preservation of cognitive
function.
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Appendices
Appendix A: Ethics Approval
A1 Animal Use Protocol #1
From: eSiriusWebServer [mailto:esiriusadmin@uwo.ca]
Sent: September 23, 2014 12:29 PM
To: David.Cechetto@schulich.uwo.ca
Cc: auspc@uwo.ca
Subject: eSirius Notification - New Protocol Modification Has Been APPROVED2008-113::6

AUP Number: 2008-113
PI Name: Cechetto, David
AUP Title: Mechanisms of Vascular Cognitive Impairment and Prevention of Stroke and Its
consequences
Official Notification of AUS Approval: A MODIFICATION to Animal Use Protocol 2008113 has been approved.
The holder of this Animal Use Protocol is responsible to ensure that all associated safety
components (biosafety, radiation safety, general laboratory safety) comply with institutional
safety standards and have received all necessary approvals. Please consult directly with
your institutional safety officers.
Submitted by: Kinchlea, Will D
on behalf of the Animal Use Subcommittee
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A2 Animal Use Protocol #2
From: eSiriusWebServer <esiriusadmin@uwo.ca>
To: <Shawn.Whitehead@schulich.uwo.ca>
Date: 04/06/2016 9:07 AM
Subject: eSirius Notification - New Protocol Modification Has Been APPROVED2014-016::1
Cc: auspc@uwo.ca

AUP Number: 2014-016
PI Name: Whitehead, Shawn N
AUP Title: Role of vascular risk factors in cognitive decline
Official Notification of AUS Approval: A MODIFICATION to Animal Use Protocol 2014-016
has been approved.
The holder of this Animal Use Protocol is responsible to ensure that all associated safety
components (biosafety, radiation safety, general laboratory safety) comply with institutional
safety standards and have received all necessary approvals. Please consult directly with your
institutional safety officers.
Submitted by: Kinchlea, Will D
on behalf of the Animal Use Subcommittee

243

Appendix B: Diet Composition
B1 Hypercaloric Diet (HCD)

The content of the pelleted rodent Western diet which was used to induce metabolic syndrome
MetS in these studies (HCD groups) and its detailed fatty acid composition are provided below.
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B2 Supplementary Syrup Drink in the hypercaloric diet (HCD) regimen
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B3 Control Diet
This rat chow from Prolab is used as a standard rodent food in the animal facility in which the rats
included in these studies were housed. This diet continued to be used in the rats from both control
diet groups (CD) for the entire duration of studies.
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Appendix C: Rat Tail Cuff Blood Pressure Measurement
Blood pressure measurements were done using the CODA High Throughput Non-Invasive Blood
Pressure System (Kent Scientific; CODA-HT6). Complete system user guide can be found online
https://www.kentscientific.com/Customer-Content/www/products/Files/CODA_HTManual.pdf.
Briefly, rats are placed in the holders, plastic tubes enclosing animal’s body and exposing the tail
for blood pressure measurements. Two cuffs are placed on the tail, occlusion cuff which is close
to the base of the tail and distally located volume change detecting cuff. Animals are placed on the
warming platforms to increase the blood flow. The system allows simultaneous measurement of 6
animal. The holders are available in two sizes and have an adjustable position of the nose cone to
accommodate rats of a different size. Prior to experiment acclimatize animals to the tube, gradually
increasing the duration of restraint, to heating, presence of cuffs and allow a few acclimation days
of test blood pressure measurements (5 days on average).
Habituate rats in the room before the start of experiment for a minimum of 30min. In the meantime,
test the cuffs for malfunctions. Preheat platforms with empty holders placed on them at 39°C (L4).
Place rats in the holders, cover with blankets and heat for 10-15min at reduced to 38-35°C (L3-2)
temperature. Maintain 32°C (L1) heat for the duration of experiment, monitoring the tail blood
volume and rat behavior. Place the cuffs on the tail and begin measurements. One session (one day
experiment) includes minimum of 25 and on average 50 cycles. Monitor position of the cuffs for
the accurate measurement, as rats tend to move and throw off the distal cuff. Clean tubes and
platforms from feces and urine, smell and porphyrin traces with detergent (Sparkleen) between
rats and at the end of experiment. Repeat the session over multiple days (3-5) choosing the same
time of a day.
At the end of the session export measurements to excel file and set up the table to calculate systolic
and diastolic pressure mean of multiple cycles within one day to account for the blood pressure
variations and then across multiple days. Apply manual filtering of the accepted by the software
cycles. Remove readings that have a tail blood volume of 15ml or less. Use the readings with inday standard deviations less than 30, with the number of good cycles greater than 15 and mean
blood volume be more than 50ml.
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Appendix D: Ketoprofen – lysine Prodrug
Structural formula of the Ketoprofen-lysine prodrug was designed by Jukka Leppänen at the
University of Kuopio, Finland. The prodrug has a molecular weight of 418.92 g/mol. The structural
formula and kinetics of the rat brain uptake of the prodrug were demonstrated in the original work
publication (Gynther, M. et al. Brain uptake of ketoprofen-lysine prodrug in rats. (2010) Int. J.
Pharm. 399, 121–128). Figures inserted in this chapter were adapted from the original paper and
have not been modifyied.
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Appendix E: Tissue Staining Protocols
E1 Solutions
Phosphate Buffered Saline (PBS) 0.1M pH 7.35 1L (10X) – STOCK
Na2HPO4 (anhydrous)

10.9g

NaH2PO4 (anhydrous)

3.2g

NaCl

90g

Distilled water (dH2O)

1000ml (˜ 980ml)

or monohydrate (NaH2PO4XH2O) 3.7 g

Mix to dissolve and adjust pH to 7.35 using HCl and NaOH dropper. Store at room temperature.
PBS 0.01M pH 7.35 1L (1X) – WORKING SOLUTION
Dilute 1:10: 1 part PBS 0.1M (10X) stock solution with 9 parts of distilled water:
PBS 0.1M

100ml

dH2O

900ml

Mix to dissolve and adjust pH to 7.35. Store at room temperature.
Phosphate Buffer Saline with 0.2% TritonX detergent (0.2% PBST) 0.01M
PBS 0.01M

˜500ml

Triton X-100

1ml

Use 1ml syringe (without a needle) to draw 1ml of triton. Stir to dissolve completely.
Parafromaldehyde (PFA) 4% pH 7.35 1L stable for 2 weeks at 4 oC
PFA

40g

ddH2O

500ml (stir and heat to 30 - max 50 oC, then cool down)

NaOH 10N

˜

PBS 0.1M

100ml

ddH2O

390ml (to from 1L solution). Filter before use.

15 drops to help dissolve

Phosphate buffer (PB) 0.1M 1L pH7.2-7.3
Na2HPO4 (anhydrous)

10.9g

NaH2PO4 (anhydrous)

3.2g

or monohydrate (NaH2PO4XH2O) 10.7g

dH2O 1000ml (˜ 980ml)
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Cryoprotectant 1L
0.1M PB

500ml

Sucrose

300g

Ethylene glycol

300ml

PVP-40

10g – optional and was not used in these studies

ddH2O

up to 1000ml

Pour a sample of solution in an Eppendorf and put in a freezer overnight to check that
cryoprotectant does not freeze.
30% Sucrose 1L
Sucrose

300g

ddH2O

1000ml

0.3% Gelatin for mounting brain sections on glass slides
Dissolve 1.5g gelatin powder in 500ml ddH2O, heat (not boil) and stir for better dissolving, cool
down to room temperature before use. Keep refrigerated. Good to use within a week. Reheat to
room temperature before each use.
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E2 Immunohistochemistry Protocol
Primary antibodies:
• Anti-Iba-1, rabbit polyclonal (1:1000; #019-19741, Wako Chemicals USA Inc., Richmond,
VA, USA)
• OX-6, mouse monoclonal (1:1000; #554926, BD Pharmingen, Mississauga ON, Canada)
• Anti-GFAP, mouse monoclonal (1:2000; #G3893 Sigma-Aldrich, St Louis MO, USA)
• Anti-NeuN, mouse monoclonal (1:1000; #MAB377 EMD Millipore Corp., USA)
• Anti- synaptophysin, mouse monoclonal (1:1000; #S5768 Sigma-Aldrich, St Louis MO, USA)
Secondary antibody:
• Biotinylated horse anti-mouse IgG (1:500; #31806 Thermo Fisher Scientific)
• Biotinylated goat anti-rabbit IgG (1:500; #31820 Invitrogen, Thermo Fisher Scientific)
Blocking solution reagents:
• Normal horse serum (#7484 Abcam)
• Normal goat serum (#S-100 Vector Laboratories, Inc. Burlingame, CA, USA)
Avidin-biotin complex (ABC) Standard reagent kit (#32020 Thermo Fisher Scientific);
(#Vectastain PK-6102,Vector Laboratories, Inc. Burlingame, CA, USA)
Staining is performed on free-floating sections; all steps are done on a shaker.
Day1
• Wash 6x10min in PBS 0.01M
• Block endogenous peroxidase with 1% H2O2 for 10 min (15min for NeuN) (prepare from 3%
stock H2O2 with 0.01M PBS)
• Wash 3x5 min in PBS 0.01M
• Block non-specific tissue binding with 2% blocking solution (1.5% for NeuN) prepared with
horse serum (goat serum for Iba-1) in PBST for 1h at room temperature
• Incubate with primary diluted in blocking solution (prepared as in a previous step) for 30min at
a room temperature following overnight in fridge (4°C cold room on a shaker)
Day2
• Continue incubation in primary for 30 min at a room temperature
• Wash 3x5 min in PBS 0.01M
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• Incubate with secondary diluted in blocking solution (prepared as in day 1) for 1h at room
temperature
• Wash 3x5 min in PBS 0.01M
• Incubate with horseradish peroxidase (ACB kit - 2 drops A, 2 drops B in 10ml 0.01M PBST –
prepare 1h before use) 1h at room temperature
• Wash 3x5 min in PBS 0.01M
• Incubate in 0.05% diaminobenzidine tetrahydrochloride (DAB, Sigma-Aldrich #D5637)
solution. Toxic! Dissolve 10mg DAB, 1 tablet or powder, in 20mL of 0.01M PBS (add 5ml
more PBS as will lose later when filtering). Stir for ˜ 15min for a tablet; powder form much
faster, and filter through filter paper (Whatman Grade 2/8μm). Add 3% H2O2 immediately
before use (20uL of 3% stock H2O2 in 20mL DAB solution). Dispose properly after.
• Wash 3x5 min in PBS 0.01M
• Mount with 0.3% Gelatin on glass slides and leave to air-dry overnight
Day3
•

Step done in fumehood. Dehydrate slides sequentially in 50%, 70%, 95%, 100% Ethyl Alcohol
(EtOH,) 50/50 EtOH/Xylene for 5 min in each Then 10 min in 100% Xylene. Coverslip with Depex
(BDH Chemicals, Poole, UK), remove air bubbles, dry overnight in the fumehood, clean slides the next
day.
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E3 Luxol Fast Blue Staining Protocol
Solutions:
0.1% Luxol fast blue solution
Luxol fast blue powder, MBS

0.1g

Ethyl Alcohol, 95%

100ml

Glacial acetic acid

0.5ml

Filter after preparation. Can be stored and reused for 5 years.

0.05% Lithium carbonate solution
Lithium carbonate

0.05g

ddH2O

100ml

Day1
• Wash 6x10min in PBS 0.01M

• Mount sections on (non ‘+’) slides using water. Do not use gelatin! Fully dry overnight
Day2
• Step done in fumehood. Dehydrate slides sequentially in 50% → 70% → 95% EtOH for 3
min in each
• Incubate in Luxol fast Blue solution for 16-18h at 56 oC. Make sure the boats are properly
sealed to prevent solution evaporation. Better use screw-cap jars, lid should be tightly sealed!
Day3
• Rinse off excess Luxol fast Blue with 70%EtOH for 1.5-2 min (thicker cut sections use more
time), continuously dip and agitate slides in a boat
• Rinse carefully with ddH2O (2 times x1 min) – dip and agitate in a boat, NOT under running
water (sections may detach from slide)
• Differentiate slides in 0.05% Lithium Carbonate solution for 1.5min in the 1st run, then 1min
in each following run. Thicker sections require more time (1.5-2min per step). This step takes
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as long as necessary to distinguish white matter, can take between 5 and 30 min. On average 3
runs are enough. If in doubt, take out a bit earlier rather than later.
• Rinse with distilled water (2 times x1min) – dip, agitate in a boat
• Dehydrate in 100% EtOH (2 times x 5min), then in Xylene (2 times x 5min)
• Coverslip with Depex resinous medium.
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Appendix F: Microscopy and Image Analysis
F1 Image Acquisition on the Microscope
Tissue sections were imaged on the Nikon Eclipse Ni-E upright microscope with a Nikon DS Fi2
color camera head (NIS Elements Imaging; Mississauga, ON) using NIS-Elements Imaging
Software Version 4.30.02 (Nikon Instruments Inc., Melville, NY).
Microscope settings:
Lamps (DIA enabled, fixed) at 43-48, LUT function disabled, Exposure 10ms, Analogue gain 1.0,
Zoom 1.0x, no Filters on Turet1, FL1 fluorescent shutter is off.
Using 2X objective: Aperture 30.6mm, Field Stop 30.6mm, condenser 5 2/4x; 10X objective:
Aperture 11.5mm, Field Stop 10.5mm, condenser 7N1; 20X objective: Aperture 19.1mm, Field
Stop 5.2mm, condenser 6N2.
Scanning image:
For every tissue section set white balance using a probe (rectangle icon) on a no-tissue spot on a
slide (direct light) and applying AWB (auto white balance) function found on the tool bar at the
top.
Adjust focus manually prior to scanning either a single focus for the entire image or using a focus
surface which allows to pre-set different focus on multiple points on the tissue, particularly when
the slide preparation resulted in uneven surface and requires different focus depth to create a sharp
image.
Select on a top tool bar Acquire → Scan Large Image: set scanning objectives (i.e. capture 2x –
scan 10x), set area of scanning manually defining number and position of fields, set stitching
overlap at 20%, shading off, automatic postprocessing off, select Focus manually at start (or Focus
surface). Extended depth of focus (EDF) is available for creating a Z-stacked image scanned at
various depth (select steps in um, range) and combining sharp signal from multiple layers into one
image.
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Capture function can be used for smaller images which do not require stitching (camera button on
top tool bar). This option is also available with EDF→ Real time EDF – select range (top and
bottom sharp focus) and step length (e.g. 0.9um) for Z-series acquisition.
Save an image as TIFF for publication purposes, as JPEG for large images and JPEG or TIFF for
small image for Image J or microscope software analysis.
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F2 Image Acquisition using Aperio
Aperio digital entire-slide scanner (Department of Pathology, Western University, London,
Ontario, Canada), allowing 20x magnification, was used to acquire images of entire series of brain
sections for initial scanning of activated microglia location and of Luxol Fast Blue stained tissue
for myelination analysis. Aperio ImageScope software (Leica Biosystems Pathology Imaging),
version 12.3.2.8013 was used to extract images of specific regions of interest for further ImageJ
analysis.
Choose magnification (zoom slider) and select Camera button on the top tool bar (Scanshot) to
acquire image of the region at a fixed resolution and with a scale bar which can not be removed
from the image. Image can be saved as TIFF/JPEG, however, is suitable for analysis and a low
magnification full-section image, but not publication. Extract region tool (floppy disk and arrow
icon on the top tool bar) allows to obtain an image of a selected region with variable resolution:
click and drag on the image, in the opened window define output format – TIFF or JPEG, LZW
compression, % extraction (80-100 on average), extract. This function does not capture scale bar.
Both methods can be used together to create a high-quality image with defined scale bar.
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F3 Image Analysis
White matter analysis
Image analysis was done in the ImageJ program (Version 1.48u4, Wayne Rasband, National
Institutes of Health, Bethesda, MD, USA). Prior to quantification set a scale: use a line tool to
outline the scale on the image and measure its length in pixels (Analyze→ Measure or Ctrl+M);
open Analyze→ Set scale, input measured and known length (in um), set pixel aspect ratio to 1.0
and apply Global to use this scale (pixel/um) for a series of images in one ImageJ session. Then
Analyze→ Set measurements: area, min and max gray value, integrated density (include raw
integrated density = sum of pixel values), mean gray value and area fraction.
To create selection for the region of interest (ROI), use the stereotaxic atlas to define ROI’s
boundaries. Outline the ROI with a polygon tool avoiding edges (DAB accumulates) and excluding
artifacts overlapping with the ROI. To add selection to the ROI Manager use Edit→ Selection→
Add to manager (Ctrl+T), then save all ROIs for an animal by selecting all and ROI Manager→
More→ Save. ROI shape and size can be changed by manipulating individual points on selection
(hold and drag, add point Shift+left mouse click, remove point Ctrl+left click) and ROI can be
updated in the Manager (ROI should be selected in the manager list prior to changes). If you click
outside of the selection, it will disappear from the image. To bring it back, use Edit→ Selection→
Restore selection (Ctrl+Shift+E). Do not crop the image to minimize the field to ROI, as such ROI
saved will not match the region boundaries on the original image when re-opening the image.
If a part of the original full selection is needed for a separate analysis (e.g. PVCC regions from the
entire corpus callosum selection), use rectangle/polygon outline tool to draw a selection around
the region to be cropped out, and add this new selection to ROI Manager. Select a newly added
ROI and Edit → Selection → Make inverse (note a fine colored line at the perimeter of the image)
program window), add to manager, select both full and inverse selections in the Manager→
More→ AND → this will generate a new selection with undesired region cropped from the full
selection. In the case of bilateral analysis (e.g. fimbria), combine several individual ROIs by
selecting those ROIs in Manager→ More→ OR (combine). Add newly created ROI to the
Manager and save.
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Convert image to black-white format: Image→ Type→ 8-bit. Measure ROI area. Process→
Subtract background (select “light” as the signal is dark; rolling ball radius 50 pixels) and finally
Image→ Adjust→ Threshold (Ctrl+Shift+T) to an adequate maximum (233-248 depending on the
stain). Do not apply threshold, limit measurement to threshold (area should not be 100%) and do
the measurement. Copy all measurements and paste into excel file to calculate weighted average
for each of the ROIs per animal and a final sum.
Automatic cell count
Neuronal cell count was done using the NIS-Elements Imaging Software Version 4.30.02 (Nikon
Instruments Inc., Melville, NY). Follow the following steps: select Binary→ Spot detection: dark
spots (spot 9pixels, typical diameter 13.5um or size of cell body, contrast 20.1); methods – select
dark, clustered, blue channel, apply to current frame, preview. ROI→ Move binary to ROI→ see
the number appearing when right- click on image – number of selected ROIs represent number of
cell bodies. If only a selection from entire image area needs to be analyzed, go to measure using
rectangle tool (record the area and dimensions of the selection for consistent application), crop at
the end of a measured box, delete the box and do same later.
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